Elucidating the mechanism of NUAK1 function in Ovarian Cancer Metastasis by Fritz, Jamie
Western University
Scholarship@Western
Electronic Thesis and Dissertation Repository
August 2019
Elucidating the mechanism of NUAK1 function in
Ovarian Cancer Metastasis
Jamie Fritz
The University of Western Ontario
Supervisor
Dr. Trevor Shepherd
The University of Western Ontario
Graduate Program in Anatomy and Cell Biology
A thesis submitted in partial fulfillment of the requirements for the degree in Master of Science
© Jamie Fritz 2019
Follow this and additional works at: https://ir.lib.uwo.ca/etd
Part of the Cancer Biology Commons
This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted for inclusion in Electronic Thesis
and Dissertation Repository by an authorized administrator of Scholarship@Western. For more information, please contact wlswadmin@uwo.ca.
Recommended Citation






Epithelial ovarian cancer (EOC) has a unique mode of metastasis, where upon shedding from 
the primary tumor, cells form spheroids and spread through the peritoneal cavity. There is a 
need to elucidate pathways driving spheroid formation to identify novel therapeutic targets. 
We previously showed that LKB1 is required for EOC metastasis. Using multiplex inhibitor 
bead-mass spectrometry, we identified NUAK1 as a top LKB1 substrate candidate. We 
confirmed LKB1 maintains NUAK1 phosphorylation and expression. NUAK1KO cells had 
lower cell adhesion and generated spheroids with reduced integrity. We identified a cell 
attachment pathway that was enriched in parental compared with NUAK1KO spheroids. The 
FN1 gene, encoding fibronectin, exhibited the greatest differential expression in NUAK1KO 
spheroids. Parental spheroids have enhanced fibronectin expression, which was undetectable 
in NUAK1KO spheroids. Treatment of NUAK1KO cells with fibronectin restored a compact 
spheroid phenotype. We have identified a novel mechanism where NUAK1 promotes 
spheroid formation through fibronectin deposition. 
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Chapter 1  
1 Introduction  
1.1 Ovarian cancer epidemiology, clinical presentation, and 
diagnosis  
Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy in the 
developed world and is characterized by early and rapid metastasis (Lheureux, Gourley, 
Vergote, & Oza, 2019). Most women are diagnosed with advanced-stage disease with a 
5- year survival rate of 29% (Siegel, Miller, & Jemal, 2019). The standard treatment plan 
for patients with late-stage ovarian cancer is maximal surgical cytoreduction with 
adjuvant chemotherapy of carboplatin and paclitaxel (Lheureux et al., 2019). However, 
with the current standard of care, the majority of patients will eventually have disease 
recurrence and resistance to chemotherapy (Bowtell et al., 2015b).  
 
A diagnosis of EOC at an advanced-stage is common because patients are often 
asymptomatic until the cancer has metastasized (Lheureux et al., 2019) . When symptoms 
present they are not-specific and include abdominal fullness, abnormal vaginal bleeding, 
gastrointestinal and urinary symptoms (Roett & Evans, 2009). A physician’s initial 
investigation will involve performing a pelvic and rectovaginal examination to check for 
an ovarian mass, measuring serum levels of CA125, and completing a transvaginal 
ultrasonography (American College of Obstetricians anf Gynecologists., 2002). CA125 is 
raised in 90 percent of patients with advanced-stage disease yet only 50 percent of 
patients in the early stage of the disease have elevated levels of CA125 (American 
College of Obstetricians anf Gynecologists., 2002). Moreover, a transvaginal ultrasound 
is associated with false-positive results and often detects ovarian masses that have already 
metastasized (Karst & Drapkin, 2009). Therefore, new strategies are required to diagnosis 
EOC in the early stages.  
 
To stage EOC, the chest, abdomen, and pelvic regions are imaged with a CT and MRI, 
but surgery is required to adequately stage the disease (Lheureux et al., 2019). In stage I, 
EOC is localized to the ovaries (Bast, Hennessy, & Mills, 2009). If the cancer has 
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metastasized within the pelvic region, it is stage II.  Once the cancer has spread to the 
abdominal region it is stage III; and distant  metastasis beyond the abdomen into areas, 
such as the liver parenchyma, lung, and brain, is considered stage IV. In addition to 
staging EOC, the pathology of the tumor tissues is assessed because EOC is a 
heterogeneous disease with multiple histological subtypes (Lheureux et al., 2019). The 
four EOC histotypes include serous, endometriod, mucinous, and clear cell (Bast et al., 
2009) 
1.2 Treatment for advanced-stage ovarian cancer  
The standard first-line treatment plan for patients with advanced-stage ovarian cancer is 
primary surgical cytoreduction with the goal of no residual tumor burden (Goff, 2012; 
Lheureux et al., 2019). Debulking surgery is the most important prognostic factor for 
survival. Surgery is then followed by chemotherapy of paclitaxel and carboplatin. 
Neoadjuvant chemotherapy is an option for patients with preexisting medical 
comorbidities or when tumours cannot be completely resected (Coleman, Monk, Sood, & 
Herzog, 2013). Carboplatin and paclitaxel are administered intravenously every 3 weeks 
for 6 cycles (Lheureux et al., 2019). Carboplatin forms crosslinks in the deoxyribonucleic 
acid (DNA), inhibiting replication and transcription in proliferating tumor cells (Martin, 
Hamilton, & Schilder, 2008). On the other hand, paclitaxel is a microtubule-stabilizing 
drug that leads to mitotic arrest (Weaver, 2014) . To reduce the risk for disease 
recurrence, maintenance therapies of anti-angiogenic therapies, including Bevacizumab, 
and PARP inhibitors (PARPi), such as Olaparib, can be given. PARPi are given to 
patients with defective homologous recombination (HR) particularly with germ line 
mutations in BRCA1 or BRCA2 (Lheureux et al., 2019). Mechanistically, inhibition of 
PARP prevents the repair of single-stranded breaks (Banerjee, Kaye, & Ashworth, 2010). 
In tumors absent of HR genes which repair double stranded breaks, the addition of 
PARPi leads to a loss of DNA repair mechanisms due to synthetic lethality and cell 
death.   
 
If cancer progresses during first-line chemotherapy, patients have refractory disease and 
and prognosis is very poor (Lheureux et al., 2019).  Moreover, even after first-line 
treatment, more than 75% of patients will have disease recurrence. Platinum-sensitive 
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recurrent ovarian cancer is defined as a disease free interval of at least 6 months 
(Matulonis, 2018). These patients have the option for a secondary debulking surgery, a 
platinum doublet with 6-8 cycles of carboplatin and paclitaxel, and maintenance therapy. 
In the case of platinum-resistant recurrent ovarian cancer, cancer recurs after an interval 
of less than 6 months. Many different non-platinum-containing chemotherapeutic agents 
can be selected, including paclitaxel alone, with the addition of bevacizumab can be 
implemented; however platinum-resistant recurrent patients tend to have a very low 
responses to these treatments.  
 
HGSOC is a highly genomically unstable disease; thus, during treatment, tumor cells can 
rapidly evolve, leading to chemoresistance (Lheureux et al., 2019). In addition to this 
issue of temporal tumor heterogeneity, spatial heterogeneity can occur within a tumor 
which makes treating this disease with a single therapeutic agent challenging. To address 
the complexity of HGSOC, combination therapy targeting DNA repair mechanisms, the 
cell cycle, and novel critical metastatic pathways will be necessary.  
1.3 High-grade serous ovarian cancer   
High-grade serous ovarian cancer (HGSOC) is the most common diagnosed histological 
subtype, representing 75 % of all cases of EOC (Lheureux et al., 2019). This subtype 
progresses rapidly, is typically diagnosed at an advanced–stage, and represents the 
majority of ovarian cancer-related deaths (Bowtell et al., 2015a; Goff, 2012). It is now 
widely regarded that the primary site of origin for HGSOC is the secretory epithelial cells 
of the distal fallopian tube (Bowtell et al., 2015a; Labidi-Galy et al., 2017; Lheureux et 
al., 2019). Cells undergo malignant transformation with mutations occurring in the TP53 
gene to form serous tubal intraepithelial carcinoma (STIC) lesions which then spread to 
the ovary. In some cases of HGSOC, ovarian cancer can arise without fallopian tube 
involvement and instead from precursor cells on the ovary (Bowtell et al., 2015a).  
 
 HGSOC appears heterogeneous with papillary, glandular, solid, and necrotic regions 
(Lheureux et al., 2019). Cancer cells have large and atypical nuclei. This subtype is 
characterized by mutations in TP53 and to a lesser extent mutations in NF1, BRCA1, 
BRCA2, RB1, and CDK12 genes. Oncogenic mutations in HGSOC are infrequent. 
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HGSOC has genome instability with widespread DNA copy number gains and losses 
being common. The prevalence of DNA alterations can make this cancer susceptible to 
acquiring chemoresistence. Furthermore, DNA repair mechanisms involving mutations in 
HR genes, such BRCA1 or BRCA2, are deficient in 50% of HGSOC (Matulonis, 2018). 
1.4 Ovarian cancer metastasis and experimental model 
system  
In EOC metastasis, cancer cells shed from the primary ovarian tumor and spread into the 
peritoneal cavity (Sodek, Murphy, Brown, & Ringuette, 2012). Ascites fluid commonly 
accumulates in the peritoneal cavity of patients with advanced-stage disease and disease 
recurrence (Al Habyan, Kalos, Szymborski, & McCaffrey, 2018; Sodek et al., 2012). 
This build-up of ascites fluid results from cancer cells impairing lymphatic drainage and 
secreting vascular endothelial growth factor (VEGF) which enhances vascular 
permeability. The ascites microenvironment consists of diverse cell types, including 
ovarian cancer cells, fibroblasts, immune cells, and endothelial cells (Cho, Howell, & 
Colvin, 2015). It also contains acellular components, such as extracellular matrix (ECM) 
proteins, matrix metalloproteinases (MMP), growth factors, and cytokines (Ahmed & 
Stenvers, 2013). The tumor microenvironment regulates cancer survival and invasion 
(Cho et al., 2015). For instance, cancer-associated fibroblasts (CAFs) interact with 
ovarian cancer cells to promote their invasiveness (Schauer et al., 2015). The release of 
interleukin 1 β (IL-1β) from ovarian cancer cells communicates to CAFs to down-
regulate levels of the tumor suppressor p53. The diminished levels of p53 enhances the 
transcriptional activation of the NF-κB promoter, leading to the release of interleukins 
that feedback on ovarian cancer cells to promote their invasiveness.  
 
Upon release from the primary tumor, cancer cells will form into multi-cellular structures 
known as spheroids to evade anoikis, a form of apoptosis due to loss of cell detachment 
(Figure 1.1A) (Al Habyan et al., 2018; Sodek et al., 2012). Eventually spheroids will 
adhere to the mesothelium and submesothelium of the peritoneum or omentum and 
continue to invade at secondary sites (Figure 1.1A) (Lengyel et al., 2014; Sodek et al., 
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2012). The phenotypic heterogeneity of the primary tumor is often retained in spheroids 
and at sites of peritoneal metastases (Al Habyan et al., 2018). 
 
Spheroids are heterogeneous structures with a necrotic core, a middle layer of quiescent 
cells, and a peripheral layer of actively proliferating cells (Weiswald, Bellet, & Dangles-
Marie, 2015). The ascites microvironment is hypoxic and devoid of glucose due to 
insufficient vascularization, and so spheroids adopt unique survival mechanisms (Figure 
1.1A) (Emmings et al., 2019). Our group has shown that spheroids exhibit decreased cell 
proliferation and are arrested in the cell cycle at G0/G1 (Correa et al., 2014).  However, 
they can reverse their dormant phenotype and enhance proliferation upon reattachment by 
reactivating AKT signaling. Spheroids also up-regulate autophagy, a system that 
degrades large and damaged proteins (Correa, Valdes, Shepherd, & DiMattia, 2015; 
Lilienbaum, 2013; Lu et al., 2008; Wang et al., 2018). Autophagy serves as a survival 
mechanism in response to stress from nutrient deprivation and hypoxia in the ascites 


































Figure 1.1 Ovarian cancer peritoneal metastasis and experimental model system. 
(A) Malignant cells shed from the primary ovarian tumor and aggregate into spheroids in 
the peritoneal cavity to evade anoikis.  In this hypoxic and nutrient-poor 
microenvironment, spheroids adopt unique survival mechanisms. The interaction between 
integrins and ECM proteins are critical for spheroid formation. These multi-cellular 
aggregates can seed on secondary sites, such as the peritoneum, to form new tumor 
nodules. (B) Metastasis can be modelled in vitro by seeding cells on ultra-low attachment 
plates to facilitate spheroid formation and reattaching spheroids on tissue culture plastic. 
 
Prior studies have provided evidence that targeting the ovarian cancer spheroid could be 
an effective therapeutic strategy because it is the primary mediator of peritoneal 
metastasis (Lengyel et al., 2014; Sodek et al., 2012). In addition, EOC cells that have a 
greater disposition to form compact spheroids have enhanced invasive properties (Sodek, 
Ringuette, & Brown, 2009). EOC spheroids can also develop resistance to paclitaxel and 
cisplatin in contrast to cells grown as a monolayer (Pease, Brewer, & Tirnauer, 2012). In 
fact, dissociation of spheroids can reestablish sensitivity to chemotherapeutic agents. This 
resistance to chemotherapy in spheroids can arise from inhibition of apoptosis or 
quiescent cells that can regrow after actively dividing peripheral cells die (Desoize & 
Jardillier, 2000). 
 
To model EOC metastasis in vitro, cells can be grown on ultra-low attachment plates 
(ULA) to facilitate spheroid formation  (Figure 1.1B) (Sant & Johnston, 2017). Due to 
the hydrophilic and neutral coating of the ULA plates, cells grow in suspension and form 
aggregates. To mimic the process of spheroids seeding on secondary surfaces, spheroids 
can then be transferred to regular tissue culture plastic (Figure 1.1B) (Shepherd, 
Thériault, Campbell, & Nachtigal, 2007). In this system, both established cell lines and 
patient-derived ascites cell lines can be used. To derive primary cells, ascites fluid is 
taken from patients during paracentesis (Shepherd et al., 2007). Spheroids are found in 
this ascites fluid and can be transferred to tissue culture plastic to grow as adherent cells. 
These patient-derived ascites cells can be grown in ULA dishes to directly maintain them 




1.5 Ovarian cancer spheroid formation  
Cell-cell attachments mediate the formation of spheroids through cadherins and indirectly 
through extracellular maxtrix (ECM) proteins (Sodek et al., 2012). Cadherins are 
transmembrane proteins that have homophilic interactions with other cadherin receptors 
(Lin, Chou, Chien, & Chang, 2006). Integrins are the primary adhesion receptor that 
anchors the ECM to the intracellular cytoskeleton (Johansson, Svineng, Wennerberg, 
Armulik, & Lohikangas, 1997). These heterodimeric receptors are comprised of alpha 
and β subunits. The compaction of spheroids occurs when integrins and cadherins signal 
to the actin cytoskeleton to induce contraction through actomyosin-mediated forces 
(Schiller & Fässler, 2013; Sodek et al., 2012) . In ovarian cancer, the interaction between 
α5β1 integrins and fibronectin has been shown to be critical for the formation and 
cohesiveness of spheroids (Figure 1.1A) (Casey et al., 2001).  
 
Fibronectin is an ECM protein that can exist in multiple forms due to alternate splicing 
(Pankov & Yamada, 2002). It has a soluble globular form in the plasma (pFN) and an 
insoluble fibrillar form in the ECM. While pFN is secreted by hepatocytes, ECM 
fibronectin is derived predominately from fibroblasts and a fraction from the plasma 
(White & Muro, 2011). EOC cells have also been shown to produce their own fibronectin 
matrix (Iwanicki et al., 2016). This glycoprotein is comprised of three types of different 
repeating units: type I, II, and III repeats (White & Muro, 2011). Fibronectin is a ligand 
for multiple integrins, however the canonical receptor is the α5β1 integrin. A tripeptide 
Arg-Gly-Asp (RGD) sequence in fibronectin interacts with the α5β1 integrin. Beyond its 
role in ovarian cancer spheroid formation, there have been multiple studies that have 
suggested a key role for fibronectin in ovarian cancer tumor progression. Elevated 
fibronectin expression has been correlated with increased tumor stage and decreased 
overall survival in ovarian cancer patients (Franke, Von Georgi, Zygmunt, & Münstedt, 
2003). Furthermore, the loss of fibronectin in the omentum reduced ovarian cancer cell 
adhesion, invasion, and tumor metastasis in mouse models (Kenny et al., 2014). In 
addition to being found in the ECM of metastatic sites, fibronectin also accumulates in 
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the ascites fluid of patients with advanced-stage ovarian cancer (Linke, Babic, & 
Gossner, 1988).  
 
Besides fibronectin and α5β1 integrin supporting the integrity of ovarian cancer 
spheroids, L1 Cell Adhesion Molecule (L1CAM) can also promote spheroid formation 
(Doberstein et al., 2018). Intriguingly, L1CAM controls fibronectin and α5β1integrin 
expression in ovarian cancer spheroids. L1CAM is a transmembrane glycoprotein that 
can have homophilic interactions with other L1CAM molecules or heterophilic 
interactions with different adhesion molecules, such as integrins (Altevogt, Doberstein, & 
Fogel, 2016). The presence of type III fibronectin repeats in L1CAM suggest that it also 
interacts with fibronectin. L1CAM can exist as a soluble form after cleavage of its 
extracellular domain at the cell surface membrane (Beer, Oleszewski, Gutwein, Geiger, 
& Altevogt, 1999).  Tumor-promoting roles for L1CAM have been demonstrated based 
on its ability to control cell invasion, metastasis, and chemoresistence (Altevogt et al., 
2016).  In ovarian cancer, high levels of membranous L1CAM was associated with 
greater lymphogenous metastases and a greater risk for incomplete debulking surgery 
(Bondong et al., 2012). Elevated levels of soluble L1CAM in the ascites fluid was 
correlated with lower overall survival and greater chemoresistance.  
1.6 The role of LKB1 in ovarian cancer metastasis  
The elucidation of key molecular pathways in ovarian cancer spheroids would allow for 
improved understanding of metastatic processes and would aid in the identification of 
novel therapeutic targets. Our group previously showed that the master stress kinase liver 
kinase B1 (LKB1) is critical for ovarian cancer metastasis (Buensuceso, Valdes, 
Figueredo, DiMattia, & Shepherd, 2018; Peart et al., 2015). LKB1 is commonly 
expressed in established ovarian cancer cell lines and patient-derived ascites cell lines 
(Peart et al., 2015). Furthermore, LKB1 expression increases in ovarian cancer spheroids 
compared to monolayer cells. The sustained loss of LKB1 decreased anchorage-
independent growth of EOC cells and decreased the viability of ovarian cancer spheroids 
(Buensuceso et al., 2018). In a xenograft model of peritoneal metastasis, LKB1 loss 




LKB1 (encoded by the STK11 gene) is a serine-threonine kinase which becomes 
activated in a complex with the accessory proteins STRAD and MO25 (Hardie & Alessi, 
2013). There is a large body of literature implicating STK11 as a tumor suppressor. 
Inactivating mutations of STK11 lead to Peutz-Jeghers syndrome, a condition 
characterized by gastrointestinal polyps and an increased risk for cancer (Beggs et al., 
2010; Hemminki et al., 1998). STK11 is commonly deleted in non-small cell lung cancer 
and somatic nonsense mutations occur in melanoma (Gill et al., 2011; Guldberg et al., 
1999). While the gene for LKB1 is frequently described as a tumor suppressor, there is 
evidence indicating the role of LKB1 is more complex because it can have tumor-
promoting functions under certain contexts. LKB1 overexpression is associated with 
worse survival outcomes in hepatocellular carcinoma (Lee et al., 2015).  It is also 
important for tumor growth by promoting cell survival under energetic stress in non-
small cell lung cancer (Shackelford et al., 2013). Indeed, as described above, our group 
showed that LKB1 is required for ovarian cancer metastasis (Buensuceso et al., 2018; 
Peart et al., 2015).  
 
The canonical downstream target of LKB1 is AMP-activated protein kinase (AMPK), a 
regulator of metabolic stress (Shackelford & Shaw, 2009). LKB1 activates AMPK by a 
phosphorylation modification at threonine 172 on the activation loop of its catalytic 
domain (Bright, Thornton, & Carling, 2009). Under conditions of nutrient deprivation, 
LKB1-AMPK signaling is induced and decreases cell growth by inhibiting mammalian 
target of rapamycin complex 1 (mTORC1). Surprisingly, our group showed that LKB1’s 
pro-metastatic role in ovarian cancer occurs through AMPK-independent signaling; in 
spheroids lacking LKB1, phospho-AMPK levels were maintained (Buensuceso et al., 
2018). While AMPK is the commonly studied substrate of LKB1, LKB1 is known as a 
master upstream kinase due to its ability to also regulate 12 other AMPK-related kinases 
(ARKs): BRSK1, BRSK2, NUAK1, NUAK2, QIK, QSK, SIK, MARK1, MARK2, 
MARK3, MARK4, and SNRK (Figure 1.2). The ARKs show sequence similarity to 
AMPK at the N-terminal serine-threonine kinase domain (Lizcano et al., 2004). Similar 
to AMPK, ARK phosphorylation at an equivalent threonine residue of the T-loop by 
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LKB1 leads to their activation . It has been reported that the ARKs have roles in cell 
polarity, motility, and cancer metastasis (Bright et al., 2009).  It would be important to 
elucidate the key downstream substrate that is allowing LKB1 to elicit its pro-metastatic 
functions in ovarian cancer. In this report, we use a multiplexed kinase inhibitor bead-
mass spectrometry (MIB/MS) analysis with spheroids lacking LKB1 to identify NUAK1 















Figure 1.2 Overview of LKB1 signaling 
Under conditions of cell stress, LKB1 complexes with the STRAD and MO25 and 
initiates signalling to AMPK to decrease cell growth and metabolism. LKB1 can also 
control 12 AMPK related kinases (ARKs). This downstream signaling serves to regulate 















1.7 NUAK1: Structure and Regulation  
The gene for NUAK1 is found on chromosome 12 at position q23.3 (Scherer et al., 
2006). This gene encodes a 660 amino acid protein and has an estimated molecular 
weight of 74 kDa (Nagase et al., 2000; Suzuki et al., 2003). NUAK1 is a member of the 
ARK family with 47% and 46 % sequence homology to AMPK-α1 and AMPK-α2, 
respectively. Its most closely related ARK family member is NUAK2 with a sequence 
homology of 55%. NUAK1 has a serine-threonine kinase domain near the N-terminus 
which is conserved amongst AMPK and the ARKs  (Lizcano et al., 2004) (Figure 1.3). 
NUAK1 is predominately localized to the cytoplasm but can also be found in the nucleus 














Figure 1.3 Structure and function of NUAK1 
NUAK1 has sites for LKB1 phosphorylation and activation. USP9X binds to NUAK1 at 
W305 and can remove the polyubiquitin chain. NUAK1 is phosphorylated and activated 
by AKT at S600 near the c-terminus. NUAK1 can also be phosphorylated by cyclin-
dependent kinases (CDKs) at serine 445 which creates a docking site for polo kinase 

















Several upstream kinases have been shown to activate NUAK1. When LKB1 complexes 
with its accessory proteins STRAD and MO25, it can phosphorylate and activate NUAK1 
at the conserved residue threonine 211 on the T-loop of its catalytic domain (Figure 1.3) 
(Lizcano et al., 2004). Furthermore, NUAK1 ubiquitination was shown to control its 
activation by LKB1 (Al-Hakim et al., 2008). NUAK1 can be ubiquitinated by unique 
Lys29 and or Lys33 linkages which do not signal for degradation. Instead these 
modifications block phosphorylation and activation by LKB1. The deubiqutinase 
Ubiquitin Specific Peptidase 9 X-Linked (USP9X) can bind to NUAK1 at W305 and 
cleave the polyubiquitin modification, allowing for LKB1 phosphorylation and activation 
(Figure 1.3).  
 
Besides regulation by LKB1, NUAK1 can also be controlled by LKB1-independent 
mechanisms.  In response to glucose starvation NUAK1 is phosphorylated and activated 
by AKT at its C-terminus (Figure 1.3) (Suzuki et al., 2003). Furthermore, in Myc-
overexpressing tumors calcium-dependent activation of PKC can activate NUAK1 
(Monteverde et al., 2018). NUAK1 can also be phosphorylated by cyclin-dependent 
kinases (CDKs) at Serine 445 which creates a docking site for polo kinase (PLK) to then 
phosphorylate NUAK1 at Serines 476 and 480 (Figure 1.3) (Banerjee et al., 2014). These 
phosphorylation modifications promote binding to the SCFBTrcp E3 ligase which leads to 














1.8 The role of NUAK1 in tumor progression  
Prior studies have shown that NUAK1 can function in tumor progression through 
regulating apoptosis, the cell cycle, invasion and metastasis, and metabolic stress in 
tumors. NUAK1 blocked cell death induced by glucose starvation or various death-
receptor stimuli in human hepatoma cells (Suzuki et al., 2003). The authors proposed that 
NUAK1 suppresses apoptosis by inhibiting the activation of caspase 8 (Figure 1.4). 
Specifically, this inhibition occurs through NUAK1 resisting the degradation of FLICE 
(FADD-like IL-1β-converting enzyme)-inhibitory protein (FLIP), which blocks the 
activation of caspase 8. Moreover, NUAK1 allows colorectal cancer cells to resist cell 
death stimulated by the Fas ligand (FasL) binding to the cell death receptor Fas (Suzuki 
et al., 2004). NUAK1 blocked apoptosis in these cells by phosphorylating caspase 6, 
leading to its inactivation (Figure 1.4). Caspase 6 is known to cleave the anti-apoptotic 
protein FLIP. Thus, inactivation of caspase 6 by NUAK1 sustained levels of FLIP and 








Figure 1.4  Roles for NUAK1 in tumor progression. 
Roles for NUAK1 in tumor progression. NUAK1 can function in tumor progression 
(green arrows) through regulating apoptosis, the cell cycle, EMT, invasion, and metabolic 
stress in tumors. NUAK1 can also have tumor-suppressive functions (red arrows) because 














Along with promoting cell survival through inhibiting apoptosis, NUAK1 can regulate 
the cell cycle. NUAK1 can induce the S-phase and cell proliferation (Banerjee et al., 
2014). During the cell cycle, PLK and NUAK1 are reciprocally regulated. In S-phase 
there are high levels of NUAK1 and low levels of PLK. In G2/M phase, PLK levels are 
high while NUAK1 levels are low. The mechanism proposed for this reciprocal control is 
PLK phosphorylates NUAK1 which results in its binding to SCFBTrcp, ubiquitination and 
subsequent degradation.  
 
NUAK1 has also been shown to promote EMT in multiple cancer cell types (Ye, Chen, & 
Chen, 2018; Zhang, Li, Li, & Wang, 2015). In ovarian cancer cells, NUAK1 
overexpression increased levels of mesenchymal markers, decreased levels of epithelial 
markers, and increased the invasion and migratory properties of cells (Zhang et al., 
2015). Mechanistically, NUAK1 was shown to inhibit miR-1181 which promotes 
mesenchymal–epithelial transition (MET). miR-1181 also degrades homeobox protein 
Hox-A10 (HOXA10) which stimulates EMT. Altogether, this study suggested that a 
NUAK1/miR-1181/HOXA10 signaling axis can induce EMT in ovarian cancer cells 
(Figure 1.4). Moreover, another study showed that siRNA-mediated knockdown of 
NUAK1 decreased the migration of ovarian cancer monolayer cells in a wound healing 
assay (Phippen et al., 2016). Furthermore, in hepatocellular carcinoma cells NUAK1 has 
been shown to promote EMT (Ye et al., 2018).  In line with a role for NUAK1 in EMT, a 
prior study has implicated NUAK1 in promoting tumor invasion and metastasis (Kusakai, 
Suzuki, Ogura, Kaminishi, & Esumi, 2004). SCID mice injected with pancreatic cancer 
cells overexpressing NUAK1 had metastasis to the liver and in some cases to peritoneal 
sites whereas metastasis was not detectable in control mice. A previous report 
investigated the molecular basis by which NUAK1 can facilitate cell detachment 
(Zagórska et al., 2010). Using HEK293 and MEF cells, the authors showed that NUAK1 
can induce cell detachment through regulation of the myosin phosphatase complex. In 
response to LKB1 activation, NUAK1 interacts with the myosin phosphatase targeting-1 
(MYPT1)-protein phosphatase-1B (PP1B) complex (Figure 1.2). NUAK1 phosphorylates 
MYPT1, which facilities its binding to 14-3-3, an adaptor protein that inhibits MYPT1 
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phosphatase activity. This leads to enhanced myosin light chain-2 (MLC2) 
phosphorylation and subsequent cell detachment.  
 
Several studies have shown that NUAK1 can also promote cancer survival through 
sustaining metabolic homeostasis (Liu et al., 2012; Port et al., 2018). It was shown that 
NUAK1 is needed to maintain energy homeostasis in tumors overexpressing myc (Liu et 
al., 2012). Myc is known to enhance activation of anabolic pathways and cell 
proliferation in tumors. To manage energetic stress, NUAK1 inhibits mTORC1 to 
suppress protein translation (Figure 1.4). It also sustains glutamine metabolism in these 
Myc-driven cancers by maintaining efficient mitochondrial respiration (Figure 1.4). Loss 
of NUAK1 led to a reduction of ATP levels and decreased proliferation in hepatocellular 
and pancreatic carcinoma cells. Moreover, in colorectal tumors NUAK1 can provide 
protection from oxidative stress by promoting nuclear translocation of the anti-oxidant 
regulator, Nrf2 (Port et al., 2018). In response to oxidative stress, NUAK1 inhibits PP1B 
which has been shown to block AKT-mediated suppression of GSK3B, a negative 
regulator of Nrf2 (Figure 1.4).  Furthermore, loss of NUAK1 reduced colorectal tumor 
burden in mouse models, and the addition of an exogenous anti-oxidant reversed this 
phenotype.  
 
A tumor-promoting role for NUAK1 is further strengthened by studies showing that 
elevated levels of NUAK1 correlates with poor prognosis in multiple cancer types 
(Phippen et al., 2016; Port et al., 2018). It was shown that high NUAK1 transcript levels 
in serous ovarian cancer patients was associated with lower progression free survival and 
lower overall survival (Phippen et al., 2016). There was also an increased risk for 
diagnosis at an advanced stage and residual disease after cytoreductive surgery. 
Similarly, high levels of NUAK1 was associated with advanced stage colorectal cancer 
and reduced overall survival in patients (Port et al., 2018). 
 
While there is a large body of literature suggesting that NUAK1 serves to promote cancer 
survival, several studies have suggested that NUAK1 can have tumor suppressive roles 
under certain contexts. Using lung adenocarcinoma and melanoma cells, it was shown 
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that in response to LKB1 activation NUAK1 phosphorylates p53, leading to cell cycle 
arrest (Figure 1.4) (Hou et al., 2011). More specifically, LKB1, NUAK1, and p53 form a 
complex in the nucleus and bind to the CDKN1A promoter to induce expression of genes 
for arrest at the G1/S checkpoint. Beyond regulating the cell cycle, a potential tumor 
suppressive role for NUAK1 was shown by its ability to induce senescence and gross 
aneuploidies (Figure 1.4) (Humbert et al., 2010).  Using normal human diploid fibroblast 
cells, NUAK1 was shown to phosphorylate Large Tumor Suppressor Drosophila 
Homolog 1 (LATS1) leading to its degradation and an induction of senescence.  NUAK1 
was also shown to elevate aberrant DNA content in breast epithelial cells which led to 
increased apoptosis. 
 
1.9 Research goal, hypothesis, and objectives  
To further elucidate LKB1 signalling in ovarian cancer, I sought to investigate the 
regulation and function of one of its AMPK-related kinase targets, NUAK1. I 
hypothesized that the LKB1 target NUAK1 promotes ovarian cancer metastasis by 
regulating EOC cell adhesion and spheroid integrity. To test this hypothesis, I examined 
whether LKB1 regulates the expression of NUAK1 in ovarian cancer spheroids and 
tumor samples. I used a metastatic model to investigate the regulatory mechanisms 
controlling NUAK1 levels between monolayer cells and quiescent spheroids. I next 
examined whether NUAK1 functions in EOC cell adhesion and spheroid integrity. To 
discover the molecular basis for NUAK1-dependent adhesion phenotype, I completed 
transcriptome analysis using Clariom S microarrays with RNA isolated from OVCAR8 
parental and OVCAR8 NUAK1-KO cells and spheroids followed by pathway analysis 
using Gene Set Enrichment Analysis and subsequently validated fibronectin as a key 
target. This project has allowed me to elucidate the LKB1-NUAK1 pathway as critically 
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Chapter 2  
2 A novel role for the LKB1 target NUAK1 in promoting 
ovarian cancer spheroid formation through regulation of 
fibronectin deposition  
2.1 Introduction  
Ovarian cancer is the most lethal gynecologic malignancy and is characterized by early 
and rapid metastasis (Lheureux et al., 2019). Most women are diagnosed with advanced-
stage disease with a 5- year survival rate of only 29% (Siegel et al., 2019). The standard 
treatment plan for patients with late-stage ovarian cancer is maximal surgical 
cytoreduction with adjuvant chemotherapy of carboplatin and paclitaxel (Lheureux et al., 
2019). However, the majority of patients will eventually develop disease recurrence and 
resistence to chemotherapy (Bowtell et al., 2015b). Therefore, there is a need to develop 
novel therapeutic strategies to impede ovarian cancer metastasis.   
 
In ovarian cancer metastasis, malignant cells shed from the primary ovarian tumor and 
spread into the peritoneal cavity (Sodek et al., 2012). Ascites commonly accumulates in 
the peritoneal cavity of patients with advanced-stage disease (Al Habyan et al., 2018; 
Sodek et al., 2012). In the ascites fluid, cancer cells will form multi-cellular structures 
known as spheroids to evade anoikis, a form of apoptosis due to loss of cell attachment. 
Eventually spheroids will adhere to the peritoneum to continue to invade at secondary 
sites (Al Habyan et al., 2018; Lengyel et al., 2014). In addition to playing a key role in 
efficient peritoneal metastasis, spheroids acquire resistance to chemotherapy due to the 
acquisition of cellular quiescence (Desoize & Jardillier, 2000; Pease et al., 2012). 
The formation of spheroids is controlled by several cell attachments through cadherins 
and indirectly through extracellular matrix (ECM) proteins and integrins (Sodek et al., 
2012). In ovarian cancer, the interaction between the ECM protein fibronectin and the 
α5β1 integrin is known to be critical for the formation of spheroids (Casey et al., 2001). 
Integrins are the primary adhesion receptor that anchors the ECM to the intracellular 
cytoskeleton (Pankov & Yamada, 2002). These heterodimeric receptors are comprised of 
alpha and β subunits. Fibronectin exists as a soluble form in the plasma and as an 
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insoluble fibrillar form in the ECM (Pankov & Yamada, 2002). Fibronectin is a ligand for 
multiple integrins, however its canonical receptor is the α5β1integrin. Multiple studies 
have indicated a key role for fibronectin in ovarian cancer tumor progression. Elevated 
fibronectin expression has been correlated with worsened tumor stage and decreased 
overall survival in ovarian cancer patients (Franke et al., 2003). In mouse models, the loss 
of fibronectin reduced ovarian cancer cell adhesion, invasion, and tumor metastasis 
(Kenny et al., 2014).  
 
The elucidation of key intracellular signaling pathways in ovarian cancer spheroids 
would allow for improved understanding of metastatic processes and would aid in the 
identification of novel therapeutic targets. Our group previously showed that liver kinase 
B1 (LKB1) is critical for ovarian cancer metastasis (Buensuceso et al., 2018; Peart et al., 
2015). LKB1 (encoded by the STK11 gene) is a serine-threonine kinase that is frequently 
described as having tumor suppressive-like activity in other cancers (Gill et al., 2011; 
Guldberg et al., 1999). STK11 inactivating mutations lead to Peutz-Jeghers syndrome, a 
condition characterized by gastrointestinal polyps and an increased risk for cancer (Beggs 
et al., 2010; Hemminki et al., 1998). However, we have shown that it has context-specific 
functions because in late-stage ovarian cancer LKB1 facilitates tumor progression 
(Buensuceso et al., 2018; Peart et al., 2015). LKB1 is commonly expressed in established 
ovarian cancer cell lines, patient-derived ascites cells, and tumor extracts (Buensuceso et 
al., 2018). The sustained loss of LKB1 decreased anchorage-independent growth of EOC 
cells and decreased the viability of ovarian cancer spheroids. In a xenograft model of 
peritoneal metastasis, LKB1 loss extended survival and decreased tumor burden.  
The canonical downstream target of LKB1 is AMP-activated protein kinase (AMPK), a 
regulator of metabolic stress (Shackelford & Shaw, 2009). Interestingly, our group 
showed that LKB1’s pro-metastatic role in ovarian cancer occurs through AMPK-
independent signaling (Buensuceso et al., 2018; Peart et al., 2015). LKB1 is known as a 
master upstream kinase due to its ability to also regulate 12 other AMPK-related kinases 
(ARKs): BRSK1, BRSK2, NUAK1, NUAK2, QIK, QSK, SIK, MARK1, MARK2, 
MARK3, MARK4, and SNRK (Lizcano et al., 2004; Manning, Whyte, Martinez, Hunter, 
& Sudarsanam, 2002). It would be important to identify the key downstream substrate 
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that is allowing LKB1 to elicit its pro-metastatic function in ovarian cancer. In the study, 
we use a multiplex inhibitor bead-mass spectrometry analysis with cells and spheroids 
lacking LKB1 to show that NUAK1 is likely a key substrate enabling LKB1 to drive 
ovarian cancer metastasis.  
 
NUAK1 is a serine-threonine kinase that can be phosphorylated by LKB1 at a conserved 
threonine 211 residue on the T-loop of its catalytic domain (Lizcano et al., 2004). Prior 
studies have shown that NUAK1 has pro-tumorigenic functions. NUAK1 can promote 
cancer survival by inhibiting apoptosis and inducing the S-phase in the cell cycle. It can 
also protect tumors from oxidative stress by increasing nuclear translocation of the anti-
oxidant regulator, Nrf2 (Port et al., 2018). Previous work has also suggested that NUAK1 
can play a role in cell adhesion (Zagórska et al., 2010; Zhang et al., 2015). In ovarian 
cancer cells, NUAK1 has been shown to increase epithelial–mesenchymal transition 
EMT.  It can also stimulate cell detachment by regulating the myosin phosphatase 
complexes. A tumor-promoting role for NUAK1 is strengthened by studies showing that 
elevated levels of NUAK1 correlate with poor prognosis in several cancers, including 
ovarian cancer (Phippen et al., 2016; Port et al., 2018).  
  
In this study, we aimed to elucidate how NUAK1 facilitates LKB1 pro-tumorigenic 
functions in ovarian cancer. We show that LKB1 regulates the phosphorylation and 
expression of NUAK1 in ovarian cancer. We present evidence that NUAK1 controls key 
steps of the metastatic cascade by regulating ovarian cancer cell adhesion and spheroid 
integrity. Mechanistically, NUAK1 regulates fibronectin along with a network of 
adhesion molecules to control spheroid formation. We have identified novel function for 
the LKB1 target NUAK1 in promoting efficient ovarian cancer metastasis. Therefore, 
strategies targeting the downstream target of this master upstream kinase may have 






2.2 Materials and Methods   
 
2.2.1 Antibodies and Reagents  
Antibodies obtained against NUAK1(#4458S), LKB1 (#3050S), p-LKB1-Ser428 
(#3482S), LC3B (#2775), p65 (#D14E12), p-p65- Ser536 (#3033S), MEK1/2 (#9122), p-
MEK1/2-Ser217/221 (#9121), ERK1/2 (#9102), p-ERK1/2-Thr202/204 (#9101), JNK 
(#9252), p-JNK-Thr182/Tyr185 (#9251), and c-myc (#5605) were obtained from Cell 
Signaling Technology (Danvers, MA). Anti-Tubulin antibody (#T5168), Anti-Actin 
antibody (#A2066), anti-rabbit FITC secondary antibody (# F9887), HRP-conjugated 
antibodies against mouse IgG (NA931V) and rabbit IgG (NA934V), and 4′, 6-diamidino-
2-phenylindole were purchased from Sigma (St. Lewis, MO). Chloroquine (#C-6628), 
MG132 (#M8699), and methylcellulose (#M0512) were also obtained from Sigma. Anti-
fibronectin (#ab2413) was purchased from Abcam (Cambridge, Ma). Antibody against 
L1CAM (#SIG-3911) was obtained from Biolegend (San Diego, CA). Anti-USP9X 
(A301-350A) was purchased from Bethyl Laboratories (Montgomery, TX). PR-619, 
control agarose beads, agarose-TUBE2, and anti-ubiquitin antibody (#VU101) were 
purchased from Lifesensors (Malvern, PA). Alexa Fluor phalloidin and plasma human 
fibronectin (#PHE0023) was obtained from Thermo Fisher Scientific (Waltham, MA). 
WZ400 (#5177) was purchased from Tocris Bioscience.  
 
2.2.2 Cell culture and treatments  
OVCAR8 (ATCC, Manassas, VA) and HEYA8 (ATCC) cells were cultured in RPMI-
1640 (Wisent, St. Bruno, QC). OVCAR5 cells (ATCC) were cultured in DMEM-F12 
(Life Technologies, Carlsbad, CA). Early passage ascites-derived cell lines (iOvCa147, 
iOvCa198, iOvCa247) were generated based on a protocol described by us previously 
and cultured in DMEM-F12 (Shepherd et al., 2007). The growth media was 
supplemented with 10% fetal bovine serum (Wisent) for all cell lines. Cells were grown 
in a humidified incubator at 37oC with 5% C02.  
 
Adherent cells were maintained on tissue cultured-treated polystyrene (Sarstedt, Newton, 
NC). Spheroids were formed by maintaining cells on ultra-low attachment dishes 
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(Corning, NY) which have a hydrophilic and neutral coating to prevent cell attachment as 
described previously (Correa et al., 2014).  
 
For specific experiments, day 3 adherent cells and spheroids were treated with DMSO or 
MG132 (10 μM) for 8 hours. Cells were also treated or untreated with chloroquine (25 
μM) for 8 hours. 
 
2.2.3 Generation of OVCAR8 STK11-KO and OVCAR8 NUAK1-KO 
Cells  
The 20-nucleotide guide sequence targeting the STK11 gene 5’-AGCTT GGCCC 
GCTTG CGGCG-3’ was selected using CRISPR Design Tool (http://tools.genome-
engineering.org). Complementary oligonucleotides 5’-CACCG AGCTT GGCCC 
GCTTG CGGCG-3’ and 5’- AAACC GCCGC AAGCG GGCCA AGCTC-3’ (Sigma-
Genosys) were annealed and ligated into the BbsI-digested restriction endonuclease site 
of pSpCas9(BB)-2A-Puro plasmid (gift from Dr. F. Dick, Western University) to 
generate the pSpCas9-sgSTK11 plasmid (Ran et al.,  2013). Cells were seeded at 200,000 
cells/well into 6-well plates and transfected with 1 μg of pSpCas9-sgSTK11 plasmid 
using LipofectAMINE 2000 (Invitrogen) according to manufacturer’s instructions. Media 
containing 1 μg/mL puromycin was replaced the following day, and cells were treated for 
one day. After growth recovery, cells were trypsinized, counted, and seeded into 96-well 
plates to perform limiting dilution subcloning of potential STK11-knockout cells. Single 
colonies were expanded for protein isolation and confirmation of STK11 knockout by 
western blotting for LKB1. A minimum of five clones lacking LKB1 protein expression 
were positively identified and subsequently mixed in equal ratios to generate the 
STK11KO cell line populations.  
 
A similar protocol was followed to create NUAK1-KO cells. The 20-nucleotide guide 
sequence targeting the NUAK1 gene 5’-GTGGC GGGGG ACCGC CCCGA-3’ was 
selected using CRISPR Design Tool (http://tools.genome-engineering.org). 
Complementary oligonucleotides 5’- CACCG TCG GGG CGG TCC CCC GCC AC -
3’and 5’- CACCG GGG TCT CCT GCA GCT CGT AG -3’ (Sigma-Genosys) were 
annealed and ligated into the BbsI-digested restriction endonuclease site of 
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pSpCas9(BB)-2A-Puro plasmid. The same protocol described above was used for 
transfection and selection of clones lacking NUAK1 
2.2.4 Generation of HEYA8 and OVCAR3 NUAK1 overexpressing 
cells  
HeyA8 and OVCAR3 cells were transfected with pPHAGE C-TAP-NUAK1 
(HsCD00462473; Harvard PlasmID Database) using Lipofectamine 2000 (Invitrogen) 
according to manufacturer’s instructions. Forty-eight hours post-transfection, 1ug/mL 
puromycin (Sigma) treatment was started until single colonies remained. Cells were re-
plated into 10-cm dishes and selection was continued at 1ug/mL puromycin. Colonies 
were picked and expanded prior to screening for NUAK1 expression by western blot 
using lysates from parental cell lines for comparison. Empty vector control (EVC) cells 
were generated using the pPHAGE C-TAP plasmid for both cell lines and represent four 
pooled clones of each line subjected to the same puromycin selection process. 
2.2.5  Immunoblot analysis   
To obtain whole cell lysates from adherent culture, cells were collected after washing the 
plate with PBS and scraping cells in lysis buffer [50mM HEPES pH7.4, 150 mM NaCl, 
10% glycerol, 1.5 mM MgCl2, 1 mM EGTA, 1 mM sodium orthovanadate, 10 mM 
sodium pyrophosphate, 10 mM NaF, 1% Triton X-100, 1% sodium deoxycholate, 0.1% 
SDS, 1 mM PMSF. 1X protease inhibitor cocktail (Roche, Laval, QC), and 225mM β-
glycerophosphate]. For spheroids, after centrifugation (2400 rpm for 5 minutes) the 
media was aspirated and the pellet was resuspended in PBS and then centrifuged.  After 
removal of PBS, lysis buffer was added to the pellet. Protein was isolated and the protein 
concentration in the supernatant was measured with a Bradford assay (Bio-Rad 
Laboratories, Hercules, CA)  
 
To isolate cytoplasmic and nuclear fractions, adherent cells and spheroids were washed in 
PBS, resuspended in a hypotonic lysis buffer (20 mM HEPES (pH 7.4), 1 mM EGTA, 1 
mM EDTA and 1 mM DTT), and incubated on ice for 15 minutes. Spheroid lysates were 
passed through a 26G needle three times. After lysates were centrifuged, supernatant was 
collected for the cytoplasmic fraction. The nuclear pellet was washed three times with 
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wash buffer [10 nM HEPES (pH 7.4), 10 mM KCl, 0.1 mM EGTA and 0.1 mM EDTA]. 
The nuclear pellet was then resuspended in lysis buffer and clarified by centrifugation.  
Protein was isolated from tumor samples by homogenizing flash-frozen tissue in lysis 
buffer (50 mM HEPES pH7.4, 150 mM NaCl, 10% glycerol, 1.5 mM MgCl2, 1 mM 
EGTA, 1 mM sodium orthovanadate, 10 mM sodium pyrophosphate, 10 mM NaF, 1% 
Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 1 mM PMSF, 1X protease inhibitor 
cocktail). Solid tumor specimens had been collected from a xenotransplantion experiment 
described previously (Buensuceso et al., 2018).  
 
For immunoblot analysis, 30-50ug of protein was resolved by SDS-PAGE using 6%, 8% 
or 12 % gels. Proteins were transferred at 100V for 1 hour to a PVDF membrane (Roche), 
blocked with 5% milk or 5% BSA diluted in TBST (10 mM Tris–HCl, pH 8.0, 150 mM 
NaCl and 0.1% Tween-20). Membranes were incubated with primary antibodies 
overnight at 4 °C. To visualize immunoreactive bands, membranes were incubated for 1h 
with peroxidase-conjugated anti-rabbit or anti-mouse antibodies (1:10 000 in 5% BSA/ 
TBST) and exposed to chemiluminescence reagent (Luminata Forte, Millipore, 
Temecula, CA). Images were captured using the ChemiDoc™ Imaging System (Bio-Rad) 
and bands were quantified using Image Lab 4.1 software. 
2.2.6 PhostagTM Western Blot  
PhostagTM lysis buffer was prepared similar to above, however EGTA, sodium 
pyrophosphate and β-glycerophosphate were excluded from preparation. PhostagTM gels 
were prepared using PhostagTM solution (Wako Chem, Richmond, VA) and 10mM 
MnCl2, as 8% acrylamide gels, according to manufacturer’s protocol. Electrophoresis 
was run for ~3 hours, after which gels were washed for 10 minutes with 1x transfer 
buffer with 1mM EDTA, followed by 10 minutes with 1x transfer buffer without EDTA. 
Wet transfer was run for 1 hour on PVDF membranes (Immobilon-P). Membranes were 




2.2.7 Immunofluorescence   
Spheroids were embedded in cryo-matrix (Thermo Fisher) and sectioned with Shandon 
cryostat microtome at 5 μM. Cryosections were fixed (10% formalin solution), 
permeabilized (0.1% Triton X-100 in PBS), and blocked (5% BSA in 0.1% Triton X-
100). After overnight incubation with Anti-fibronectin antibody (1:100; #ab2413), 
sections were washed with PBS and then incubated for 1 hour with anti-rabbit FITC 
secondary antibody (1:300; # F9887). For counterstaining, sections were incubated for 1h 
with Alexa Fluor phalloidin (1:1000) followed by incubation for 1 hour with 4′, 6-
diamidino-2-phenylindole (1:1000).  Sections were mounted on coverslips with 
Vectashield (Vector Laboratories, Burlingame CA). Fluorescence images were captured 
using Olympus AX70 upright microscope and ImagePro image capture software.  
2.2.8  Quantitative RT-PCR  
Total RNA was isolated from adherent cells and spheroids using the RNeasy Mini Kit 
(Qiagen, Hilden, Germany). The concentration and purity of the RNA was determined 
with the ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE). 
Reverse transcription was performed using High Capacity cDNA Reverse Transcription 
Kit (Applied Biosystems, Foster City, CA). The resulting cDNA was used for qRT-PCR 
using Brilliant SYBR Green QPC1R Master Mix (Agilent Technologies/Stratagene, 
Mississauga, ON) and was run on the Quantstudios 3 (Applied Biosystems). Human-
specific primer sequences (Sigma) are described in table 2.1. GAPDH was used as an 
internal control. Relative gene expression was quantified by calculating 2 -∆∆Ct  (Livak & 
Schmittgen, 2001). 
2.2.9 Tandem Ubiquitin Binding Entities (TUBEs) 
OVCAR8 cells cultured as adherent cells or as spheroids were treated with MG132 (10 
μM, 8 hours) and a deubiquitinating enzyme inhibitor PR-619 (20 μM, 2 hours). Cells 
were collected, washed and lysed in buffer containing 50mM Tris-HCl, pH 7.5, 0.15M 
NaCl, 1mM EDTA, 1% NP-40, 10% glycerol, 10x protease inhibitor, and 100 μM PR-
619. Protein was isolated and the concentration was determined using a Bradford assay. 
Lysates were passed through a 25G needle three times on ice. Lysates containing 1 mg of 
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protein was incubated with 40 uL of pre-washed control agarose beads for 60 minutes at 
4°C. Unbound supernatant was removed and then incubated with 100 uL Agarose-
TUBE2 overnight at 4°C.  Beads were washed in 20mM Tris-HCl, pH 8.0, 0.15M NaCl, 
0.1% Tween-20 (TBS-T) and the unbound supernatant was removed. Beads were re-
suspended in 2x SDS loading buffer and boiled for 5 minutes to elute ubiquitinated 
proteins. Eluted samples were analyzed by western blot, immunoblotting for NUAK1, c-
myc, and total ubiquitin.  An input of 50ug of protein lysate along with an aliquot from 
the fraction not bound to control agarose or agarose-TUBEs were also analyzed by 
western blot. The western blot procedure was completed as described above except 
transfer occurred at 30V for 2.5 hours and the stacking gel was included for the transfer.   
2.2.10 Determination of Doubling Time  
Cells were seeded into a 96-well adherent culture at a density of 2000 cells per well. The 
following day, cells were treated with DMSO or 0.5 μM of WZ4003. Using the Incucyte 
ZOOM (Essen Bioscience, Ann Arbor, MI), confluence was measured for 3 days by 
capturing phase contrast images every 3 hours. To calculate doubling time, an 
exponential growth curve was fitted to the confluence-over-time results in Graphpad 
PRISM. 
 
To calculate doubling time for OVCAR8 NUAK1-KO and HEYA8 NUAK1 
overexpressing cells along with their respective controls, cells were transfected with 
NucLight Green Lentivirus Reagent (Essen BioScience) and selection was completed 
using bleomycin (10 μg/ml) (#203408) (Sigma). OVCAR8 cells and OVCAR8 NUAK1-
KO cells labelled with GFP were seeded at 1500 cells per well in ultra-low attachment 
dishes (ULA, Corning). HEYA8 cells and HEYA8 NUAK1 overexpressing cells labelled 
with GFP were seeded at 1000 cells per well in ULA plates.  IncuCyte Zoom imaging 
system measured number of GFP-labeled nuclei per field of view every 2 hours. 
Doubling time was calculated by fitting an exponential growth curve to GFP-labeled 




2.2.11 IncuCyte Zoom Live Cell Analysis System to image spheroid 
morphology in real-time 
OVCAR8 cells and OVCAR8 NUAK1-KO cells labelled with GFP were seeded at 5000 
cells/ well in round bottom ultra-low attachment dishes (ULA, Corning). The ULA plates 
were placed in IncuCyte Zoom (Essen BioScience) for 17 days and spheroids were 
imaged every 3 hours.   
2.2.12  Phase contrast images of spheroids  
To facilitate spheroid formation, cells were seeded in a 24 well ULA dish (1000 cells per 
well) and cultured in complete media and methylcellulose (Leung, Lesher-Perez, 
Matsuoka, Moraes, & Takayama, 2015; Ware et al., 2016). For the fibronectin rescue 
experiment, 5 ug/ml of plasma fibronectin was also included in the media. After 11 days, 
spheroids were washed with PBS and transferred to a new ULA dish with only complete 
media. Images were immediately taken with the Leica DMI 4000B inverted microscope 
using the Leica Application Suite version 4.4 software. 
2.2.13  Spheroid viability assay  
Spheroids from 24-well ULA plates were transferred to 1.5mL Eppendorf tubes and 
centrifuged at 4000rpm for 5 minutes. Media was completely aspirated from tubes, 
without disturbing spheroid pellet. Pellets were washed twice with 1mL of PBS, and 
centrifuged at 4000rpm for 5 minutes between each wash. A volume of 250μL of trypsin- 
EDTA (0.25%) was added to each sample and pellet was resuspended in trypsin-EDTA. 
Samples were left in 37oC water bath for 30 minutes, and were vortexed every 10 minutes 
during this time. After incubation, 250μL of FBS was added to each sample to inactivate 
trypsin. Pellet was resuspended in mixture and completely dissociated using trituration. 
Each sample was aliquoted at 50 μL into new Eppendorf tubes. An additional 50 μL of 
Trypan Blue dye (ThermoFischer Scientific) was added to each tube and vortexed. The 
mixture was pipetted at a 15 μL volume on to cell counter slide and viability readings 
were taken using TC10 cell counter (Bio-Rad). Total cell number and live cell number 
were recorded, indicating Trypan Blue excluded cells (Strober, 2001).  
2.2.14  Timed adhesion assay  
Cells were seeded in a 24 well adherent dish at 200 000 cells per well. After a specified 
amount of time (15 minutes for HEYA8 cells, 2 hours for OVCAR3 cells, and 4 hours for 
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OVCAR8 cells), non-adherent cells were aspirated, the plate was washed with PBS, and 
adherent cells were counted with Trypan blue cell counting to quantify single cell 
adhesion.  
2.2.15  Small-interfering RNA Transfection  
Cells were seeded at a density of 2.5 x 10
5 
cells/well in a 6-well dish. The following day 
cells were transfected according to the manufacturer’s protocol (Dharmacon, Thermo 
Fisher Scientific). Briefly, 4 uL of DharmaFECT-1 (T-2001-02) was combined with 10 
nM of siRNA in 2 ml of media and allowed to incubate for 20 minutes. NUAK1 (M-
004931-00), USP9X (M-006099-02), and non-targeting control pool (D-001206-14-05) 
siGenome SMARTpool siRNAs were obtained from Dharmacon. The 
siRNA/DharmaFect1 complexes were then added to the wells. 24 hours after transfection 
the media was replaced. After transfection (72 hours) cells were trypsinized and seeded 
for experimental conditions (6-well, 24- well, 96-well). Three days after seeding cell 
viability was measured with the TC10 cell counter as described above (Bio-Rad). Lysates 
were also collected 3 days post-seeding for western blot analysis.  
2.2.16  Tritiated Thymidine Incorporation Assay  
Cells were seeded in adherent and spheroid culture in 24-well format, at a density of 50 
000 cells/well. Spheroids were immediately treated with 0.5μM WZ4003 at time of 
seeding. Adherent cells were treated with 0.5μM WZ4003 the following day. Cells were 
exposed to tritiated thymidine 24 hours after treatment. Tritiated thymidine was added (1 
μCi/μL) to each well and incubated for either 24 hours for spheroids or 2 hours for 
adherent cells. For spheroids, media was collected and cells were pelleted. Cell pellets 
were washed twice in cold 1x PBS followed by cold 10% TCA (trichloroacetic acid, 
Sigma). Cells were lysed by adding 500 μL of lysis buffer (1N NaOH/0.1% SDS) to the 
pellet and resuspending. For adherent cells, wells were washed twice in cold 1x PBS 
followed by a wash with cold 10% TCA. Cells were lysed in the wells by adding 500 μL 
of lysis buffer. For spheroids and adherent cells, 400 μL of cell lysate was then added to 
400 μL of 1N HCl and mixed with 5 mL of scintillation fluid (ScintiVerse BD Cocktail, 
Fisher Chemical) in scintillation vials. Counts per minute (cpm) was measured using a 
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liquid scintillation counter (MacDonald et al., 2016).  
2.2.17 Multiplexed Inhibitor Bead (MIB) Chromatography  
Lysates were collected from OVCAR8 parental and OVCAR8 STK11-KO cells cultured 
as adherent cells and spheroids. Multiplexed Inhibitor Bead (MIB) Chromatography was 
performed as described below.  
 
Broad spectrum Type I kinase inhibitors (CTx0294885, VI-16832, PP58, Purvalanol B, 
UNC-2147A, UNC-8088A) were custom-synthesized with hydrocarbon linkers and 
terminal amine groups and covalently attached to ECH-activated Sepharose beads as 
previously described (Stuhlmiller et al., 2015)to form the multiplexed inhibitor beads. 
Enrichment of kinases from OVCAR8 cells by MIB chromatography was adapted from 
(Duncan et al., 2012).  Cell pellets were lysed in MIB lysis buffer (50 mM Hepes pH 7.5, 
150 mM NaCl, 0.5% Triton X-100, 1 mM EDTA, 1 mM EGTA freshly supplemented 
with 10 mM NaF, 2.5 mM NaVO4, protease inhibitor cocktail (Sigma-Aldrich, Catalog 
#P8340), phosphatase inhibitor cocktail 2 (Sigma-Aldrich, Catalog #P5726) and 
phosphatase inhibitor cocktail 3 (Sigma-Aldrich, Catalog #P0044)) while on ice for 20 
minutes. The lysate was homogenized with an 18-gauge syringe needle and centrifuged at 
20,800 x g for 15 minutes at 4oC.  The total protein amount in the supernatant was 
quantified using the Bio-Rad protein assay (Catalog #5000006) according to the 
manufacturer’s instructions.  The supernatant was brought to 1M NaCl and 4 mg of total 
protein was loaded on a column (Bio-Rad, Catalog #731-1550) of 100 µl packed ECH 
sepharose 4B (GE Healthcare, Catalog # 17057101), pre-equilibrated with 2 ml of high 
salt Buffer B (50 mM Hepes pH 7.5, 1 M NaCl, 0.5% Triton X-100, 1 mM EDTA, 1 mM 
EGTA).   The flowthrough was transferred to a column consisting of layered MIBs (50 l 
each of a 50% slurry of CTx0294885, VI-16832, PP58, Purvalanol B, UNC-2147A, and 
UNC-8088A) pre-equilibrated with 2 ml of Buffer B.  The flowthrough was reapplied to 
the column and the column was then washed with 5 ml of Buffer B and 5 ml of 50 mM 
ammonium bicarbonate (ABC). After washing, the beads were transferred to 1.5 ml 
centrifuge tubes in 1 ml of 50 mM ABC and washed twice more in 1 ml of 50 mM ABC.  
The samples were digested overnight at 37oC with 1 g trypsin and LysC (Promega, 
Catalog # V5073).  The supernatant was collected and the samples were reduced in 5mM 
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DTT at 53oC for 30 min, cooled to room temperature and then alkylated in 10 mM 
iodoacetamide in the dark at RT for 45 min.  Trypsin (Sigma-Aldrich, Catalog # T6567) 
was added and the samples were incubated at 37oC for 4 hours. Formic Acid was added 
to a final concentration of 2%, and the samples were dried by speed vac.   
2.2.18 Mass Spectrometry Analysis 
Digested peptides were dissolved in 5% Formic Acid and transferred to autosampler vials 
for analysis by nano-LC-MS/MS using a SCIEX 5600 TripleTOF mass spectrometer and 
an Eksigent Ultra nanoHPLC. Samples were loaded onto a home-packed emitter tip 
column (15 cm x 75 um; 3 m C18, Reprosil, Dr. Maisch). After sample loading, a linear 
gradient from 2% acetonitrile to 35% acetonitrile over 90 min at 200 nl/min was used to 
elute all peptides. A further increase to 80% acetonitrile from 90 min – 95 min, hold from 
95 min – 105 min at 80% acetonitrile and return to 2% acetonitrile from 105 min to 120 
min was used to ensure full peptide elution. During peptide elution, data was acquired on 
the mass spectrometer in data-independent acquisition (DIA) mode. Cycle time was 3.5 
seconds, consisting of a 250 ms MS1 scan (400-1250 Da) and 34 x 25 Da SWATH 
windows covering the range of 400-1250 m/z.  
2.2.19 Mass Spectrometry Data Analysis 
All raw MS files were saved in our local interaction proteomics LIMS, ProHits (G. Liu et 
al., 2010).  The WIFF raw files were converted into mzXML format using the SCIEX 
converter through the Proteowizard module implemented within ProHits. The mzXML 
files were processed by the signal extraction (SE) module of DIA-Umpire (version 2.0, 
[Tsou et al., 2015]). to generate pseudo MS/MS spectra for data base searches.  The 
following parameters were used: isolation window (fixed, 25 Da), fragment grouping 
(RPmax 25, RFmax 300, correlation threshold 0.2, delta apex 0.6, RT overlap 0.3), signal 
extraction parameters (mass tolerance (30 ppm MS1, 40 ppm MS2), signal to noise (2 for 
MS1 and MS2), minimum intensity threshold (1 for MS1, 0.1 for MS2),  charge state 
range (2+ to 4+ for MS1 and MS2), maximum curve in RT range (1.5), and resolution 
(17,000).  Files were searched using X! tandem (version Jackhammer, 2013.06.15.1) and 
Comet (version 2014.02 revision 2) using the following parameters: allow tryptic 
peptides only, carbamidomethylation on cysteine as a fixed modification, and 
deamidation on asparagine and glutamine, oxidation on methionine, and phosphorylation 
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on serine, threonine and tyrosine as variable modifications.  Additional Comet parameters 
were 2 missed cleavages, monisotopic parent and fragment mass, 35 ppm peptide mass 
tolerance, 2+ to 4+ precursor charge state, fragment ion binding (1.005 amu with 0.4 
offset).  Additional X! tandem parameters were:  1 missed cleavage, 50 ppm parent mass 
error, 40 ppm fragment mass error, monoisotopic fragment, 4+ maximum parent charge.  
The searched database contained the human and adenovirus complements of the RefSeq 
protein database (version 57) supplemented with ‘‘common contaminants’’ from the Max 
Planck Institute (http://141.61.102.106:8080/share.cgi?ssid=0f2gfuB) and the Global 
Proteome Machine (GPM; http://www.thegpm.org/crap/index.html) as well as sequences 
from common fusion proteins and epitope tags. The sequence database consisted of 
forward and reversed sequences; in total 72,226 sequences were searched.  The resulting 
Comet and X! tandem search results were individually processed by PeptideProphet 
(Keller, Nesvizhskii, Kolker, & Aebersold, 2002), and peptides were assembled into 
proteins using parsimony rules first described in ProteinProphet  (Nesvizhskii, Keller, 
Kolker, & Aebersold, 2003) into a final iProphet (Shteynberg et al., 2011) protein output 
using the Trans-Proteomic Pipeline (TPP; Linux version, v4.7, Polar Vortex rev 1, Build 
201410231114). TPP options were as follows: general options were -p0.05 -x20 -PPM - 
d’’DECOY,’’ iProphet options were pPRIME and PeptideProphet options were pPAEd.  
Parameters for DIA-Umpire Quant (version 2.0) were peptide FDR (0.05), protein FDR 
(0.05), probability threshold (0.9), filter weight (group), minimum weight (0.9), top 
number of fragments (20), top number peptides (20), and frequency (0).  mapDIA 
analysis (version 2.3.3, [Teo et al., 2015]) was then performed on the DIA-Umpire results 
for intensity normalization, selection of fragments and peptides and determination of 
significantly changed proteins.  For this, only peptides that were unique at the gene level 
were considered.  mapDIA used the following parameters: impute (group 0.9, missing 
values are assigned 0.9 of the smallest value of the group in the row;  if none above zero, 
then 0.9 the smallest value of the column), experimental design (replicate), normalization 
(retention time normalized with standard deviation of 10, rounded to 2 decimal places 
(RT 10 2)), standard deviation factor (SDF) filter (2), minimum correlation (2), minimum 
observation (2), minimum fragments per peptide (3), maximum fragments per peptide 
(5), minimum peptides per protein (2), maximum peptides per protein (infinity), 
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minimum proportion of differentially expressed proteins (0.01), and maximum proportion 
of differentially expressed proteins (0.99). 
2.2.20  Transcriptome analysis and GSEA  
RNA was isolated from OVCAR8 parental spheroids and OVCAR8 NUAK1-KO 
spheroids as described above. The RNA was reverse transcribed into cDNA and then 
labelled with biotin using the Affymetrix Genechip WT pico kit (Thermo Fisher 
Scientific). The labelled cDNA was hybridized to the Human Clariom S microarray 
(Thermo Fisher Scientific). After washing, the microarray was scanned using the 
Affymetrix Gene Chip Scanner 3000. Data analysis was completed with the 
Transcriptome Analysis Console software at the Centre for Applied Genomics at 
SickKids (University of Toronto).  
 
Pathway analysis was completed using Gene set enrichment analysis (GSEA) version 3.0 
developed by the Broad institute at MIT (Subramanian et al., 2005). The gene list was 
imported into GSEA without limiting the genes by applying cut-offs.  GSEA identifies 
groups of genes that are enriched in a gene list.  The Hallmark collection of 50 gene sets 
and the Curated Canonical collection of 1329 gene sets from the Molecular Signatures 
Database (MSigDB, Broad Institute) were used for the analysis. These gene sets were 
limited to those with 15 to 500 genes. Permutations were completed 1000 times. Signal-
to-noise was calculated and used to rank genes based on their differential expression. 
Significant gene sets were those with a p< 0.05 and an FDR< 0.25. 
2.2.21  Statistical analysis  
Statistical analysis was completed using Graphpad PRISM 7 (GraphPad Software, San 
Diego, CA). Analyses were performed using two-tailed Student’s t-test, one-way 
ANOVA, and two-way ANOVA followed by Sidak’s or Tukey’s post-hoc test. A p-value 




2.3 Results  
2.3.1 NUAK1 expression is regulated by the master stress kinase 
LKB1 in ovarian cancer spheroids and xenograft tumors 
We previously showed that the master upstream kinase LKB1 is needed for efficient 
ovarian cancer metastasis (Buensuceso et al., 2018; Peart et al., 2015). While AMPK is 
the canonical target of LKB1, our group showed that LKB1’s pro-metastatic role in 
ovarian cancer likely occurs through AMPK-independent signaling (Shackelford & 
Shaw, 2009). To elucidate at least one key substrates of LKB1 mediating its tumor-
promoting functions in ovarian cancer, multiplex inhibitor bead-mass spectrometry 
(MIB/MS) was completed. Briefly this involves the use of multiplex inhibitor beads 
(MIBs) which are immobilized kinase inhibitors that will capture kinases present in 
lysates. MIBs can be coupled to mass spectrometry to identify and quantify the kinases. 
Our MIB/MS analysis was completed using OVCAR8 parental and OVCAR8 STK11-KO 
cells generated by CRISPR/CAS9 that lack LKB1 expression (Figure 2.1A-B). Out of 12 
ARKs, NUAK1 was the only ARK that was significantly decreased in STK11-KO 
adherent cells and spheroids. It was also the 6th most down-regulated kinase overall (-2.8 
fold change in adherent cells; -8.75 fold change in spheroids) (Table S 2.2 and Table S 
2.3). Therefore, this discovery based the MIB/MS analysis provided a rationale to pursue 































































































































































































Figure 2.1 NUAK1 expression is regulated by the master stress kinase LKB1 in ovarian 
cancer spheroids and xenograft tumors. 
 (A) Western blot analysis of OVCAR8 parental and OVCAR8 STK11-KO cells to 
confirm the loss of LKB1 expression in CRISPR/CAS9 genome edited cell lines. (B) 
Multiplexed kinase inhibitor bead-mass spectrometry analysis was completed using 
OVCAR8 STK11-KO cells and OVCAR8 parental cells. Log2fold change is presented 
for STK11 –KO/parental for both adherent culture and spheroid culture. Points on graph 
represent differentially expressed kinases as determined by multiplex inhibitor beads-
mass spectrometry (NUAK1 colored in red). (C) Immunoblot analysis to determine 
NUAK1 levels in OVCAR8 parental and OVCAR8 STK11-KO cells cultured as 
monolayer cells (Adh) or as spheroids (Sph). Tubulin was used as a loading control. 
Densitometric analysis shows NUAK1 expression relative to tubulin and normalized to 
parental control. Two-way ANOVA was performed followed by Tukey’s post-hoc test (*, 
p<0.05; ****, p<0.0001). (n=3) (D) Immunoblot analysis was completed using 
PhostagTM acrylamide gels to determine phosphorylated NUAK1 expression in OVCAR8 
parental and OVCAR8 STK11-KO cells cultured as adherent cells (adh) and spheroids 
(sph). Tubulin was used as a loading control. Densitometric analysis shows p-NUAK1 
expression relative to tubulin and normalized to parental control. Two-tailed Student’s t-
test was performed (****, p<0.0001). (n=3) (E) Immunoblot analysis of NUAK1 
expression in OVCAR8 parental and OVCAR8 STK11-KO tumors. 6-week old NOD-
SCID females were administered OVCAR8 parental or OVCAR8 STK11-KO cells by 
intraperitoneal injection. Necropsy was performed on day 51 to remove tumors. 
Densitometric analysis showing NUAK1 expression relative to tubulin for parental 
tumors (n=5) and STK11-KO tumors (n=7). Analysis was performed using two-tailed 
Student’s t-test (*, p<0.05). MIB/MS preparation and analysis was completed by Dr. 
Adrian Buensuceso and Dr. Trevor Shepherd. Parima Saxena completed the Phostag 







To confirm the MIB/MS results, we assessed NUAK1 expression by immunoblot 
analysis. There was a significant decrease in NUAK1 expression levels in OVCAR8 
STK11-KO spheroids (Figure 2.1C). To further study the regulation of NUAK1 by this 
master upstream kinase, the ability of LKB1 to control NUAK1 phosphorylation was 
examined.  Because there are no commercially available antibodies to detect NUAK1 
phosphorylation by LKB1 at threonine 211, the established target site for NUAK1, 
PhostagTM acrylamide gels were used (Lizcano et al., 2004; Tomida, Kitao, Kinoshita, & 
Takata, 2008). There was a significant decrease in phosphorylated-NUAK1 in OVCAR8 
STK11-KO spheroids (Figure 2.1D). Thus, NUAK1 expression and phosphorylation both 
appear to be regulated by LKB1 in EOC cells and spheroids.  
 
Next, we wanted to test if LKB1 also regulates NUAK1 expression levels in tumors. 
Tumor samples were collected from a prior EOC xenograft study (Buensuceso et al., 
2018). NOD-SCID female mice were administered OVCAR8 parental cells or OVCAR8 
STK11-KO cells. Tumors were removed on day 51 and protein was isolated for western 
blot analysis. Despite variability in NUAK1 expression amongst the tumor sample 
conditions, there was a significant decrease in NUAK1 expression in STK11-KO tumors 
(Figure 2.1E). Altogether, our findings suggest that LKB1 regulates NUAK1 expression 
in ovarian cancer spheroids and tumor samples.  
2.3.2 NUAK1 expression is differentially expressed in spheroids 
and this is mediated by the ubiquitin-proteasome system and 
lysosomal degradation  
In ovarian cancer, spheroids are the primary mediator of metastasis. Spheroids are 
commonly found in patient ascites and are critical for efficient dissemination as they 
resist anoikis and adhere to the peritoneum to invade at secondary sites (Lengyel et al., 
2014; Sodek et al., 2012, 2009). Using an in vitro model for metastasis, we sought to 
understand if NUAK1 expression levels change. NUAK1 expression was compared 
between proliferative adherent cells and quiescent spheroids (Al Habyan et al., 2018). By 
examining spheroids generated from high-grade serous ovarian cancer (HGSOC) 
established cells lines (OVCAR8 and OVCAR5), we found that NUAK1 protein levels 
are down-regulated in spheroids compared to monolayer (Figure 2.2A) (Domcke, Sinha, 
Levine, Sander, & Schultz, 2013). This trend was also apparent in multiple ascites-
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derived cell lines cultured as spheroids , including cells from a stage IIIB HGSOC patient 
when she received 6 cycles of carboplatin and paclitaxel (iOvCa198) and later when she 
developed carboplatin resistance (iOvCa247) (Figure 2.2A). As a control, a non-HGSOC 
cell line (HEYA8) was examined. HEYA8 cells are a moderately differentiated papillary 
cystadenocarcinoma (Hernandez et al., 2016).  In contrast to HGSOC spheroids, HEYA8 
spheroids showed increased NUAK1 compared to monolayer cells, suggesting this down-
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Figure 2.2 NUAK1 expression is differentially expressed in spheroids and this is 
mediated by the ubiquitin-proteasome system and lysosomal degradation. 
(A) Immunoblot analysis to assess NUAK1 expression in HGSOC cell lines (OVCAR8, 
OVCAR5), a non-HGSOC cell line (HEYA8), and patient-derived ascites cell lines 
(iOvCa147, iOvCa198, iOvCa247) cultured under adherent (adh) or suspension (sph) 
conditions. Tubulin and actin were used as loading controls. NUAK1 expression fold 
change is indicated on the immunoblots. (B) Time course analysis of NUAK, p-LKB1 
(S428), and total LKB1 in OVCAR8 spheroid formation. Densitometric analysis shows 
pixel intensity volume for NUAK1 relative to tubulin, p-LKB1 relative to LKB1, and 
LKB1 relative to tubulin. One-way ANOVA and Sidak’s multiple comparison test was 
performed (*, p<0.05; ***, p<0.001). (n=3) (C) RT-qPCR analysis of NUAK1 gene 
expression in OVCAR8 parental and STK11-KO cells cultured under adherent (adh) 
conditions or as spheroids (sph). Gene expression is relative to GADPH and normalized 
to parental adherent. Two-way ANOVA and Tukey’s multiple comparisons test was 
performed (NS= non-significant). (n=3) (D) Immunoblot analysis of NUAK1 expression 
in OVCAR8 cells and OVCAR8 STK11-KO cells treated with DMSO or MG132 (10 μM 
for 8h). Cells were cultured in adherent (adh) conditions or as spheroids (sph). Data is 
quantified as NUAK1 expression relative to tubulin and normalized to DMSO adherent. 
Two-way ANOVA and Tukey’s multiple comparisons test was performed (NS= not 
significant; *, p< 0.05, **, p<0.01, ****, p<0.0001) (n=3) (E) Immunoblot analysis of 
NUAK1 and USP9X expression in OVCAR8 cells transfected with control siRNA (siNT) 
or siRNA targeting USP9X. Cells were cultured in adherent (adh) conditions or as 
spheroids (sph). Data is quantified as NUAK1 expression relative to tubulin and 
normalized to siNT control. Two-way ANOVA and Tukey’s multiple comparisons test 
was performed (**, p<0.01, ***, p<0.001). (n=3) (F) Immunoblot analysis of NUAK1 
and LC3 1 and II expression in OVCAR8 cells treated with chloroquine (8h; 25 μM) or 
untreated. Cells were cultured in adherent (adh) conditions or as spheroids (sph). Data is 
quantified as NUAK1 relative to tubulin and normalized no treatment control. Two-way 




To study these changes in NUAK1 expression in greater detail, time course analysis was 
completed in OVCAR8 spheroids (Figure 2.2B). During early spheroid formation, 
NUAK1 expression is relatively high and this parallels the increased levels of phospho-
LKB1 levels in spheroids (Figure 2.2B). NUAK1 levels decrease significantly compared 
to monolayer later during spheroid formation and this correlates with the drop in 
phospho-LKB1. NUAK1 continues to be expressed at a lower yet detectable level at 
these later points (Figure 2.2B). Interestingly, total LKB1 expression starts to increase in 
late spheroid formation (Figure 2.2B). This trend supports our previous data which 
implicates LKB1 as being critical for ovarian cancer metastasis (Buensuceso et al., 2018; 
Peart et al., 2015)  
 
To understand the mechanism that mediates this decrease in NUAK1 levels in spheroids, 
we first performed RT-qCR to determine whether NUAK1 is regulated at the transcript 
level. There was no significant difference in NUAK1 gene expression between adherent 
cells and 24h spheroids (Figure 2.2C). Furthermore, there was no significant difference in 
NUAK1 mRNA between parental and STK11-KO conditions. These results suggest that 
the regulation is not occurring at the transcriptional level but rather NUAK1 expression is 
being controlled at the protein level whether it be translational or post-translational. 
Interestingly, previous studies have shown that NUAK1 protein levels can be regulated 
by the ubiquitin-proteasome system (UPS) (Banerjee et al., 2014). Hence, we sought to 
test whether the UPS was playing a role in NUAK1 down-regulation by treating cells 
with the proteasome inhibitor, MG132. The addition of MG132 to OVCAR8 cells 
prevented the decrease in NUAK1 levels in spheroids and significantly increased levels 
of this kinase (Figure 2.2D). These findings suggest that the UPS regulates NUAK1 
expression in spheroids and contributes to the down-regulation of this kinase. 
Intriguingly, in spheroids absent of LKB1, MG132 did not significantly increase NUAK1 
levels in OVCAR8 cells (Figure 2.2D). These results support the importance of LKB1 in 
regulating NUAK1 expression levels in spheroids.  
 
A previous report indicated that NUAK1 is ubiquitinated and the Ubiquitin Specific 
Peptidase 9 X-Linked (USP9X) can remove the polyubiquitin modification on NUAK1 
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(Al-Hakim et al., 2008). To continue to examine the involvement of the UPS in 
controlling NUAK1 expression, we tested whether USP9X regulates NUAK1 levels in 
spheroids. Using an siRNA-mediated approach to knockdown USP9X, we predicted that 
reduced levels of USP9X would lead to decreased NUAK1 expression possibly by 
promoting its degradation at the proteasome. Indeed, USP9X knockdown significantly 
decreased levels of NUAK1 in OVCAR8 adherent cells and spheroids (Figure 2.2E). 
Therefore, USP9X regulates NUAK1 expression in EOC spheroids.  
 
Based on our results implicating the UPS in regulating NUAK1 levels in spheroids, we 
next examined levels of ubiquitinated-NUAK1 in EOC. We predicted that if the UPS was 
contributing to the down-regulation of NUAK1 in spheroids there may be increased 
levels of ubiquitinated-NUAK1 in spheroids compared to adherent cells. To test this, 
cells were treated with a proteasome inhibitor and deubiquitinase inhibitor to preserve the 
ubiquitin modification (Emmerich & Cohen, 2015). To pulldown ubiquitinated proteins, 
lysates were incubated with Tandem Ubiquitin Binding Entities (TUBEs) which capture 
all types of ubiquitin linkages (Emmerich & Cohen, 2015). Subsequently, 
immunoblotting for NUAK1 should be able to detect endogenous ubiquitinated-NUAK1. 
c-myc was used as a positive control based on a prior report showing that it is 
ubiquitinated in OVCAR8 cells (Kedves et al., 2017). While ubiquitinated-c-myc was 
present in spheroids, ubiquitinated-NUAK1 was not detected in adherent cells or 
spheroids (Figure S2.1). These results suggest that NUAK1 may not be highly 
ubiquitinated in ovarian cancer cells.  
 
While the UPS is the primary degradation pathway for short-lived and small proteins, the 
autophagy-lysosome pathway is another degradation system in eukaryotic cells 
responsible for the clearance of large and damaged proteins. In response to stress from 
nutrient deprivation and hypoxia, autophagy can be activated as a survival mechanism 
due to its ability to recycle cellular components and nutrients. Indeed, our group and 
others have shown that autophagy is activated in ovarian cancer and spheroids have 
higher levels of autophagy compared to monolayer cells (Correa et al., 2014; Lu et al., 
2008; Wang et al., 2018). To determine if lysosomal degradation contributes to NUAK1 
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down-regulation spheroids were treated with the lysosome inhibitor, chloroquine. 
Chloroquine treatment led to a significant increase in NUAK1 expression levels in 
spheroids; NUAK1 levels in adherent cells approached significance after chloroquine 
treatment (Figure 2.2F). Altogether these findings suggest while the UPS controls 
NUAK1 expression, the lysosome is also implicated in regulating NUAK1 in spheroids 
compared to adherent cells.   
2.3.3 NUAK1 controls EOC cell adhesion and ovarian cancer 
spheroid integrity  
Prior studies have indicated that NUAK1 can play a role in cell adhesion (Ye et al., 2018; 
Zagórska et al., 2010; Zhang et al., 2015). NUAK1 promotes EMT in cancer cells and 
induces cell detachment by regulating the MYPT-PP1β complex. Cell adhesion is critical 
in the context of ovarian cancer metastasis because cell-ECM interactions have been 
shown to mediate the formation of ovarian cancer spheroids (Casey et al., 2001; 
Doberstein et al., 2018).  Therefore, we aimed to determine whether NUAK1 regulates 
cell adhesion in ovarian cancer in several EOC cell lines.  To investigate the role of 
NUAK1 in ovarian cancer metastasis, we used OVCAR8 cells (HGSOC), OVCAR3 
(HGSOC), and HEYA8 (moderately-differentiated high-grade ovarian cancer) because 
they readily form dense spheroids in vitro and can establish tumors when injected i.p into 
immune-compromised mice. OVCAR8 cells express high levels of NUAK1, while 
OVCAR3 and HEYA8 cells express very low levels of NUAK1. We generated a stable 
line lacking NUAK1 expression (OVCAR8 NUAK1-KO) using CRISPR-Cas9 genome 
editing (Figure 2.3A). We engineered the OVCAR3 and HEYA8 cell lines to stably 
overexpress NUAK1 (Figure 2.3A). To examine NUAK1’s ability to regulate adhesion 
timed adhesion assays were completed. By measuring the number of cells that adhered to 
a tissue culture plate after 15 minutes, we found that HEYA8 NUAK1 overexpressing 
cells had significantly greater single cell adhesion compared to HEYA8 cells (Figure 
2.3B). Similarly, after 2 hours OVCAR3 NUAK1 overexpressing cells had significantly 
greater cell adhesion (Figure 2.3B). In examining the reciprocal system, after 4 hours 
OVCAR8 NUAK1-KO cells had significantly lower cell adhesion compared to OVCAR8 
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Figure 2.3 NUAK1 regulates EOC cell adhesion and ovarian cancer spheroid integrity 
 (A) Immunoblot analysis of OVCAR8 NUAK1-KO, HEYA8 NUAK1-overexpressor, and 
OVCAR3 NUAK1 cells and matched controls to validate loss or overexpression of 
NUAK1. Tubulin is used as a loading control. (B) Single cell adhesion was quantified 
with Trypan blue cell counting for OVCAR8 NUAK1-KO, HEYA8 NUAK1 and 
OVCAR3 NUAK1 cells and matched controls. Data is presented as absolute cell counts 
from pooled data among multiple clones. Analysis was performed using two-tailed 
Student’s t-test (**, p < 0.01). (n=3) (C) Images of OVCAR8 parental and OVCAR8 
NUAK1-KO spheroids cultured for 11 days in ultra-low attachment dishes with 
methylcellulose. Scale bars represent 125 μM. (n=3) (D) Images of 11 day OVCAR8 
parental and OVCAR8 NUAK1-KO spheroids transduced with NucLight Green 
Lentivirus Reagent. Live cells were imaged in real-time with IncuCyte Zoom imaging 
system. (n=3) Experiments were completed by Olga Collins. 
 
Given our data suggesting a role for NUAK1 in EOC cell adhesion we next investigated 
whether NUAK1 may also regulate the formation of ovarian cancer spheroids. To 
facilitate spheroid formation, cells were cultured in ultra-low attachment (ULA) culture 
plates and methylcellose was added to the media (Leung et al., 2015). After 11 days in 
culture, OVCAR8 spheroids formed dense spheroids (Figure 2.3C). However, OVCAR8 
NUAK1-KO spheroids were less compact and there was an abundance of budding cells at 
the periphery (Figure 2.3C). To further examine this altered phenotype, OVCAR8 and 
OVCAR8 NUAK1-KO cells were transfected NucLight Green Lentivirus Reagent and 
live cells were imaged during single spheroid culture in real-time with IncuCyte Zoom 
imaging system. At 11 days, there were an abundance of live cells in highly compact 
OVCAR8-GFP spheroids (Figure 2.3D). In contrast, OVCAR8 NUAK1-KO-GFP 
spheroids showed decreased integrity with many protruding non-viable cells as visualized 
by loss of GFP expression. Altogether, NUAK1 loss reduces EOC spheroid integrity 




2.3.4 NUAK1 promotes EOC spheroid formation through up-
regulating fibronectin deposition 
To understand the molecular basis for the impaired spheroid integrity in NUAK1-KO 
spheroids, global transcriptome analysis was performed to compare OVCAR8 NUAK1-
KO spheroids and parental spheroids. A total of 606 genes were differentially expressed 
with Affymetrix’s Clariom S array (fold change ≥2 or ≤-2) (Table 2.4). Hierarchical 
clustering demonstrated that there were distinct gene expression profiles between 
OVCAR8 parental spheroids and OVCAR8 NUAK1-KO spheroids (Figure 2.4A); thus, to 
determine the pathways through which NUAK1 may act, Gene Set Enrichment analysis 
(GSEA) was completed. Using the Hallmark database in GSEA it was revealed that 
interferon, metabolism, and epithelial mesenchymal transition signatures were enriched 
in the OVCAR8 parental spheroids compared to NUAK1-KO spheroids (Figure 2.4B; 
Table 2.5). A previous study had shown that NUAK1 can promote epithelial 
mesenchymal transition in ovarian cancer (Zhang et al., 2015). In examining the curated 
canonical database, several metabolism pathways were up-regulated, including electron 
transport chain and oxidative phosphorylation pathways (Figure 2.4B, Table 2.6). 
Interestingly, in line with our in vitro cell adhesion data we found multiple pathways 
involved in integrin cell attachment that were enriched in parental compared to NUAK1-
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Figure 2.4 NUAK1 promotes EOC spheroid formation through fibronectin deposition 
 (A) Hierarchical clustering heat map showing gene expression profiles for OVCAR8 
parental and OVCAR8 NUAK1-KO 24h spheroids. Up-regulated genes and down-
regulated genes are shown in red and blue, respectively. Differentially expressed genes 
with a fold change ≥ 2 or ≤-2 with a p< 0.05 are displayed. Three replicates were used for 
each respective group. (B) Top 10 gene sets up-regulated in OVCAR8 parental spheroids 
compared to OVCAR8 NUAK1-KO spheroids. Gene sets were derived from GSEA 
Hallmark database and Curated Canonical database. Normalized enrichment score (NES) 
is presented. (C) Integrin cell surface interaction enrichment plot is presented. Vertical 
black lines represent the position of genes in the ordered data set. Green line represents 
the enrichment score curve. Normalized enrichment score (NES), nominal p-value, and 
FDR are shown. (D) RT-qPCR analysis to validate core enriched genes from the integrin 
cell surface interaction signature. Fold change in mRNA levels is presented for OVCAR8 
parental and OVCAR8 NUAK1-KO 24h spheroids. Analysis was performed using two-
tailed Student’s t-test (***, p < 0.001; ****, p<0.0001). (n=3) (E) Immunoblot analysis 
showing fibronectin and L1CAM expression for OVCAR8 NUAK1-KO and HEYA8 
NUAK1-overexpressor cells along with their respective controls cells cultured in adherent 
conditions (adh) or in suspension (sph). Tubulin was used as a loading control. Data is 
quantified as fibronectin expression relative to tubulin and normalized to adherent 
control. Two-way ANOVA and Tukey’s multiple comparisons test was performed (**, 
p<0.01, ***, p<0.001) (n=3) (F) Immunofluorescence images showing fibronectin, 
phalloidin (cytoskeleton stain), and DAPI (nuclear stain) for OVCAR8 NUAK1-KO and 
HEYA8 NUAK1 cells along with their respective control cells cultured in adherent 
conditions (adh) or in suspension (sph). Images were captured using Olympus AX70 
upright microscope and ImagePro image capture software. Scale bar represents 100 μM. 
(n=3) (G) Images of OVCAR8 parental and OVCAR8 NUAK1-KO spheroids cultured for 
11 days in ultra-low attachment dishes with methylcellulose and supplemented with 
5ug/ml of plasma fibronectin (pFN). Scale bars represent 100 μM. Images were captured 






To confirm this adhesion signature, key target genes were chosen to validate by RT-
qPCR. This list of target genes was based on the core enriched gene set from the 
REACTOME_INTEGRIN_CELL_SURFACE_INTERACTION signature and genes 
with a fold change greater than 2 were chosen to be validated (Figure 2.4C-D; Table 2.7). 
While L1CAM was not a core enriched gene, it was included in the gene list to validate 
because this transmembrane adhesion molecule promotes EOC spheroid formation 
(Doberstein et al., 2018). Furthermore, out of 605 differentially expressed genes it was 
the 10th most down-regulated gene in NUAK1-KO spheroids (fold change = -10) (Table 
2.4). We validated a significant decrease in FN1 mRNA levels in OVCAR8 NUAK1-KO 
spheroids (Figure 2.4D), and mRNA levels of L1CAM were also significantly decreased 
(Figure 2.4D). Interestingly, while there was no change in levels of the canonical 
fibronectin receptor, α5 β1 integrins, there was a significant decrease in components of 
non-canonical receptors, such as integrin β5 and integrin β8 (Johansson et al., 1997; 
Venstrom & Reichardt, 1995) (Figure 2.4D). There was a significant decrease in several 
other adhesion molecules, including Thrombospondin 1 (THBS1) and F11 Receptor 
(F11R) (Figure 2.4D). Therefore, key core enriched genes from the integrin cell surface 
interaction signature were validated by RT-qPCR analysis.  
 
To further investigate this adhesion signature at the protein level, we focused on 
assessing the expression of fibronectin in NUAK1-KO spheroids. Fibronectin showed the 
greatest differential expression, with a 745-fold decrease in NUAK1-KO spheroids, which 
drove the enrichment score for the integrin cell attachment pathway (Figure 2.4C) (Table 
2.4). Moreover, several reports have implicated fibronectin as being critical for spheroid 
formation (Casey et al., 2001; Doberstein et al., 2018).  In comparison to OVCAR8 
monolayer cells, spheroids had increased levels of fibronectin with a multiple isoforms 
appearing by western blot analysis (Figure 2.4E). Previous reports have similarly shown 
many fibronectin bands and this has been attributed to an up-regulation of cleaved 
fibronectin fragments due to proteinases (Bonnans, Chou, & Werb, 2014; Gopal et al., 
2017). In ovarian cancer metastasis, matrix metalloproteinase-2 (MMP-2) is up-regulated 
and cleaves fibronectin (Kenny et al., 2014). Smaller fibronectin fragments increase 
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ovarian cancer adhesion because they can more easily bind to integrin receptors 
compared to uncleaved fragments. Strikingly, there was no detectable fibronectin in 
OVCAR8 NUAK1-KO spheroids (Figure 2.4E). In a reciprocal fashion, HEYA8 NUAK1 
overexpressing cells and spheroids had a dramatic increase in fibronectin expression 
compared to HEYA8 parental cells and spheroids (Figure 2.4E). Similar to fibronectin, 
L1CAM decreased in OVCAR8 NUAK1-KO spheroids compared to parental and 
increased in HEYA8 NUAK1-overexpressor spheroids relative to HEYA8 spheroids 
(Figure 2.4E).  Moreover, the fibronectin immunoblot results was further supported by 
immunofluorescence data showing a loss of fibronectin in OVCAR8 NUAK1-KO 
spheroids and increased fibronectin in HEYA8 NUAK1-overexpressor spheroids (Figure 
2.4F). Therefore, out results strongly suggest that NUAK1 regulates fibronectin 
expression in ovarian cancer spheroids.  
 
To understand the mechanism by which NUAK1 controls spheroid integrity, we tested 
whether NUAK1 regulates fibronectin deposition in spheroids to establish spheroid 
formation. To test this, exogenous plasma fibronectin was added to the culture to observe 
whether a compact spheroid morphology could be rescued in OVCAR8 NUAK1-KO 
spheroids. Plasma fibronectin (5 ug/ml) was supplemented to OVCAR8 NUAK1-KO 
cells in suspension and after 11 days spheroids appeared densely packed without 
protruding peripheral cells (Figure 2.4G). Thus, NUAK1 is required to promote cell 
cohesion in spheroids through its regulation of fibronectin deposition.  
 
2.3.5 Transient and sustained loss of NUAK1 increases spheroid 
viability without altering proliferation of EOC cells  
The results from our adhesion experiments suggest that NUAK1 increases cell adhesion 
and promotes spheroid formation. Using our OVCAR8 GFP-labeled spheroids, we found 
that with NUAK1 loss there was diminished spheroid integrity and an increase in dead 
cells that accumulated around the periphery of the spheroid. This up-regulation of dead 
cells could be a consequence of impaired spheroid integrity due to a loss of adhesion 
molecules and cell death by anoikis. However, these results could also be due to 
NUAK1’s ability to regulate cell growth (Banerjee et al., 2014). Therefore, we 
investigated whether NUAK1 has a role in EOC cell proliferation in addition to its ability 
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to regulate cell adhesion.  We first transiently knocked down NUAK1 using an siRNA-
mediated approach and confirmed NUAK1 loss in OVCAR8 and HEYA8 cells (Figure 
2.5A). NUAK1 knockdown significantly increased viability in HEYA8 spheroids and 
there was a trend toward increased viability in OVCAR8 spheroids (Figure 2.5B).  To 
assess the effect on viability with sustained loss of NUAK1, we used our OVCAR8 
NUAK1-KO spheroids. There was a significant increase in spheroid viability in OVCAR8 
NUAK1-KO spheroids (Figure 2.5C). In the reciprocal system, HEYA8 NUAK1-
overexpressor spheroids showed a significant decrease in viability. Therefore, loss of 
NUAK1 appeared to increase the viability of spheroids and cells.   
 
Next, we wanted to discern whether these changes in viability were because of altered 
EOC cell proliferation. To test this cells were treated with the dual NUAK1/2 inhibitor 
WZ4003 and doubling time was measured (Banerjee et al., 2014). While WZ4003 
treatment led to a significant decrease in doubling time in HEYA8 cells, there was no 
difference in doubling time for OVCAR8 cells (Figure 2.5D). Furthermore, there was no 
change in doubling time for both OVCAR8 NUAK1-KO spheroids and HEYA8 NUAK1-
overexpressor cells (Figure 2.5E). A thymidine incorporation assay is another method to 
measure proliferating cells. However, we found no significant difference in thymidine 
incorporation between OVCAR8 and HEYA8 cells treated with the WZ4003 compound 
and their respective controls (Figure 2.5F). Altogether, these findings suggest that 
NUAK1 loss can increase spheroid viability however these effects are not due to 














































































































































































































































































Figure 2.5 Transient and sustained loss of NUAK1 increases spheroid viability without 
altering proliferation of EOC cells 
 (A) Immunoblot analysis of OVCAR8 and HEYA8 cells transfected with control siRNA 
(siNT) or siRNA targeting NUAK1 (siNUAK1) to confirm transient loss of NUAK1. 
Tubulin was used as a loading control. (B) Spheroid viability for OVCAR8 siNUAK1 and 
HEYA8 siNUAK1 and their respective siNT controls. Viable cell number was 
determined by trypan blue exclusion cell counting 3 days after transfection. Data is 
presented as viable cell number normalized to siNT control. Analysis was performed 
using a two-tailed Student’s t-test (*, p<0.05). (n=3) (C) Spheroid viability for OVCAR8 
NUAK1-KO and HEYA8 NUAK1 cells and their respective controls. Viable cell number 
was determined by trypan blue exclusion cell counting after 7 days (OVCAR8) or 14 
days (HEYA8) in culture. Data is presented as viable cell number normalized to 
OVCAR8 and HEYA8 controls. Analysis was performed using a two-tailed Student’s t-
test (*, p<0.05, ****, p<0.0001). (n=3) (D) Doubling time for OVCAR8 and HEYA8 
cells treated with DMSO or WZ4003 (0.5 μM). IncuCyte Zoom Imaging system 
measured percent confluence over 3 days. Graphpad PRISM was used to generate growth 
curves. Using non-linear regression analysis, doubling times were calculated with 
Graphpad PRISM. (*, p<0.05) (n=3) (E) Doubling time for OVCAR8 NUAK1-KO and 
HEYA8 NUAK1 cells and their respective controls. Cells were transduced with NucLight 
Green Lentivirus Reagent and GFP-labeled cells were counted in real-time using the 
IncuCyte Zoom imaging system. Analysis was performed using a two-tailed Student’s t-
test (NS= not significant). (n=3) (F) Thymidine incorporation assay was completed on 
OVCAR8 and HEYA8 spheroids treated with DMSO or WZ4003 (0.5 μM). Spheroids 
were pulsed with tritiated thymidine for 24 hours. Counts per minute (cpm) was 
measured using a liquid scintillation counter. Analysis was performed using a two-tailed 
Student’s t-test (NS= not significant). (n=3) Experiments shown in figure 5A and B were 
completed by Parima Saxena. Experiment shown in figure 5F was completed by Parima 
in collaboration Pirunthan Perampelam and Dr. Fred Dick.  Experiments were also 
performed by Olga Collins as shown in figure 5C and 5E. 
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2.3.6 Loss of NUAK1 increases NF-κB signaling in EOC spheroids  
To understand the molecular basis for the increased spheroid viability, we reinvestigated 
our transcriptome analysis data. Using the hallmark database, we found that Kras, TNF-a/ 
NF-κB, and inflammatory signaling were up-regulated in OVCAR8 NUAK1-KO 
spheroids compared to parental spheroids (Figure 2.6A). The curated canonical database 
also showed enrichment of several NF-κB signaling pathways (Figure 2.6A). 
Interestingly, KRAS and NF-κB signaling both contribute to cell survival and tumor 
progression (Figure 2.6B; Figure S2.2A) (Bell et al., 2011; Hew et al., 2016; House et al., 
2017; Nakamura et al., 2017). Because KRAS activates the MAPK signaling we assessed 
the expression of several MAP kinases in NUAK1-KO spheroids as a readout of its 
activity (F. Liu, Yang, Geng, & Huang, 2018; Sabio & Davis, 2014). We found that there 
was no change in phosphorylated protein levels of ERK, MEK, and JNK (Figure S2.2B-
D). To determine if NF-κB signaling was up-regulated in NUAK1-KO spheroids, we 
assessed the activation of the canonical p65 transcription factor by its phosphorylation 
status in whole cell lysates (Espín-Palazón & Traver, 2016; Viatour, Merville, Bours, & 
Chariot, 2005). Phospho-p65 was significantly higher in NUAK1-KO spheroids, 
indicating increased activation of this transcription factor (Figure 2.6C). Next, to 
investigate if loss of NUAK1 promotes nuclear translocation of the p65 transcription 
factor, we examined p65 expression in nuclear and cytoplasmic fractions. Nuclear p65 
was increased in NUAK1-KO spheroids (Figure 2.6D). Because our data suggests 
enhanced activation of the p65 transcription in NUAK1-KO spheroids, we subsequently 
examined which target genes were being expressed by p65. To generate a list of NF-κB 
target genes, we used the core enriched genes from the HALLMARK_ 
TNFA_SIGNALING_VIA_ NF-κB (Figure 2.6B) and focused on 6 up-regulated genes 
and 1 down-regulated gene for validation since they represent established NF-κB target 
genes using the “NF-κB Target Genes” list maintained by Thomas Gilmore’s lab (Boston 
University) (http://www.bu.edu/nf-kb/gene-resources/target-genes/) (Table 2.8). 
Inflammatory target genes were found to be significantly upregulated in NUAK1-KO 
spheroids, including IL-1α and IL-1β (Figure 2.6E). Interestingly, NF-κB2 (p100), a 
transcription factor in the non-canonical NF-κB pathway, was the only NF-κB family 
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Figure 2.6 Loss of NUAK1 increases NF-κB signaling in EOC spheroids. 
 (A) Top 10 gene sets up-regulated in OVCAR8 NUAK1-KO spheroids compared to 
OVCAR8 parental spheroids. Gene sets were derived from GSEA Hallmark database and 
Curated Canonical database. Normalized enrichment score (NES) is presented. (B) TNFα 
signaling through NF-κB enrichment plot is shown. Vertical black lines represent the 
position of genes in the ordered data set. Green line represents the enrichment score 
curve. Normalized enrichment score (NES), nominal p-value, and FDR are presented. (C) 
Immunoblot analysis showing p-p65 (S536) and p65 in OVCAR8 NUAK1-KO and 
OVCAR8 parental cells cultured on monolayer conditions (adh) or in suspension (sph). 
Tubulin was used as a loading control.  Densitometric analysis showing the pixel 
intensity volume for p-p65 relative to tubulin. Analysis was performed using a Two-
tailed Student’s t-test (NS= not significant; *, p<0.05). (n=3) (D) Immunoblot analysis 
showing p-p65 (S536) and p65 in the nuclear and cytoplasmic fractions from OVCAR8 
NUAK1-KO and OVCAR8 parental cells cultured on monolayer conditions (adh) or in 
suspension (sph). Tubulin was used as a loading control for the cytoplasmic fraction. 
Lamin A/C was used as a loading control for the nuclear fraction. Densitometric analysis 
showing the pixel intensity volume for nuclear p-p65 and nuclear p65 relative to lamin 
A/C. (n=2) (E) RT-qPCR analysis to validate core enriched genes from the TNFα 
signaling through NF-κB signature. Fold change in mRNA is presented for OVCAR8 
parental and OVAR8 NUAK1-KO 24h spheroids. Statistical analysis was performed 
using two-tailed Student’s t-test (**, p<0.01; ***, p < 0.001; ****, p<0.0001). (n=3) 
 
Furthermore, several anti-apoptotic genes were significantly increased in NUAK1-KO 
spheroids, including BCL2A1 and BIRC3 (Figure 2.6E). Therefore, NF-κB signaling is 
up-regulated in NUAK1-KO spheroids and may represent a means for increased cell 
viability in EOC spheroids lacking NUAK1. 
 
2.4 Discussion  
Advanced–stage EOC is characterized by the accumulation of ascites fluid in the 
peritoneal cavity (Al Habyan et al., 2018; Sodek et al., 2009). Ascites contains spheroids 
68 
 
which are a key mediator of peritoneal metastasis and can facilitate chemoresistence (Al 
Habyan et al., 2018; Desoize & Jardillier, 2000; Lengyel et al., 2014; Pease et al., 2012). 
Our group previously reported that the master kinase LKB1 is required for efficient 
ovarian cancer metastasis (Buensuceso et al., 2018; Peart et al., 2015). To elucidate the 
downstream target eliciting the pro-metastatic function of LKB1, we completed a 
multiplex inhibitor beads-mass spectrometry analysis and identified NUAK1 as a top 
candidate substrate. NUAK1 is differentially expressed in quiescent spheroids compared 
to proliferative monolayer cells and this is regulated by lysosome degradation and the 
UPS. Furthermore, NUAK1 increases EOC cell adhesion and promotes spheroid 
integrity. Using transcriptome analysis with GSEA and subsequent validation 
experiments we demonstrated that NUAK1 regulates spheroid formation by controlling 
fibronectin deposition in spheroids. Thus, we propose that the LKB1 target NUAK1 has 
tumor-promoting functions by facilitating spheroid integrity through matrix deposition.   
 
LKB1 is known as a master kinase in the literature due to its ability to regulate AMPK as 
well as 12 AMPK-related kinases (Shackelford & Shaw, 2009). Through these substrates, 
LKB1 can have multiple functions related to cell polarity, metabolism and growth. While 
LKB1 is commonly known as a tumor suppressor, there is a growing body of literature 
implicating it as having pro-metastatic roles under certain contexts (Lee et al., 2015; 
Shackelford et al., 2013; Shackelford & Shaw, 2009). In fact, we previously 
demonstrated that LKB1 is required for EOC spheroid viability and metastasis in in vivo 
xenograft models (Buensuceso et al., 2018; Peart et al., 2015). Because LKB1 can have a 
broad range of functions it is critical to elucidate its downstream targets to identify 
specific substrates that could serve as more suitable therapeutic targets. Most of the 
literature examining targets of LKB1 have focused on AMPK, which is a regulator of 
metabolic stress (Shackelford & Shaw, 2009). However, our prior work indicated that in 
EOC, LKB1 elicits its tumorigenic functions through AMPK-independent signalling 
(Buensuceso et al., 2018; Peart et al., 2015). Thus to determine the critical target for 
LKB1 in EOC, we completed multiplexed kinase inhibitor bead-mass spectrometry and 
identified the ARK NUAK1 as a top candidate substrate. To confirm these findings, we 
showed that LKB1 regulates the phosphorylation and expression of NUAK1 in EOC 
69 
 
adherent cells and spheroids. We found that early in spheroid formation NUAK1 is 
highly expressed and this correlates with the levels of phosphorylated-LKB1. However, 
later during spheroid formation NUAK1 levels decrease but are still expressed at 
detectable levels. This down-regulation of NUAK1 was observed in several HGSOC 
established cell lines and patient-derived ascites cells cultured as spheroids. We showed 
that lysosome degradation and the UPS both contribute to the down-regulation of 
NUAK1 in spheroids. Previous studies have shown that the UPS plays a role in 
regulating NUAK1. NUAK1 can be phosphorylated by cyclin-dependent kinases and 
polo kinase which lead to NUAK1 binding to the SCFBTrcp E3 ligase, its ubiquitination 
and subsequent degradation (Banerjee et al., 2014). NUAK1 was also shown to be 
ubiquitinated by unique Lys29 and or Lys33 linkages which block phosphorylation and 
activation by LKB1 (Al-Hakim et al., 2008). USP9X can bind to NUAK1 and cleave the 
polyubiquitin modification, allowing for LKB1 phosphorylation and activation. In this 
report, we show that USP9X also regulates NUAK1 expression in EOC. Therefore, we 
found that NUAK1 is a target of LKB1 in EOC and shows differential expression 
between proliferative adherent cells and quiescent spheroids.  
 
Multiple studies have provided evidence that NUAK1 can have tumor-promoting 
functions. In human hepatoma cells, NUAK1 blocked cell death by inhibiting caspase 8 
(Suzuki et al., 2003). Along with increasing cell survival through inhibiting apoptosis, 
NUAK1 can induce the S-phase in the cell cycle and increase cell proliferation (Banerjee 
et al., 2014). Several reports have shown that NUAK1 can also enhance cancer survival 
through supporting metabolic homeostasis (Liu et al., 2012). In tumors overexpressing 
myc, NUAK1 reduces metabolic stress by inhibiting mTORC1 and sustaining glutamine 
metabolism. A tumor-promoting role for NUAK1 is strengthened by studies showing that 
elevated levels of NUAK1 correlate with poor prognosis (Phippen et al., 2016; Port et al., 
2018). High NUAK1 transcript levels in serous ovarian cancer patients was associated 
with lower progression free survival and lower overall survival (Phippen et al., 2016). 
There was also an increased risk for diagnosis at an advanced stage and residual disease 
after cytoreductive surgery. The molecular basis underlying the poor prognosis in EOC 
had not previously been elucidated. Herin, we found that NUAK1 regulates EOC cell 
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adhesion and the formation of spheroids, which are the key mediators of metastasis in 
ovarian cancer. 
 
In the context of EOC metastasis, cell adhesion is critical as cancer cells aggregate 
through cell-ECM interactions to form spheroids which then spread through the 
peritoneal cavity (Casey et al., 2001). Previous research has suggested NUAK1 plays a 
role in cell adhesion due to its roles in promoting EMT and invasion. In ovarian cancer 
cells, NUAK1 increases EMT and migration of cells by inhibiting miR-1181 (Zhang et 
al., 2015). Furthermore, NUAK1 overexpression in a pancreatic cancer mouse model 
increased in vivo metastasis (Kusakai et al., 2004). Mechanistically, NUAK1 has been 
shown to promote cell detachment by controlling the myosin phosphatase complex in 
HEK293 and MEF cells (Zagórska et al., 2010). Moreover, in colorectal cancer, loss of 
NUAK1 reduced tumor-initiating capacity because spheroids appeared smaller in size 
and were less abundant. To identify the molecular basis for this phenotype, the authors 
proposed that NUAK1 protects tumors from oxidative stress through nuclear 
translocation of Nrf2 (Port et al., 2018). In our study, we show that loss of NUAK1 
impairs single cell adhesion and spheroid formation as spheroids appeared less compact. 
By examining spheroid formation in real-time NUAK1-KO-GFP spheroids showed 
decreased integrity with an accumulation of dead cells around the periphery. We propose 
that in EOC the ability of NUAK1 to control adhesion molecules is likely the primary 
mechanism mediating EOC spheroid formation. Two of the top signatures up-regulated in 
OVCAR8 parental spheroids compared to OVCAR8 NUAK1-KO spheroids were related 
to cell attachment. Interestingly, in the Nrf2 study described above they also observed 
several cell adhesion pathways using the Metacore GeneGO analysis (Port et al., 2018). 
These cell adhesion pathway had a higher ranking than the Nrf2 oxidative stress response 
pathway yet were not pursued in that study. We observed FN1 as the most differentially 
expressed gene in OVCAR8 NUAK1-KO spheroids with a 745-fold decrease. 
Importantly, the addition of soluble fibronectin also completely restored the native 
phenotype in NUAK1-KO spheroids. Altogether, we have elucidated a novel mechanism 
of NUAK1 in promoting EOC cell adhesion and spheroid compaction through fibronectin 




Our GSEA indicated a cell attachment signature that was enriched in OVCAR8 spheroids 
compared to OVCAR8 NUAK1-KO spheroids. Multiple adhesion molecules were 
identified, including FN, L1CAM, ITGβ8, ITGβ5, THBS1, and F11R (Table 2.7). This 
suggests that NUAK1 regulates a network of adhesion molecules. We focused our 
validation experiments on fibronectin because it demonstrated the greatest differential 
expression and prior studies have shown it plays a key role in spheroid formation. 
Previous work in OVCAR5 cells showed that fibronectin mediates the formation of 
spheroids (Casey et al., 2001). The authors showed that the fibronectin receptor α5β1 
integrin also contributes to spheroid integrity. Interestingly, the canonical fibronectin 
receptor subunits were not present in our transcriptome analysis with only the ITGβ5 and 
ITGβ8 subunits being differentially expressed (Table 2.4). A prior study showed that 
ITGβ8 may interact with fibronectin, however this interaction has only been shown in 
chick sensory neurons and the alpha subunit has not yet been elucidated (Venstrom & 
Reichardt, 1995). In addition, ITGβ8 had a relatively small fold change of 10, while FN1 
has a fold change of 745, suggesting that regulation of matrix expression is the principal 
mechanism by which NUAK1 is controlling cell adhesion in spheroids. Another study 
similarly demonstrated the importance of fibronectin in spheroids generated from 
fallopian tube epithelial cells (FTE) which represent the putative cell of origin in HGSOC 
(Iwanicki et al., 2016; Labidi-Galy et al., 2017). FTE cells with p53 mutations have an 
increased propensity to aggregate into spheroids due to autocrine fibronectin deposition. 
In addition to FN1, L1CAM was differentially expressed in our analysis with a fold 
change of 10. Indeed, L1CAM was previously shown to promote OVCAR8 and FTE 
spheroid formation (Doberstein et al., 2018). In FTE spheroids, L1CAM up-regulated 
expression of integrins and fibronectin to facilitate spheroid formation. In our study, we 
similarly showed an interesting relationship between L1CAM and fibronectin expression. 
In OVCAR8 NUAK1-KO spheroids there was no detectable levels of either L1CAM or 
fibronectin expression. Therefore, we may have identified a novel signaling pathway 
controlling fibronectin and its molecules that mediates the formation of EOC spheroids.  
 
In conclusion, we have identified NUAK1 as a key target of LKB1 in EOC. We show 
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that NUAK1 has pro-metastatic functions because it increases EOC cell adhesion and 
promotes spheroid integrity. Mechanistically, NUAK1 controls the deposition of 
fibronectin in spheroids to facilitate spheroid formation. Altogether, we provide evidence 
that the LKB1 substrate NUAK1 could serve as a potential therapeutic target in ovarian 
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2.6 Supplementary Figures 
 
 
Figure S 2.1 Tandem ubiquitin binding entities (TUBEs) to detect ubiqutinated-NUAK1 
in EOC cells and spheroids. 
Immunoblot analysis was completed to assess ubiquitinated-c-myc (positive control) and 
ubiquitnated-NUAK1. Input, lysates unbound to control agarose and Agarose-TUBEs 







































Figure S 2.2 Validation experiments for KRAS signaling signature. (A) KRAS Signaling 
enrichment plot is presented.  
Vertical black lines represent the position of genes in the ordered data set. Green line 
represents the enrichment score curve. Normalized enrichment score (NES), nominal p-
value, and FDR are presented. (B-D) Immunoblot analysis showing (B) p-ERK1/2 
(Thr202/Thyr204) and ERK, (C) p-MEK1/2 (Ser217/221) and MEK, and (D) p-
SAPK/JNK (Thr183/Thyr185) and SAPK/JNK in OVCAR8 NUAK1-KO and OVCAR8 
parental cells cultured on monolayer conditions (Adh) or in suspension (sph). Tubulin 



















2.7 Supplementary Tables  
 
Table S 2.1 Primer sequences for qPCR 
Gene  Forward Primer  Reverse Primer  
Il1B  5'CCACAGACCTTCCAGGAGAATG3' 5'GTGCAGTTCAGTGATCGTACAGG3' 
NFKB2 5'GGCAGACCAGTGTCATTGAGCA3' 5'CAGCAGAAAGCTCACCACACTC3' 
BCL2A1 5'GGATAAGGCAAAACGGAGGCTG3' 5'CAGTATTGCTTCAGGAGAGATAGC3' 
IL1A 5'TGTATGTGACTGCCCAAGATGAAG3' 5'AGAGGAGGTTGGTCTCACTACC3' 
BIRC3 5'GCTTTTGCTGTGATGGTGGACTC3' 5'CTTGACGGATGAACTCCTGTCC3' 
G0S2 5'GCCTGATGGAGACTGTGTGCAG3' 5'TCCTGCTGCTTGCCTTTCTCCT3' 
il6 5'AGACAGCCACTCACCTCTTCAG3' 5'TTCTGCCAGTGCCTCTTTGCTG3' 
FN1 5'ACAACACCGAGGTGACTGAGAC3' 5'GGACACAACGATGCTTCCTGAG3' 
THBS1 5'GCTGGAAATGTGGTGCTTGTCC3' 5'CTCCATTGTGGTTGAAGCAGGC3' 
F11R 5'GTGAAGTTGTCCTGTGCCTACTC3' 5'ACCAGTTGGCAAGAAGGTCACC3' 
ITGB5 5'GCCTTTCTGTGAGTGCGACAAC3' 5'CCGATGTAACCTGCATGGCACT3' 
INTGB8 5'CTGTTTGCAGTGGTCGAGGAGT3' 5'TGCCTGCTTCACACTCTCCATG3' 
COL4A1 5'TGTTGACGGCTTACCTGGAGAC3' 5'GGTAGACCAACTCCAGGCTCTC3' 
L1CAM 5'TCGCCCTATGTCCACTACACCT3' 5'ATCCACAGGGTTCTTCTCTGGG3' 































Table S 2.2 Differentially expressed kinases from MIB/MS analysis completed using 
OVCAR8 parental and OVCAR8 STK11-KO adherent cells 
Comparison log2Foldchange FDR Kinases  
Adh STK11KO/Adh WT -1.97366 0 CSNK1G3 
Adh STK11KO/Adh WT -1.95801 1.73E-12 CYB5B 
Adh STK11KO/Adh WT -1.89108 0 FYN 
Adh STK11KO/Adh WT -1.78728 0 VAV2 
Adh STK11KO/Adh WT -1.74778 3.64E-15 UNC50 
Adh STK11KO/Adh WT -1.51883 0 NUAK1 
Adh STK11KO/Adh WT -1.46016 4.06E-05 NDUFB4 
Adh STK11KO/Adh WT -1.34657 1.57E-09 SFXN3 
Adh STK11KO/Adh WT -1.32789 8.01E-10 INTS5 
Adh STK11KO/Adh WT -1.28441 1.49E-07 PFKL 
Adh STK11KO/Adh WT -1.23542 4.04E-13 EPHB1 
Adh STK11KO/Adh WT -1.20998 1.66E-05 TAOK1 
Adh STK11KO/Adh WT -1.16754 8.87E-08 NBEAL2 
Adh STK11KO/Adh WT -1.12512 3.12E-13 SLC25A13 
Adh STK11KO/Adh WT -1.0996 2.33E-09 VDAC3 
Adh STK11KO/Adh WT -1.06842 0.00207 SPTLC1 
Adh STK11KO/Adh WT -1.01661 0 TEX10 
Adh STK11KO/Adh WT -0.994782 2.16E-07 UQCRC2 
Adh STK11KO/Adh WT -0.969536 0.000820923 PPP6R3 
Adh STK11KO/Adh WT -0.964587 0 ARFGEF1 
Adh STK11KO/Adh WT -0.946974 9.08E-14 PRDX1 
Adh STK11KO/Adh WT -0.846994 0.00555427 CAMK2D 
Adh STK11KO/Adh WT -0.841552 0.00165305 TUBA4A 
Adh STK11KO/Adh WT -0.781043 1.05E-07 INCENP 
Adh STK11KO/Adh WT -0.737074 1.28E-07 MRPS21 
Adh STK11KO/Adh WT -0.6914 0.000243573 ELOVL2 
Adh STK11KO/Adh WT -0.68825 7.25E-09 TBCD 
Adh STK11KO/Adh WT -0.678653 2.04E-13 RPL15 
Adh STK11KO/Adh WT -0.670448 0.0053879 MRPS5 
Adh STK11KO/Adh WT -0.662074 1.28E-14 KRT1 
Adh STK11KO/Adh WT -0.636737 0.00204682 SLC25A32 
Adh STK11KO/Adh WT -0.624303 0.0141178 RPL19 
Adh STK11KO/Adh WT -0.618517 4.05E-08 AURKB 
Adh STK11KO/Adh WT -0.590932 5.68E-17 TIMM44 
Adh STK11KO/Adh WT -0.587071 0 BRAF 
Adh STK11KO/Adh WT -0.584215 0.00292699 CCNE2 
Adh STK11KO/Adh WT -0.583903 0 HSD17B4 
Adh STK11KO/Adh WT -0.55642 0.037613 RPS6KB1 
Adh STK11KO/Adh WT -0.556194 0.00789811 HSP90B1 
Adh STK11KO/Adh WT -0.554032 1.93E-06 GNB2L1 
Adh STK11KO/Adh WT -0.523702 0.0159977 UBE2J1 
Adh STK11KO/Adh WT -0.523676 4.92E-10 RPL8 
Adh STK11KO/Adh WT -0.513712 0.000342438 HSPD1 
Adh STK11KO/Adh WT -0.507747 2.48E-06 STK3 
Adh STK11KO/Adh WT -0.50498 0.0280614 ATAD3B 
Adh STK11KO/Adh WT -0.503351 1.66E-09 ACAD10 
Adh STK11KO/Adh WT -0.497607 0.000139223 NNT 
Adh STK11KO/Adh WT -0.497478 9.49E-06 COX5B 
Adh STK11KO/Adh WT -0.4915 0.0226465 GRK6 
Adh STK11KO/Adh WT -0.459123 0.00362162 COX2 
Adh STK11KO/Adh WT -0.454173 0.0200689 SCD5 
Adh STK11KO/Adh WT -0.450508 7.32E-16 EPHB2 
Adh STK11KO/Adh WT -0.44844 0.0498535 RPS23 
Adh STK11KO/Adh WT -0.442644 0.000129016 MAP4K3 
Adh STK11KO/Adh WT -0.423766 0.0236518 MELK 
Adh STK11KO/Adh WT -0.423274 0.0139878 COX6C 
Adh STK11KO/Adh WT -0.422743 6.89E-13 VAC14 
Adh STK11KO/Adh WT -0.416894 0.00718978 FAM213A 
Adh STK11KO/Adh WT -0.41585 0 TUBGCP3 
Adh STK11KO/Adh WT -0.410997 0 AGK 
Adh STK11KO/Adh WT -0.399654 0.0284335 CERS5 
Adh STK11KO/Adh WT -0.397477 0.0419112 OXA1L 
Adh STK11KO/Adh WT -0.384582 0.00346759 HIST1H2BD 
Adh STK11KO/Adh WT -0.378792 0.0179724 ACVR1 
Adh STK11KO/Adh WT -0.366113 0.00269768 DPH5 
Adh STK11KO/Adh WT -0.357246 0.00471562 PRSS21 
Adh STK11KO/Adh WT -0.352448 0.00145417 TM9SF1 
Adh STK11KO/Adh WT -0.337459 1.76E-15 RPL17 
Adh STK11KO/Adh WT -0.327478 0.00260508 SLC43A3 
Adh STK11KO/Adh WT -0.318707 0.00354371 YIF1B 
Adh STK11KO/Adh WT -0.317724 0.000296681 PDE1C 
Adh STK11KO/Adh WT -0.316452 0.00903223 FAR1 
Adh STK11KO/Adh WT -0.313114 0.000383626 COA3 
Adh STK11KO/Adh WT -0.28207 4.25E-11 VDAC1 
Adh STK11KO/Adh WT -0.261335 0.00424384 OPA1 
Adh STK11KO/Adh WT -0.258441 0.0489084 CEPT1 
Adh STK11KO/Adh WT -0.239501 8.45E-13 ISOC2 
Adh STK11KO/Adh WT -0.231117 0 EDC4 
Adh STK11KO/Adh WT -0.178488 5.57E-10 TM9SF3 
Adh STK11KO/Adh WT -0.171577 0.0416818 GIGYF2 
Adh STK11KO/Adh WT -0.159034 0.000190905 COG6 
Adh STK11KO/Adh WT -0.149491 0 RPL18A 
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Adh STK11KO/Adh WT -0.129702 5.92E-05 ABCC1 
Adh STK11KO/Adh WT -0.128553 0.00178038 ATM 
Adh STK11KO/Adh WT -0.0972751 0.0493807 STK17B 
Adh STK11KO/Adh WT -0.0845323 0 SLC25A11 
Adh STK11KO/Adh WT -0.0845323 0 SLC25A11 
Adh STK11KO/Adh WT -0.0736675 2.07E-10 MTOR 
Adh STK11KO/Adh WT -0.0731486 1.26E-07 MYH9 
Adh STK11KO/Adh WT -0.051941 0.000482044 TAOK2 
Adh STK11KO/Adh WT -0.0339553 0.000147797 ATP6V1H 
Adh STK11KO/Adh WT -0.00184483 3.41E-18 PAICS 
Adh STK11KO/Adh WT 0.000899655 0 GAPDH 
Adh STK11KO/Adh WT 0.0040975 0.00725857 CALU 
Adh STK11KO/Adh WT 0.0352471 0.0264291 SCFD1 
Adh STK11KO/Adh WT 0.0379827 5.63E-06 RPS10 
Adh STK11KO/Adh WT 0.0553931 1.22E-09 HSPB1 
Adh STK11KO/Adh WT 0.0618257 3.04E-08 DCK 
Adh STK11KO/Adh WT 0.0657621 0.0015314 CCNT2 
Adh STK11KO/Adh WT 0.0704602 1.04E-08 RPL10A 
Adh STK11KO/Adh WT 0.0707662 0 HSPA9 
Adh STK11KO/Adh WT 0.0941577 0 RPL21 
Adh STK11KO/Adh WT 0.105502 2.64E-09 PHB2 
Adh STK11KO/Adh WT 0.14163 2.75E-05 TIA1 
Adh STK11KO/Adh WT 0.157962 0.000729769 RNF213 
Adh STK11KO/Adh WT 0.166101 0.00457025 MINK1 
Adh STK11KO/Adh WT 0.169961 0.03418 FAM162A 
Adh STK11KO/Adh WT 0.181769 0 PI4K2A 
Adh STK11KO/Adh WT 0.185245 3.40E-17 PRKCSH 
Adh STK11KO/Adh WT 0.215049 0.0153185 ARF4 
Adh STK11KO/Adh WT 0.222232 0.0295811 BSG 
Adh STK11KO/Adh WT 0.225771 0.0005843 TBC1D9B 
Adh STK11KO/Adh WT 0.255818 8.07E-08 SLC25A6 
Adh STK11KO/Adh WT 0.260043 3.71E-09 SLC16A1 
Adh STK11KO/Adh WT 0.26512 0 RPN1 
Adh STK11KO/Adh WT 0.2865 0.0276945 CCNA2 
Adh STK11KO/Adh WT 0.288231 0 COG8 
Adh STK11KO/Adh WT 0.289714 2.93E-05 RPS8 
Adh STK11KO/Adh WT 0.291447 0.000857973 RPS26 
Adh STK11KO/Adh WT 0.303143 0.000332934 TARBP1 
Adh STK11KO/Adh WT 0.304468 0.00011446 SACM1L 
Adh STK11KO/Adh WT 0.30747 0.000121591 PIK3C3 
Adh STK11KO/Adh WT 0.347208 0.030947 XPO4 
Adh STK11KO/Adh WT 0.347277 3.90E-06 HIST1H4J 
Adh STK11KO/Adh WT 0.363014 0.00251438 LIMS1 
Adh STK11KO/Adh WT 0.363014 0.00254449 LIMS1 
Adh STK11KO/Adh WT 0.366503 0.036514 VPS51 
Adh STK11KO/Adh WT 0.367443 1.44E-05 HNRNPK 
Adh STK11KO/Adh WT 0.373718 0.000542926 RPL27 
Adh STK11KO/Adh WT 0.373779 1.02E-17 THADA 
Adh STK11KO/Adh WT 0.373941 0.0396227 TUBB 
Adh STK11KO/Adh WT 0.377802 4.60E-05 NCAPD2 
Adh STK11KO/Adh WT 0.38051 0.00138048 COPG1 
Adh STK11KO/Adh WT 0.381063 0.0387216 VPS53 
Adh STK11KO/Adh WT 0.382492 0.0133487 LRRC59 
Adh STK11KO/Adh WT 0.383964 0.0122381 DECR2 
Adh STK11KO/Adh WT 0.385521 0.000288474 RPL7A 
Adh STK11KO/Adh WT 0.389964 0.014379 CHP1 
Adh STK11KO/Adh WT 0.391984 1.54E-07 PRKAB1 
Adh STK11KO/Adh WT 0.394835 0.00639954 HNRNPH1 
Adh STK11KO/Adh WT 0.396247 9.00E-05 HLA-C 
Adh STK11KO/Adh WT 0.396505 8.50E-05 FER 
Adh STK11KO/Adh WT 0.397083 4.63E-17 NPEPPS 
Adh STK11KO/Adh WT 0.40146 4.48E-07 RPS15A 
Adh STK11KO/Adh WT 0.401673 0.000173157 COPB1 
Adh STK11KO/Adh WT 0.402277 0.00257458 PSMC4 
Adh STK11KO/Adh WT 0.405217 2.95E-15 MAP4K5 
Adh STK11KO/Adh WT 0.412628 0.002318 SLC38A2 
Adh STK11KO/Adh WT 0.413082 0.0231467 MTX2 
Adh STK11KO/Adh WT 0.413623 0.00108195 RAB3B 
Adh STK11KO/Adh WT 0.426703 4.39E-05 ZAK 
Adh STK11KO/Adh WT 0.430613 1.01E-05 UNC45A 
Adh STK11KO/Adh WT 0.434 0.0299697 BMPR2 
Adh STK11KO/Adh WT 0.436717 8.18E-11 AAK1 
Adh STK11KO/Adh WT 0.437721 0.00124144 GCDH 
Adh STK11KO/Adh WT 0.439058 4.67E-05 KHSRP 
Adh STK11KO/Adh WT 0.439397 4.74E-05 SYMPK 
Adh STK11KO/Adh WT 0.43977 4.25E-05 PGRMC1 
Adh STK11KO/Adh WT 0.446492 0.0439828 MEST 
Adh STK11KO/Adh WT 0.448815 0.000870669 RAB5A 
Adh STK11KO/Adh WT 0.449834 0.0398511 CSNK1E 
Adh STK11KO/Adh WT 0.450538 0.00147347 CSK 
Adh STK11KO/Adh WT 0.451037 0.0453831 RRAS2 
Adh STK11KO/Adh WT 0.451862 4.07E-07 HSD17B11 
Adh STK11KO/Adh WT 0.453166 0.0472618 ARL8B 
Adh STK11KO/Adh WT 0.471068 0.0271477 MAPK3 
Adh STK11KO/Adh WT 0.476938 3.26E-05 LRPPRC 
Adh STK11KO/Adh WT 0.480287 8.61E-06 PIK3R4 
Adh STK11KO/Adh WT 0.49383 0.00342963 RPN2 
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Adh STK11KO/Adh WT 0.497743 0.00835616 VAPB 
Adh STK11KO/Adh WT 0.497771 0.00481327 NIPA1 
Adh STK11KO/Adh WT 0.498001 1.46E-05 C2CD5 
Adh STK11KO/Adh WT 0.505949 2.53E-10 SGPL1 
Adh STK11KO/Adh WT 0.50667 0.000264912 ESYT1 
Adh STK11KO/Adh WT 0.507799 8.38E-05 MAP2K4 
Adh STK11KO/Adh WT 0.51111 9.21E-11 PSMC5 
Adh STK11KO/Adh WT 0.513231 0.000158839 CCDC132 
Adh STK11KO/Adh WT 0.514691 0.0303599 VAPA 
Adh STK11KO/Adh WT 0.521043 0 HSP90AB1 
Adh STK11KO/Adh WT 0.52197 0.000178115 EXOC4 
Adh STK11KO/Adh WT 0.527881 0.00117524 DHRS1 
Adh STK11KO/Adh WT 0.530027 0.0145119 TMED2 
Adh STK11KO/Adh WT 0.531871 1.39E-07 CDC42 
Adh STK11KO/Adh WT 0.532354 0.00171648 TMEM115 
Adh STK11KO/Adh WT 0.536388 1.58E-05 STX7 
Adh STK11KO/Adh WT 0.541503 0.0105622 SCD 
Adh STK11KO/Adh WT 0.543172 3.07E-18 ATP5C1 
Adh STK11KO/Adh WT 0.545072 6.50E-07 RPL27A 
Adh STK11KO/Adh WT 0.545172 0 CAD 
Adh STK11KO/Adh WT 0.551233 0.00491254 RPS11 
Adh STK11KO/Adh WT 0.552937 1.10E-05 RAB32 
Adh STK11KO/Adh WT 0.553884 0 JAK1 
Adh STK11KO/Adh WT 0.555762 4.13E-06 PRKAR2A 
Adh STK11KO/Adh WT 0.557391 1.36E-09 SUN2 
Adh STK11KO/Adh WT 0.558509 1.62E-07 MST4 
Adh STK11KO/Adh WT 0.559623 5.54E-12 RPL18 
Adh STK11KO/Adh WT 0.561136 1.07E-06 RAB11B 
Adh STK11KO/Adh WT 0.56144 4.45E-06 MFSD10 
Adh STK11KO/Adh WT 0.565941 0.00739726 EXOC5 
Adh STK11KO/Adh WT 0.56733 0.00234493 DPM1 
Adh STK11KO/Adh WT 0.57271 0 ATP5H 
Adh STK11KO/Adh WT 0.583931 1.32E-17 PRKAG1 
Adh STK11KO/Adh WT 0.587826 0.00143511 HAX1 
Adh STK11KO/Adh WT 0.605673 0.0456171 MYLK 
Adh STK11KO/Adh WT 0.607101 0.000165845 TMPO 
Adh STK11KO/Adh WT 0.610695 4.72E-07 MAP3K2 
Adh STK11KO/Adh WT 0.614964 5.37E-12 PRKACA 
Adh STK11KO/Adh WT 0.620686 0.0369529 FLOT1 
Adh STK11KO/Adh WT 0.621648 8.46E-07 NEK1 
Adh STK11KO/Adh WT 0.621813 5.42E-08 ATP2C1 
Adh STK11KO/Adh WT 0.623269 0.00313501 PDCD6 
Adh STK11KO/Adh WT 0.634237 0.0096666 BCAP31 
Adh STK11KO/Adh WT 0.634687 2.47E-11 GANAB 
Adh STK11KO/Adh WT 0.64084 5.65E-07 INF2 
Adh STK11KO/Adh WT 0.641106 9.33E-07 RPL13 
Adh STK11KO/Adh WT 0.642757 2.51E-12 MAP2K3 
Adh STK11KO/Adh WT 0.644499 6.85E-06 LGALS1 
Adh STK11KO/Adh WT 0.649045 1.10E-12 RPSA 
Adh STK11KO/Adh WT 0.655986 0 CKAP4 
Adh STK11KO/Adh WT 0.660884 1.95E-11 SLC16A3 
Adh STK11KO/Adh WT 0.667495 9.70E-05 TGFBR1 
Adh STK11KO/Adh WT 0.674772 0.0021187 GPX8 
Adh STK11KO/Adh WT 0.678617 0.0260763 TMEM43 
Adh STK11KO/Adh WT 0.682487 3.75E-07 TM9SF4 
Adh STK11KO/Adh WT 0.683913 2.38E-07 PNPLA6 
Adh STK11KO/Adh WT 0.685659 2.01E-08 RDH11 
Adh STK11KO/Adh WT 0.686854 0 ECI2 
Adh STK11KO/Adh WT 0.690096 0 ADK 
Adh STK11KO/Adh WT 0.69751 0.000602095 UBQLN1 
Adh STK11KO/Adh WT 0.698872 9.72E-15 GALNT2 
Adh STK11KO/Adh WT 0.701559 0 SLK 
Adh STK11KO/Adh WT 0.703021 0 PHGDH 
Adh STK11KO/Adh WT 0.714852 1.53E-08 TYK2 
Adh STK11KO/Adh WT 0.737739 9.18E-09 UBE3C 
Adh STK11KO/Adh WT 0.741539 0 HSPA5 
Adh STK11KO/Adh WT 0.744566 0.0149142 ACADVL 
Adh STK11KO/Adh WT 0.745209 0 ATP5O 
Adh STK11KO/Adh WT 0.748681 5.30E-10 SLC3A2 
Adh STK11KO/Adh WT 0.757592 0.000257416 PDS5A 
Adh STK11KO/Adh WT 0.765241 2.28E-05 G6PC3 
Adh STK11KO/Adh WT 0.770124 0.00753697 RALB 
Adh STK11KO/Adh WT 0.776687 4.70E-13 TUBGCP2 
Adh STK11KO/Adh WT 0.79873 8.70E-08 ADCK5 
Adh STK11KO/Adh WT 0.80656 3.81E-05 INSR 
Adh STK11KO/Adh WT 0.807434 5.63E-11 EEF1D 
Adh STK11KO/Adh WT 0.838763 0.00197884 RPS3A 
Adh STK11KO/Adh WT 0.839279 0 RPS13 
Adh STK11KO/Adh WT 0.848706 3.10E-14 EXOC7 
Adh STK11KO/Adh WT 0.85824 0.00324261 ASPH 
Adh STK11KO/Adh WT 0.861662 0 SLC25A24 
Adh STK11KO/Adh WT 0.870775 7.32E-17 COMT 
Adh STK11KO/Adh WT 0.879903 0.0165513 USMG5 
Adh STK11KO/Adh WT 0.880792 2.74E-06 BTAF1 
Adh STK11KO/Adh WT 0.882589 0.00578086 COG2 
Adh STK11KO/Adh WT 0.898664 0 ATP5J 
Adh STK11KO/Adh WT 0.901232 6.22E-09 PRAF2 
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Adh STK11KO/Adh WT 0.901359 0 PRKACB 
Adh STK11KO/Adh WT 0.905981 4.35E-15 ECH1 
Adh STK11KO/Adh WT 0.912835 2.10E-14 ATP5J2 
Adh STK11KO/Adh WT 0.942541 1.75E-06 DOLK 
Adh STK11KO/Adh WT 0.973739 1.78E-13 ACSL3 
Adh STK11KO/Adh WT 0.991613 1.79E-09 SLC7A5 
Adh STK11KO/Adh WT 0.994583 0.00027255 STK24 
Adh STK11KO/Adh WT 1.00966 4.32E-10 DDOST 
Adh STK11KO/Adh WT 1.01372 0 MYOF 
Adh STK11KO/Adh WT 1.02419 9.36E-10 RPS18 
Adh STK11KO/Adh WT 1.02915 1.89E-05 NDUFS8 
Adh STK11KO/Adh WT 1.03988 1.33E-16 RHOT2 
Adh STK11KO/Adh WT 1.05973 0.00419912 OSTC 
Adh STK11KO/Adh WT 1.06171 0 ALDH2 
Adh STK11KO/Adh WT 1.06869 0.0005592 SAR1A 
Adh STK11KO/Adh WT 1.08542 0 TMED9 
Adh STK11KO/Adh WT 1.09571 3.04E-12 ECI1 
Adh STK11KO/Adh WT 1.13834 3.58E-13 VAMP7 
Adh STK11KO/Adh WT 1.17824 1.93E-16 RPL35A 
Adh STK11KO/Adh WT 1.237 1.26E-05 TAPBP 
Adh STK11KO/Adh WT 1.26017 1.92E-10 ITM2C 
Adh STK11KO/Adh WT 1.26472 1.69E-06 QPCTL 
Adh STK11KO/Adh WT 1.28596 1.09E-15 RPL38 
Adh STK11KO/Adh WT 1.32405 0 TAP1 
Adh STK11KO/Adh WT 1.34945 3.94E-11 TXLNA 
Adh STK11KO/Adh WT 1.35898 0 SCAMP1 
Adh STK11KO/Adh WT 1.37277 6.97E-07 ATP5L 
Adh STK11KO/Adh WT 1.39034 2.06E-18 PIK3C2A 
Adh STK11KO/Adh WT 1.40418 0 ATP5F1 
Adh STK11KO/Adh WT 1.40572 0 PDS5B 
Adh STK11KO/Adh WT 1.40666 0.0491441 TM9SF2 
Adh STK11KO/Adh WT 1.41433 2.29E-12 RRBP1 
Adh STK11KO/Adh WT 1.41741 5.52E-16 ICAM1 
Adh STK11KO/Adh WT 1.44288 0 ATP5A1 
Adh STK11KO/Adh WT 1.45806 0 MAGED2 
Adh STK11KO/Adh WT 1.4772 0 TOR1AIP1 
Adh STK11KO/Adh WT 1.55833 1.10E-13 SLC25A1 
Adh STK11KO/Adh WT 1.66223 0 MAP3K11 
Adh STK11KO/Adh WT 1.69199 0 SERPINH1 
Adh STK11KO/Adh WT 1.74111 0 MGST1 
Adh STK11KO/Adh WT 1.84896 3.54E-10 PIK3R1 
Adh STK11KO/Adh WT 1.90803 0 ATP5B 
Adh STK11KO/Adh WT 1.95366 0 TAP2 
Adh STK11KO/Adh WT 1.98368 0 GNG12 
Adh STK11KO/Adh WT 2.00741 0 CDK18 
Adh STK11KO/Adh WT 2.04915 6.00E-10 ST13 
Adh STK11KO/Adh WT 2.07961 0 ANXA2 
Adh STK11KO/Adh WT 2.11967 1.51E-09 CANX 
Adh STK11KO/Adh WT 2.19426 0 FECH 
Adh STK11KO/Adh WT 2.22504 0 FLT4 
Adh STK11KO/Adh WT 2.28825 0 IFIT1 
Adh STK11KO/Adh WT 2.52651 0 CSNK1G1 
Adh STK11KO/Adh WT 2.61056 0 CYB5A 
Adh STK11KO/Adh WT 2.6386 7.09E-12 UQCRQ 
Adh STK11KO/Adh WT 2.98745 0 LMAN1 


















Table S 2.3 Differentially expressed kinases from MIB/MS analysis completed using 
OVCAR8 parental and OVCAR8 STK11-KO spheroids 
Comparison log2Foldchange FDR Kinases  
Sph STK11KO/Sph WT -3.48543 5.19E-17 SCD 
Sph STK11KO/Sph WT -3.37233 0 FLNC 
Sph STK11KO/Sph WT -3.34529 0 STK17B 
Sph STK11KO/Sph WT -3.13482 0 NRAS 
Sph STK11KO/Sph WT -3.13154 0 NUAK1 
Sph STK11KO/Sph WT -2.66969 4.55E-12 RPS6 
Sph STK11KO/Sph WT -2.65475 0 ACSL3 
Sph STK11KO/Sph WT -2.57629 2.44E-14 KRT18 
Sph STK11KO/Sph WT -2.54447 1.17E-09 NCAPG2 
Sph STK11KO/Sph WT -2.30289 0 PYGB 
Sph STK11KO/Sph WT -2.22807 2.63E-12 AGTRAP 
Sph STK11KO/Sph WT -2.22772 0 PRKCA 
Sph STK11KO/Sph WT -2.21951 5.96E-15 PGRMC1 
Sph STK11KO/Sph WT -1.99452 0 TIMM44 
Sph STK11KO/Sph WT -1.87695 4.78E-12 SYMPK 
Sph STK11KO/Sph WT -1.83333 7.48E-08 SMEK1 
Sph STK11KO/Sph WT -1.8075 0 RHOG 
Sph STK11KO/Sph WT -1.77886 3.25E-07 TUBB2B 
Sph STK11KO/Sph WT -1.73956 1.33E-11 NSDHL 
Sph STK11KO/Sph WT -1.7236 0 RPS16 
Sph STK11KO/Sph WT -1.69924 1.77E-14 RAB32 
Sph STK11KO/Sph WT -1.64759 0 MAPK9 
Sph STK11KO/Sph WT -1.62553 0 FLAD1 
Sph STK11KO/Sph WT -1.60555 0 VPS51 
Sph STK11KO/Sph WT -1.57303 5.50E-15 PLIN3 
Sph STK11KO/Sph WT -1.5591 0 MYBBP1A 
Sph STK11KO/Sph WT -1.55809 2.60E-09 SF3B3 
Sph STK11KO/Sph WT -1.55766 0 LRPPRC 
Sph STK11KO/Sph WT -1.52809 1.63E-09 PPP6R3 
Sph STK11KO/Sph WT -1.52255 7.75E-09 EMD 
Sph STK11KO/Sph WT -1.5114 0 NCAPD2 
Sph STK11KO/Sph WT -1.39845 1.81E-06 PDCD6 
Sph STK11KO/Sph WT -1.35815 1.18E-15 COMT 
Sph STK11KO/Sph WT -1.35057 0 SUN2 
Sph STK11KO/Sph WT -1.32342 0 FUBP1 
Sph STK11KO/Sph WT -1.31536 4.89E-05 FADS2 
Sph STK11KO/Sph WT -1.26534 0 COPA 
Sph STK11KO/Sph WT -1.24441 4.24E-18 RPS18 
Sph STK11KO/Sph WT -1.23605 0.000352212 RRAS2 
Sph STK11KO/Sph WT -1.23138 1.39E-13 SCFD1 
Sph STK11KO/Sph WT -1.20503 8.13E-07 EPHB1 
Sph STK11KO/Sph WT -1.1891 2.30E-16 RPS15 
Sph STK11KO/Sph WT -1.14106 0 GBF1 
Sph STK11KO/Sph WT -1.13765 0 FLT4 
Sph STK11KO/Sph WT -1.12471 2.52E-06 PIK3R1 
Sph STK11KO/Sph WT -1.11742 1.72E-06 CYB5B 
Sph STK11KO/Sph WT -1.11272 0 RPS11 
Sph STK11KO/Sph WT -1.11085 1.46E-16 LIMS1 
Sph STK11KO/Sph WT -1.11085 1.50E-16 LIMS1 
Sph STK11KO/Sph WT -1.11068 3.32E-14 RPS14 
Sph STK11KO/Sph WT -1.10309 0 STK10 
Sph STK11KO/Sph WT -1.08591 0 ECI2 
Sph STK11KO/Sph WT -1.08205 7.90E-13 RPL32 
Sph STK11KO/Sph WT -1.08095 1.72E-15 LIMS1 
Sph STK11KO/Sph WT -1.05264 6.97E-06 CDK12 
Sph STK11KO/Sph WT -1.05 0 EXOC6B 
Sph STK11KO/Sph WT -1.04736 7.51E-17 THADA 
Sph STK11KO/Sph WT -1.03093 6.46E-15 MINK1 
Sph STK11KO/Sph WT -1.02728 0.00339175 UBAP2L 
Sph STK11KO/Sph WT -1.01132 0 TTK 
Sph STK11KO/Sph WT -0.984035 0.00216746 DHCR7 
Sph STK11KO/Sph WT -0.97816 3.30E-09 UBE3C 
Sph STK11KO/Sph WT -0.974436 6.90E-11 RPL38 
Sph STK11KO/Sph WT -0.970422 5.72E-13 EXOC8 
Sph STK11KO/Sph WT -0.966921 6.31E-11 EXOC1 
Sph STK11KO/Sph WT -0.958858 0.000156553 PIP4K2A 
Sph STK11KO/Sph WT -0.955781 0 ATM 
Sph STK11KO/Sph WT -0.942437 2.84E-05 STK35 
Sph STK11KO/Sph WT -0.941719 7.50E-09 RSU1 
Sph STK11KO/Sph WT -0.924964 7.67E-05 TPR 
Sph STK11KO/Sph WT -0.907183 2.92E-11 TUBA4A 
Sph STK11KO/Sph WT -0.900196 0.0496171 CCNB2 
Sph STK11KO/Sph WT -0.894975 1.50E-08 MAP3K2 
Sph STK11KO/Sph WT -0.886649 0 VAC14 
Sph STK11KO/Sph WT -0.882996 2.36E-08 TBCD 
Sph STK11KO/Sph WT -0.869391 7.05E-11 NDUFA5 
Sph STK11KO/Sph WT -0.855434 2.56E-14 RPL27A 
Sph STK11KO/Sph WT -0.848177 0 ECH1 
Sph STK11KO/Sph WT -0.843394 0 RPL23 
Sph STK11KO/Sph WT -0.839247 1.56E-12 FAM213A 
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Sph STK11KO/Sph WT -0.838761 0.0229795 HMOX2 
Sph STK11KO/Sph WT -0.838396 2.89E-06 LRRC59 
Sph STK11KO/Sph WT -0.837998 0 RPS13 
Sph STK11KO/Sph WT -0.832002 0.00712098 PDS5A 
Sph STK11KO/Sph WT -0.827391 0.00608555 PARVA 
Sph STK11KO/Sph WT -0.827368 0.00665596 PAM16 
Sph STK11KO/Sph WT -0.827025 0.000175625 PREB 
Sph STK11KO/Sph WT -0.822008 0 CLTC 
Sph STK11KO/Sph WT -0.813709 0.0335604 TMEM109 
Sph STK11KO/Sph WT -0.809857 2.13E-15 ILK 
Sph STK11KO/Sph WT -0.80725 7.45E-06 RAB21 
Sph STK11KO/Sph WT -0.782623 8.15E-09 ACAD10 
Sph STK11KO/Sph WT -0.777727 1.07E-12 MAP2K2 
Sph STK11KO/Sph WT -0.763121 0.00136247 UTP20 
Sph STK11KO/Sph WT -0.757222 0.000446193 CCDC51 
Sph STK11KO/Sph WT -0.757061 1.95E-05 RAN 
Sph STK11KO/Sph WT -0.756724 0.00894558 MLST8 
Sph STK11KO/Sph WT -0.753915 3.86E-10 RPL35A 
Sph STK11KO/Sph WT -0.752124 0 ADK 
Sph STK11KO/Sph WT -0.738901 0.00200141 RPL24 
Sph STK11KO/Sph WT -0.736196 3.43E-07 STX7 
Sph STK11KO/Sph WT -0.731367 8.75E-06 ATP6V1H 
Sph STK11KO/Sph WT -0.729044 0 MAP3K11 
Sph STK11KO/Sph WT -0.726824 1.97E-08 FAM96B 
Sph STK11KO/Sph WT -0.724824 1.59E-07 MAPK3 
Sph STK11KO/Sph WT -0.719494 0.0221523 UQCRH 
Sph STK11KO/Sph WT -0.718692 5.58E-05 ACAD9 
Sph STK11KO/Sph WT -0.718458 5.14E-06 CYB5R3 
Sph STK11KO/Sph WT -0.708042 0 HSPA9 
Sph STK11KO/Sph WT -0.707496 1.76E-17 RPS2 
Sph STK11KO/Sph WT -0.701246 3.86E-14 RPSA 
Sph STK11KO/Sph WT -0.690842 5.01E-09 MAP4K4 
Sph STK11KO/Sph WT -0.687111 3.02E-07 CSK 
Sph STK11KO/Sph WT -0.684726 7.78E-05 ABL1 
Sph STK11KO/Sph WT -0.665492 0.00195647 TBC1D9B 
Sph STK11KO/Sph WT -0.663198 3.37E-07 FASN 
Sph STK11KO/Sph WT -0.662588 3.76E-05 RPS17L 
Sph STK11KO/Sph WT -0.661202 0.0384989 GOSR2 
Sph STK11KO/Sph WT -0.651518 0.00820132 RAP1B 
Sph STK11KO/Sph WT -0.625081 1.56E-14 CDK7 
Sph STK11KO/Sph WT -0.622898 0.0168326 KPNB1 
Sph STK11KO/Sph WT -0.615883 3.50E-07 FIG4 
Sph STK11KO/Sph WT -0.610085 3.97E-10 RPS9 
Sph STK11KO/Sph WT -0.604385 0.000413051 ARL8B 
Sph STK11KO/Sph WT -0.594726 1.30E-05 RAB6A 
Sph STK11KO/Sph WT -0.594431 0.00760757 ATAD3B 
Sph STK11KO/Sph WT -0.592084 4.55E-08 COG5 
Sph STK11KO/Sph WT -0.588008 2.80E-05 RPL28 
Sph STK11KO/Sph WT -0.584233 0.0011594 ROCK2 
Sph STK11KO/Sph WT -0.578767 0.000145634 EBP 
Sph STK11KO/Sph WT -0.573096 0.0067214 CLTB 
Sph STK11KO/Sph WT -0.570763 0 RPL13A 
Sph STK11KO/Sph WT -0.567429 0.0121203 VAV2 
Sph STK11KO/Sph WT -0.562133 0 PRKAG2 
Sph STK11KO/Sph WT -0.561848 5.85E-07 SAV1 
Sph STK11KO/Sph WT -0.561772 0.00134446 COG2 
Sph STK11KO/Sph WT -0.561682 6.78E-09 MAP4K5 
Sph STK11KO/Sph WT -0.560547 7.04E-05 RPS6KA3 
Sph STK11KO/Sph WT -0.556208 0.00282658 SLK 
Sph STK11KO/Sph WT -0.551321 0.015724 PDPK1 
Sph STK11KO/Sph WT -0.540664 0 DYNC1H1 
Sph STK11KO/Sph WT -0.537804 4.79E-10 XPOT 
Sph STK11KO/Sph WT -0.537411 0.0243349 MAGED2 
Sph STK11KO/Sph WT -0.536687 0.012479 ST13 
Sph STK11KO/Sph WT -0.535633 0 RPL4 
Sph STK11KO/Sph WT -0.534414 0.0382769 MTAP 
Sph STK11KO/Sph WT -0.533489 0.000143486 RAB6A 
Sph STK11KO/Sph WT -0.51912 0.000504507 MROH1 
Sph STK11KO/Sph WT -0.514274 1.60E-06 KHSRP 
Sph STK11KO/Sph WT -0.505031 2.34E-12 DOLK 
Sph STK11KO/Sph WT -0.503148 0.000796961 GCDH 
Sph STK11KO/Sph WT -0.501827 0 RAB7A 
Sph STK11KO/Sph WT -0.494759 0 CAD 
Sph STK11KO/Sph WT -0.481615 0 IPO4 
Sph STK11KO/Sph WT -0.46631 6.00E-09 SART3 
Sph STK11KO/Sph WT -0.459903 0.00193414 RPS8 
Sph STK11KO/Sph WT -0.458644 3.21E-05 RARS2 
Sph STK11KO/Sph WT -0.458448 0 PTK2 
Sph STK11KO/Sph WT -0.458448 0 PTK2 
Sph STK11KO/Sph WT -0.45423 1.62E-11 XPO5 
Sph STK11KO/Sph WT -0.432373 0 PRKDC 
Sph STK11KO/Sph WT -0.425538 0 AXL 
Sph STK11KO/Sph WT -0.419782 0 TYK2 
Sph STK11KO/Sph WT -0.419402 5.22E-15 MAP2K1 
Sph STK11KO/Sph WT -0.415588 0.00501328 DPH5 
Sph STK11KO/Sph WT -0.412965 3.39E-13 RAB5C 
Sph STK11KO/Sph WT -0.408632 0 PRKDC 
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Sph STK11KO/Sph WT -0.407457 0.0371724 ZAK 
Sph STK11KO/Sph WT -0.404475 5.85E-17 RAB14 
Sph STK11KO/Sph WT -0.397436 0 RPL18A 
Sph STK11KO/Sph WT -0.394666 1.97E-06 KRT1 
Sph STK11KO/Sph WT -0.392986 0 HSPA1B 
Sph STK11KO/Sph WT -0.391635 0.0127224 RTN4 
Sph STK11KO/Sph WT -0.379502 1.95E-12 XPO7 
Sph STK11KO/Sph WT -0.374165 0 EPHB2 
Sph STK11KO/Sph WT -0.367441 0 MAP4K4 
Sph STK11KO/Sph WT -0.360693 3.53E-09 MARK3 
Sph STK11KO/Sph WT -0.357642 0.040308 NEK6 
Sph STK11KO/Sph WT -0.353954 1.46E-10 COPB1 
Sph STK11KO/Sph WT -0.339952 9.77E-17 PKMYT1 
Sph STK11KO/Sph WT -0.336012 0 KIAA0368 
Sph STK11KO/Sph WT -0.333549 3.74E-15 PKMYT1 
Sph STK11KO/Sph WT -0.331876 2.51E-05 ACLY 
Sph STK11KO/Sph WT -0.328222 0.000512077 ACLY 
Sph STK11KO/Sph WT -0.32409 0.000389264 SEC61A1 
Sph STK11KO/Sph WT -0.314597 0.0255496 PNPLA6 
Sph STK11KO/Sph WT -0.313107 0.0233145 UBXN4 
Sph STK11KO/Sph WT -0.310368 0 HNRNPM 
Sph STK11KO/Sph WT -0.306897 2.78E-13 USP34 
Sph STK11KO/Sph WT -0.30457 0.00544312 PI4KA 
Sph STK11KO/Sph WT -0.2942 0.0253741 RALA 
Sph STK11KO/Sph WT -0.292206 0.000527279 RASSF2 
Sph STK11KO/Sph WT -0.288472 0.000253914 SAR1A 
Sph STK11KO/Sph WT -0.285302 4.96E-08 RAB2A 
Sph STK11KO/Sph WT -0.281487 0.0465567 TRIM59 
Sph STK11KO/Sph WT -0.27655 0 IPO7 
Sph STK11KO/Sph WT -0.275875 0.00452219 RPL9 
Sph STK11KO/Sph WT -0.260112 0 RPS15A 
Sph STK11KO/Sph WT -0.245535 0 RPL7 
Sph STK11KO/Sph WT -0.240227 0.0470268 TUBB 
Sph STK11KO/Sph WT -0.237629 1.11E-08 IPO9 
Sph STK11KO/Sph WT -0.234483 1.45E-08 SRC 
Sph STK11KO/Sph WT -0.233395 0 SEC22B 
Sph STK11KO/Sph WT -0.224332 0.00046737 SF3B1 
Sph STK11KO/Sph WT -0.221411 0.00163216 PIK3R4 
Sph STK11KO/Sph WT -0.20482 1.82E-11 RIOK2 
Sph STK11KO/Sph WT -0.17614 1.37E-17 PAICS 
Sph STK11KO/Sph WT -0.154366 0.0435202 RPL6 
Sph STK11KO/Sph WT -0.137936 1.97E-16 PIP5K1A 
Sph STK11KO/Sph WT -0.132278 3.74E-11 HEATR2 
Sph STK11KO/Sph WT -0.132108 7.09E-06 MAGT1 
Sph STK11KO/Sph WT -0.124091 0.00428854 RPL3 
Sph STK11KO/Sph WT -0.109493 0 CSE1L 
Sph STK11KO/Sph WT -0.108647 0.00242741 TAOK2 
Sph STK11KO/Sph WT -0.10796 7.91E-17 USP9X 
Sph STK11KO/Sph WT -0.100679 1.20E-18 PDS5A 
Sph STK11KO/Sph WT -0.10025 0.0026357 AURKB 
Sph STK11KO/Sph WT -0.0967982 0.000202289 CDK9 
Sph STK11KO/Sph WT -0.0945296 0.00302984 STK3 
Sph STK11KO/Sph WT -0.0696641 3.86E-17 PIP5K1A 
Sph STK11KO/Sph WT -0.0434375 0.000657187 RHOT2 
Sph STK11KO/Sph WT -0.0335419 0 EPHA2 
Sph STK11KO/Sph WT -0.0308265 0.000740506 COPE 
Sph STK11KO/Sph WT -0.0188178 0 PAK4 
Sph STK11KO/Sph WT -0.0126456 0 KIAA1524 
Sph STK11KO/Sph WT 0.00994845 1.69E-12 HSPA8 
Sph STK11KO/Sph WT 0.0305907 3.64E-11 AHNAK 
Sph STK11KO/Sph WT 0.0389252 3.65E-09 PKN2 
Sph STK11KO/Sph WT 0.0426871 0 PRKACA 
Sph STK11KO/Sph WT 0.0557955 9.39E-14 TNPO3 
Sph STK11KO/Sph WT 0.056888 0 MNAT1 
Sph STK11KO/Sph WT 0.0594787 0.000211225 TNPO1 
Sph STK11KO/Sph WT 0.0837652 0 HINT1 
Sph STK11KO/Sph WT 0.0911725 0 PHGDH 
Sph STK11KO/Sph WT 0.0924039 0 TEX10 
Sph STK11KO/Sph WT 0.0938864 1.01E-11 PFKP 
Sph STK11KO/Sph WT 0.0968534 5.07E-14 PRKCD 
Sph STK11KO/Sph WT 0.100792 0.0460864 INTS8 
Sph STK11KO/Sph WT 0.101184 0 UBR4 
Sph STK11KO/Sph WT 0.105433 0.0239912 STK24 
Sph STK11KO/Sph WT 0.106974 2.77E-07 MRPS21 
Sph STK11KO/Sph WT 0.120785 0.000496981 NBEAL2 
Sph STK11KO/Sph WT 0.130432 0.0130971 TIMM50 
Sph STK11KO/Sph WT 0.131135 0 RPL21 
Sph STK11KO/Sph WT 0.131431 4.61E-06 TRIM32 
Sph STK11KO/Sph WT 0.163193 0.0267874 SGPL1 
Sph STK11KO/Sph WT 0.167619 0.0367335 TUBB3 
Sph STK11KO/Sph WT 0.168077 0 TUBGCP2 
Sph STK11KO/Sph WT 0.177168 0 HNRNPF 
Sph STK11KO/Sph WT 0.178642 0 EXOC7 
Sph STK11KO/Sph WT 0.19059 0.0118864 RPL14 
Sph STK11KO/Sph WT 0.207646 0 RPS21 
Sph STK11KO/Sph WT 0.22576 2.12E-09 FGFR1 
Sph STK11KO/Sph WT 0.233995 0.0321386 CDK1 
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Sph STK11KO/Sph WT 0.238455 0 TUBGCP3 
Sph STK11KO/Sph WT 0.301526 0.0245072 SSR1 
Sph STK11KO/Sph WT 0.319336 2.34E-07 FRYL 
Sph STK11KO/Sph WT 0.323551 6.56E-18 CDKN2A 
Sph STK11KO/Sph WT 0.327106 0 HSD17B4 
Sph STK11KO/Sph WT 0.334737 4.95E-06 RPL10 
Sph STK11KO/Sph WT 0.406535 0 ACAD11 
Sph STK11KO/Sph WT 0.412437 0.000337626 EEF1E1 
Sph STK11KO/Sph WT 0.419752 0.0339727 IKBKG 
Sph STK11KO/Sph WT 0.420021 0.0138581 RAB18 
Sph STK11KO/Sph WT 0.436476 0.0184064 TM9SF1 
Sph STK11KO/Sph WT 0.44087 0.00415574 YIPF5 
Sph STK11KO/Sph WT 0.467627 0 MAP2K3 
Sph STK11KO/Sph WT 0.467945 0.0120027 RPS6KA1 
Sph STK11KO/Sph WT 0.487755 3.19E-17 EPHB4 
Sph STK11KO/Sph WT 0.491705 6.09E-12 LTN1 
Sph STK11KO/Sph WT 0.493764 3.93E-05 DYNC1LI1 
Sph STK11KO/Sph WT 0.495303 9.42E-16 CCNT2 
Sph STK11KO/Sph WT 0.497198 0.00804752 MFSD10 
Sph STK11KO/Sph WT 0.498326 0 RRP12 
Sph STK11KO/Sph WT 0.512546 0.000188231 SYNGR2 
Sph STK11KO/Sph WT 0.521347 0 MTOR 
Sph STK11KO/Sph WT 0.523994 3.95E-13 ILVBL 
Sph STK11KO/Sph WT 0.525103 0.00386097 SSR4 
Sph STK11KO/Sph WT 0.554577 4.18E-08 VIM 
Sph STK11KO/Sph WT 0.560299 4.56E-07 RPL18 
Sph STK11KO/Sph WT 0.562575 1.58E-11 GALNT2 
Sph STK11KO/Sph WT 0.566858 4.90E-18 SMS 
Sph STK11KO/Sph WT 0.57452 0 TAP2 
Sph STK11KO/Sph WT 0.581634 0.00041941 RPL17 
Sph STK11KO/Sph WT 0.589561 0.000924406 ALDH2 
Sph STK11KO/Sph WT 0.594809 0.000629128 CANX 
Sph STK11KO/Sph WT 0.60419 1.21E-14 GAK 
Sph STK11KO/Sph WT 0.605527 3.09E-16 RALB 
Sph STK11KO/Sph WT 0.610454 1.95E-07 VDAC1 
Sph STK11KO/Sph WT 0.611646 0.000323635 ICAM1 
Sph STK11KO/Sph WT 0.614173 0.0146458 SDR39U1 
Sph STK11KO/Sph WT 0.614519 0.0479665 SCARB1 
Sph STK11KO/Sph WT 0.616813 1.14E-06 AIMP1 
Sph STK11KO/Sph WT 0.62146 0 DDX20 
Sph STK11KO/Sph WT 0.622915 5.34E-05 ZW10 
Sph STK11KO/Sph WT 0.635481 0.00506618 SACM1L 
Sph STK11KO/Sph WT 0.639644 0 EPRS 
Sph STK11KO/Sph WT 0.640733 0.00141675 ATP5L 
Sph STK11KO/Sph WT 0.643645 0 ATP2A2 
Sph STK11KO/Sph WT 0.648459 2.20E-11 MET 
Sph STK11KO/Sph WT 0.649707 1.01E-10 SLC25A24 
Sph STK11KO/Sph WT 0.656151 0.000309939 CAMK2G 
Sph STK11KO/Sph WT 0.657703 0 MDN1 
Sph STK11KO/Sph WT 0.664574 3.53E-05 STK4 
Sph STK11KO/Sph WT 0.667561 0 IMMT 
Sph STK11KO/Sph WT 0.673845 8.25E-05 TIA1 
Sph STK11KO/Sph WT 0.681871 5.96E-08 SLC25A10 
Sph STK11KO/Sph WT 0.683606 4.57E-11 PRKCSH 
Sph STK11KO/Sph WT 0.685454 1.09E-08 CSNK1G1 
Sph STK11KO/Sph WT 0.691497 3.68E-07 VCP 
Sph STK11KO/Sph WT 0.692219 3.01E-10 PRDX1 
Sph STK11KO/Sph WT 0.699264 0 IMMT 
Sph STK11KO/Sph WT 0.70019 2.04E-09 GNG12 
Sph STK11KO/Sph WT 0.701648 0.00032825 NDUFB4 
Sph STK11KO/Sph WT 0.709266 1.10E-06 FECH 
Sph STK11KO/Sph WT 0.719011 2.83E-12 TM9SF3 
Sph STK11KO/Sph WT 0.722003 0.0104575 COX2 
Sph STK11KO/Sph WT 0.722561 8.07E-06 SLC25A40 
Sph STK11KO/Sph WT 0.729783 0 NNT 
Sph STK11KO/Sph WT 0.730483 3.79E-08 LYN 
Sph STK11KO/Sph WT 0.734356 0.001038 CAMK2G 
Sph STK11KO/Sph WT 0.744702 1.77E-05 LGALS1 
Sph STK11KO/Sph WT 0.747761 0.0354334 MCCC2 
Sph STK11KO/Sph WT 0.764555 3.01E-16 RPLP0 
Sph STK11KO/Sph WT 0.768713 9.35E-09 MARS 
Sph STK11KO/Sph WT 0.773101 3.98E-17 RPS10 
Sph STK11KO/Sph WT 0.775334 3.07E-05 TMEM43 
Sph STK11KO/Sph WT 0.778184 0.032949 TAPBP 
Sph STK11KO/Sph WT 0.784423 0.00175903 TMEM115 
Sph STK11KO/Sph WT 0.7873 1.61E-08 TMEM209 
Sph STK11KO/Sph WT 0.794399 0 PHB2 
Sph STK11KO/Sph WT 0.794407 1.23E-11 MST4 
Sph STK11KO/Sph WT 0.794935 6.15E-10 AGPAT6 
Sph STK11KO/Sph WT 0.80084 4.37E-06 CCT6A 
Sph STK11KO/Sph WT 0.801168 6.94E-08 CDS2 
Sph STK11KO/Sph WT 0.802242 2.36E-16 GIGYF2 
Sph STK11KO/Sph WT 0.808216 0.000845363 SAMM50 
Sph STK11KO/Sph WT 0.81053 4.16E-14 DHRS7 
Sph STK11KO/Sph WT 0.813699 0.000130982 SLC16A3 
Sph STK11KO/Sph WT 0.821761 1.15E-17 ISOC2 
Sph STK11KO/Sph WT 0.828303 3.62E-12 ATP2C1 
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Sph STK11KO/Sph WT 0.828375 1.21E-06 KIAA0196 
Sph STK11KO/Sph WT 0.837102 1.74E-05 ALG1 
Sph STK11KO/Sph WT 0.837604 0.020383 ABCA3 
Sph STK11KO/Sph WT 0.864074 0 RPS29 
Sph STK11KO/Sph WT 0.872143 0.000453092 SLC25A5 
Sph STK11KO/Sph WT 0.875218 1.48E-12 MLEC 
Sph STK11KO/Sph WT 0.880406 0.000832934 ERLIN2 
Sph STK11KO/Sph WT 0.885284 3.08E-09 GNB2L1 
Sph STK11KO/Sph WT 0.888295 0 SURF4 
Sph STK11KO/Sph WT 0.894558 5.85E-13 ABL2 
Sph STK11KO/Sph WT 0.899008 1.24E-07 HIGD2A 
Sph STK11KO/Sph WT 0.910625 0 TBK1 
Sph STK11KO/Sph WT 0.914653 0 HIST1H4J 
Sph STK11KO/Sph WT 0.916817 0 NEK9 
Sph STK11KO/Sph WT 0.919027 0.00885921 SLC3A2 
Sph STK11KO/Sph WT 0.921194 0.00590018 CAMK2G 
Sph STK11KO/Sph WT 0.925895 3.44E-10 FER 
Sph STK11KO/Sph WT 0.936974 1.77E-10 QARS 
Sph STK11KO/Sph WT 0.944069 1.91E-08 OSBPL3 
Sph STK11KO/Sph WT 0.949747 2.76E-14 IKBKB 
Sph STK11KO/Sph WT 0.949965 1.52E-17 MBOAT7 
Sph STK11KO/Sph WT 0.950227 0 JAK1 
Sph STK11KO/Sph WT 0.954273 1.51E-05 RER1 
Sph STK11KO/Sph WT 0.960666 1.34E-15 THEM6 
Sph STK11KO/Sph WT 0.963373 1.32E-07 SLC35F6 
Sph STK11KO/Sph WT 0.978513 2.87E-07 ATP6 
Sph STK11KO/Sph WT 0.978904 0 DCK 
Sph STK11KO/Sph WT 0.992695 4.46E-11 ATP5J2 
Sph STK11KO/Sph WT 0.993561 1.33E-09 RPL15 
Sph STK11KO/Sph WT 0.993607 9.57E-10 BDH1 
Sph STK11KO/Sph WT 0.99791 0 LYN 
Sph STK11KO/Sph WT 0.999429 0 PI4K2A 
Sph STK11KO/Sph WT 1.00927 0 ATAD3A 
Sph STK11KO/Sph WT 1.01155 0.0142484 G6PC3 
Sph STK11KO/Sph WT 1.01437 0 ATP5A1 
Sph STK11KO/Sph WT 1.03493 0 EIF2AK2 
Sph STK11KO/Sph WT 1.04449 4.58E-15 VPS53 
Sph STK11KO/Sph WT 1.06255 1.26E-10 KDELR1 
Sph STK11KO/Sph WT 1.07429 1.39E-16 FYN 
Sph STK11KO/Sph WT 1.08442 9.19E-18 TMX2 
Sph STK11KO/Sph WT 1.08648 2.67E-17 PRKAB1 
Sph STK11KO/Sph WT 1.08895 1.87E-08 STT3A 
Sph STK11KO/Sph WT 1.08895 1.09E-05 SLC25A32 
Sph STK11KO/Sph WT 1.09101 3.75E-10 SLC43A3 
Sph STK11KO/Sph WT 1.09578 0 ATP5J 
Sph STK11KO/Sph WT 1.10222 6.73E-06 YIPF4 
Sph STK11KO/Sph WT 1.10245 1.27E-12 UBAC2 
Sph STK11KO/Sph WT 1.11123 0 RAB3B 
Sph STK11KO/Sph WT 1.11664 9.65E-06 CD44 
Sph STK11KO/Sph WT 1.12337 6.58E-17 RPL10A 
Sph STK11KO/Sph WT 1.13242 3.03E-14 PDE12 
Sph STK11KO/Sph WT 1.13749 2.25E-16 SFXN1 
Sph STK11KO/Sph WT 1.14882 9.24E-13 TXLNA 
Sph STK11KO/Sph WT 1.15577 1.47E-13 HIST1H2BD 
Sph STK11KO/Sph WT 1.15889 2.19E-12 COG6 
Sph STK11KO/Sph WT 1.16145 8.73E-09 SFXN3 
Sph STK11KO/Sph WT 1.16812 1.09E-16 SMPD4 
Sph STK11KO/Sph WT 1.16812 1.12E-16 SMPD4 
Sph STK11KO/Sph WT 1.16858 4.64E-07 DARS 
Sph STK11KO/Sph WT 1.17451 3.55E-08 PIK3C2A 
Sph STK11KO/Sph WT 1.17675 6.10E-05 CLK3 
Sph STK11KO/Sph WT 1.18208 2.40E-06 EXOC6 
Sph STK11KO/Sph WT 1.19217 3.56E-07 TMEM165 
Sph STK11KO/Sph WT 1.197 1.72E-05 MAP2K5 
Sph STK11KO/Sph WT 1.20759 7.88E-18 CSNK1E 
Sph STK11KO/Sph WT 1.20886 0 DHRS1 
Sph STK11KO/Sph WT 1.21131 0 SLC25A3 
Sph STK11KO/Sph WT 1.21761 0.000123407 PTDSS1 
Sph STK11KO/Sph WT 1.23069 0 VDAC3 
Sph STK11KO/Sph WT 1.23647 1.22E-08 IARS 
Sph STK11KO/Sph WT 1.23799 2.26E-14 CAMK2G 
Sph STK11KO/Sph WT 1.24467 6.46E-11 COX6C 
Sph STK11KO/Sph WT 1.25214 1.82E-10 CDK17 
Sph STK11KO/Sph WT 1.25507 5.49E-09 FAM3C 
Sph STK11KO/Sph WT 1.25942 4.11E-17 SLC1A5 
Sph STK11KO/Sph WT 1.26179 0 ATP5B 
Sph STK11KO/Sph WT 1.2836 9.45E-13 COX4I1 
Sph STK11KO/Sph WT 1.28481 7.19E-15 BSG 
Sph STK11KO/Sph WT 1.28798 0 ULK3 
Sph STK11KO/Sph WT 1.29375 2.19E-08 INTS5 
Sph STK11KO/Sph WT 1.29677 0 ATP5H 
Sph STK11KO/Sph WT 1.30073 4.69E-16 DYNC2H1 
Sph STK11KO/Sph WT 1.3136 0 MCU 
Sph STK11KO/Sph WT 1.33362 2.14E-11 RPS6KA4 
Sph STK11KO/Sph WT 1.35614 5.39E-09 PLP2 
Sph STK11KO/Sph WT 1.36174 2.36E-06 STX5 
Sph STK11KO/Sph WT 1.36681 0 PRKACB 
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Sph STK11KO/Sph WT 1.37186 0 UNC45A 
Sph STK11KO/Sph WT 1.38364 6.19E-08 COX5B 
Sph STK11KO/Sph WT 1.38913 0 ABCD3 
Sph STK11KO/Sph WT 1.39326 0.00102365 TIMM23B 
Sph STK11KO/Sph WT 1.41228 0 ATR 
Sph STK11KO/Sph WT 1.41276 3.10E-08 NCLN 
Sph STK11KO/Sph WT 1.42546 0 LMAN1 
Sph STK11KO/Sph WT 1.45926 1.36E-11 EPT1 
Sph STK11KO/Sph WT 1.46067 8.38E-10 PIP4K2B 
Sph STK11KO/Sph WT 1.48257 0 ATP5C1 
Sph STK11KO/Sph WT 1.49042 0 ARL1 
Sph STK11KO/Sph WT 1.50071 6.80E-10 OXA1L 
Sph STK11KO/Sph WT 1.50409 0 CHUK 
Sph STK11KO/Sph WT 1.50667 2.21E-17 RARS 
Sph STK11KO/Sph WT 1.51822 0 MAPK8 
Sph STK11KO/Sph WT 1.52171 0 NUP205 
Sph STK11KO/Sph WT 1.52609 4.00E-07 YIF1B 
Sph STK11KO/Sph WT 1.52701 5.80E-15 FKBP11 
Sph STK11KO/Sph WT 1.52828 1.03E-06 SLC35F2 
Sph STK11KO/Sph WT 1.52944 0 MON2 
Sph STK11KO/Sph WT 1.53392 3.87E-05 PIK3C3 
Sph STK11KO/Sph WT 1.53668 0 ANXA2 
Sph STK11KO/Sph WT 1.54135 0 TRRAP 
Sph STK11KO/Sph WT 1.55556 0 STOM 
Sph STK11KO/Sph WT 1.56808 0 SCAMP1 
Sph STK11KO/Sph WT 1.58165 4.68E-11 SLC25A17 
Sph STK11KO/Sph WT 1.59683 0 ACVR1 
Sph STK11KO/Sph WT 1.65054 0 SLC35A3 
Sph STK11KO/Sph WT 1.66084 0 YES1 
Sph STK11KO/Sph WT 1.70278 0 USMG5 
Sph STK11KO/Sph WT 1.72408 3.58E-14 DHCR24 
Sph STK11KO/Sph WT 1.72477 2.78E-11 MRPS5 
Sph STK11KO/Sph WT 1.75029 1.49E-15 HM13 
Sph STK11KO/Sph WT 1.86365 1.40E-11 CLPTM1L 
Sph STK11KO/Sph WT 1.88443 2.59E-16 CHEK1 
Sph STK11KO/Sph WT 1.88886 3.02E-15 SLC25A13 
Sph STK11KO/Sph WT 1.9451 2.57E-07 FLOT1 
Sph STK11KO/Sph WT 1.97657 1.11E-17 BMPR2 
Sph STK11KO/Sph WT 2.00539 0 HSPA5 
Sph STK11KO/Sph WT 2.05881 2.38E-14 IFIT1 
Sph STK11KO/Sph WT 2.07378 2.48E-15 SCD5 
Sph STK11KO/Sph WT 2.10827 0 TMEM205 
Sph STK11KO/Sph WT 2.11547 0 CSNK1G3 
Sph STK11KO/Sph WT 2.14808 0 FAR1 
Sph STK11KO/Sph WT 2.149 2.96E-14 GOLT1B 
Sph STK11KO/Sph WT 2.1772 1.95E-14 PRSS21 
Sph STK11KO/Sph WT 2.18722 0 COX20 
Sph STK11KO/Sph WT 2.1926 0 AZI2 
Sph STK11KO/Sph WT 2.19488 0 SOAT1 
Sph STK11KO/Sph WT 2.22416 2.71E-11 EEF1G 
Sph STK11KO/Sph WT 2.23739 0 ATP5F1 
Sph STK11KO/Sph WT 2.24375 0 BMP2K 
Sph STK11KO/Sph WT 2.26545 6.82E-15 RPS23 
Sph STK11KO/Sph WT 2.30779 0 LBR 
Sph STK11KO/Sph WT 2.37631 0 ATP5O 
Sph STK11KO/Sph WT 2.48406 0 TAP1 
Sph STK11KO/Sph WT 2.48581 0 PRKAA2 
Sph STK11KO/Sph WT 2.50144 2.08E-12 MEST 
Sph STK11KO/Sph WT 2.50181 1.18E-14 SLC38A2 
Sph STK11KO/Sph WT 2.52814 0 CMTM6 
Sph STK11KO/Sph WT 2.55842 0 OPA1 
Sph STK11KO/Sph WT 2.59186 0 ANAPC1 
Sph STK11KO/Sph WT 2.62651 0 NDUFA11 
Sph STK11KO/Sph WT 2.77471 2.87E-13 INTS7 
Sph STK11KO/Sph WT 2.77545 0 GAPDH 
Sph STK11KO/Sph WT 2.84706 0 PCID2 
Sph STK11KO/Sph WT 2.913 0 HSP90B1 
Sph STK11KO/Sph WT 2.93831 0 TARBP1 
Sph STK11KO/Sph WT 2.98146 2.39E-18 ITM2C 
Sph STK11KO/Sph WT 3.14963 0 CYB5A 
Sph STK11KO/Sph WT 3.15967 1.03E-18 SLC25A1 
Sph STK11KO/Sph WT 3.77099 0 HLA-C 
Sph STK11KO/Sph WT 4.35891 7.99E-15 CERS5 








Table S 2.4 Differentially expressed genes from the Affymetrix Clariom S array using 
OVCAR8 parental and OVCAR8 NUAK1-KO spheroids 
Gene  
Log2 fold change (NUAK1 
Knockout/Parental) 
P-value FDR P-value 
FN1 -745.23 3.67E-19 7.87E-15 
NFIB -49.17 2.23E-16 1.19E-12 
CD24 -38.36 3.53E-12 3.79E-09 
PAX8 -33.57 6.53E-11 4.52E-08 
TFAP2A -23.16 4.28E-14 1.15E-10 
NNMT -22.27 4.44E-15 1.91E-11 
IL6 -16.61 4.16E-05 0.0026 
NID2 -10.96 6.42E-12 6.26E-09 
FAM198B -10.44 2.75E-09 1.11E-06 
L1CAM -10.43 1.43E-07 2.58E-05 
ADGRG1 -10.36 1.64E-09 8.00E-07 
ITGB8 -10.21 6.27E-07 8.85E-05 
S100A2 -9.84 1.30E-07 2.37E-05 
P3H2 -9.46 8.11E-07 0.0001 
GNG11 -9.4 9.19E-13 1.23E-09 
RUNX2 -9.16 7.88E-08 1.60E-05 
GALNT7 -8.46 5.01E-11 3.71E-08 
THBS1 -8.33 3.00E-13 5.35E-10 
SPOCK1 -8.21 9.93E-08 1.87E-05 
SEMA3C -7.97 4.88E-13 7.47E-10 
PLEKHA7 -7.72 9.90E-08 1.87E-05 
KRT7 -7.58 4.20E-12 4.29E-09 
GDA -7.21 3.33E-08 8.50E-06 
ID3 -6.47 1.24E-07 2.28E-05 
PMEPA1 -6.42 7.56E-10 3.86E-07 
PDE1C -6.35 7.13E-10 3.83E-07 
SEMA3E -6.2 6.80E-06 0.0006 
IL7R -6.17 3.33E-07 5.24E-05 
TRPC4 -5.9 8.07E-09 2.83E-06 
SERTAD4 -5.75 2.21E-10 1.40E-07 
TGFBI -5.67 4.97E-09 1.84E-06 
EFEMP1 -5.65 1.92E-08 6.05E-06 
RBPMS -5.46 0.0001 0.0065 
FAM129A -5.46 2.34E-07 3.84E-05 
TENM2 -5.44 1.03E-07 1.91E-05 
SLC16A2 -5.37 3.12E-08 8.24E-06 
SMAD3 -5.33 4.32E-07 6.62E-05 
PTPN20 -5.32 4.44E-09 1.70E-06 
GFRA1 -5.13 9.59E-07 0.0001 
SMAD6 -5.13 1.44E-05 0.0011 
PSMB9 -4.93 6.88E-06 0.0007 
CLDN1 -4.91 0.0027 0.0494 
NREP -4.8 5.42E-05 0.0032 
EDNRA -4.76 2.23E-05 0.0015 
PHLDB2; PLCXD2 -4.68 3.62E-09 1.41E-06 
GBP1 -4.67 0.0035 0.0599 
LRRN4 -4.66 8.50E-06 0.0007 
PLPP3 -4.51 1.36E-06 0.0002 
LHX1 -4.5 1.93E-09 9.00E-07 
FERMT1 -4.41 5.02E-08 1.12E-05 
UBE2L6 -4.38 1.85E-08 6.00E-06 
GPR143 -4.35 3.52E-08 8.78E-06 
PDPN -4.24 1.45E-07 2.59E-05 
SERTAD4 -4.24 1.73E-08 5.69E-06 
THSD4 -4.23 7.50E-05 0.004 
METTL7B -4.23 6.24E-05 0.0035 
DDX60 -4.17 4.29E-07 6.62E-05 
RBMS3 -4.12 0.0006 0.0189 
DNAJA4 -4.05 1.15E-06 0.0001 
PARP14 -4.01 0.0001 0.0057 
COL1A1 -4 3.26E-10 1.89E-07 
KRT80 -3.96 8.98E-05 0.0045 
PLXND1 -3.93 1.47E-06 0.0002 
HCFC1R1 -3.88 0.0013 0.0306 
ARHGEF5 -3.87 2.49E-08 7.20E-06 
DPYSL2 -3.86 4.85E-08 1.10E-05 
PSMB8 -3.86 1.47E-05 0.0011 
MCAM; MIR6756 -3.86 2.31E-06 0.0003 
HES1 -3.82 1.32E-05 0.001 
SYT17 -3.82 1.19E-07 2.20E-05 
OR2A7; ARHGEF34P -3.75 3.83E-08 9.22E-06 
LGR4 -3.75 3.02E-08 8.09E-06 
CAMK1D -3.74 6.53E-10 3.59E-07 
ERBB3 -3.73 5.84E-05 0.0033 
S100A16 -3.64 8.36E-06 0.0007 
ESRP1 -3.64 0.0001 0.0056 
VANGL2 -3.63 4.81E-05 0.0029 
EGR1 -3.61 0.0011 0.0272 
PLXDC2 -3.61 3.71E-08 9.11E-06 
OLFML2B -3.6 2.41E-07 3.89E-05 
IGFBP6 -3.6 7.60E-08 1.57E-05 
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ENAH -3.59 1.00E-09 5.00E-07 
SERTAD4 -3.58 8.66E-08 1.69E-05 
PCDHB5 -3.56 8.31E-08 1.65E-05 
TLR3 -3.55 6.18E-05 0.0034 
F11R -3.52 2.67E-06 0.0003 
ACTBL2 -3.51 5.51E-05 0.0032 
PLOD2 -3.48 6.19E-07 8.79E-05 
APOL1 -3.4 9.88E-05 0.0048 
MAGED1 -3.39 4.42E-05 0.0027 
TMEM184A -3.38 0.0003 0.0109 
LOX -3.35 0.0018 0.0383 
MFSD6 -3.33 0.0006 0.0184 
MAGED4; MAGED4B; SNORA11D; 
SNORA11E 
-3.33 0.0003 0.012 
FAM84B -3.31 1.24E-05 0.001 
SIM1 -3.31 4.96E-07 7.33E-05 
TINAGL1 -3.31 0.0009 0.0242 
LITAF -3.29 6.44E-09 2.34E-06 
ACTC1 -3.27 0.0315 0.2279 
STXBP6 -3.26 1.49E-05 0.0011 
IFIT3 -3.26 3.74E-08 9.11E-06 
TSPAN2 -3.25 3.12E-07 4.96E-05 
CTAGE8 -3.23 9.70E-05 0.0048 
GRAMD3 -3.21 8.79E-06 0.0008 
AGPAT3 -3.2 6.07E-07 8.68E-05 
SCIN -3.18 0.0048 0.0728 
ANXA3 -3.15 3.21E-06 0.0003 
LTBP3 -3.14 2.93E-08 8.06E-06 
UGT3A2 -3.14 7.96E-08 1.60E-05 
FGF2 -3.1 7.38E-10 3.86E-07 
TXNIP -3.09 0.0082 0.1034 
PSG9 -3.08 0.0116 0.1271 
SAMD9L -3.06 4.67E-05 0.0028 
CELSR2 -3.05 2.45E-06 0.0003 
GPER1 -3.03 7.00E-05 0.0038 
LIMCH1 -3.02 0.0004 0.0132 
IFIT2 -2.99 9.71E-05 0.0048 
CNTNAP3B -2.98 0.0016 0.0344 
KLF9 -2.98 0.0043 0.0677 
S100A13 -2.97 2.46E-05 0.0017 
ITGB4 -2.95 0.0001 0.0051 
ERCC6; ERCC6-PGBD3; PGBD3 -2.94 5.57E-05 0.0032 
PLEKHG1 -2.94 7.65E-05 0.004 
ME3 -2.94 0.0399 0.2601 
INPP4B -2.9 9.08E-06 0.0008 
PROSER2 -2.88 6.27E-08 1.32E-05 
INADL -2.87 0.0026 0.049 
KRT7 -2.87 1.20E-06 0.0002 
FBXO32 -2.86 0.0003 0.0105 
PSMB8-AS1 -2.86 1.02E-05 0.0009 
FAM167A -2.85 0.018 0.1653 
ZSCAN31 -2.83 7.07E-06 0.0007 
MKX -2.8 2.74E-09 1.11E-06 
GSN -2.8 8.77E-05 0.0044 
GPRC5A; MIR614 -2.77 1.19E-05 0.001 
DYRK1B -2.76 0.0001 0.0057 
ACSF2 -2.76 0.0006 0.0179 
MBNL2 -2.75 9.27E-07 0.0001 
PERP -2.75 2.13E-06 0.0002 
SLC26A2 -2.74 1.30E-05 0.001 
MAGED4B; MAGED4; SNORA11D -2.73 1.66E-05 0.0012 
C1R -2.71 0.0018 0.0378 
FLT1 -2.7 0.002 0.0408 
RBM24 -2.69 0.0003 0.0117 
CARD16 -2.69 0.0006 0.0186 
PROS1 -2.67 1.94E-07 3.32E-05 
IFI16 -2.66 1.76E-05 0.0013 
APOBEC3G -2.63 1.15E-05 0.0009 
DTX3L -2.63 0.0002 0.0069 
EMP1 -2.62 0.0008 0.0219 
LRRC16A -2.61 1.89E-08 6.05E-06 
ACKR3 -2.59 0.0034 0.0582 
DENND2D -2.58 0.0057 0.0819 
SHISA2 -2.57 4.00E-06 0.0004 
NPAS2 -2.57 0.0005 0.0173 
APOL2 -2.56 8.02E-07 0.0001 
SGK223 -2.56 2.21E-05 0.0015 
APOE -2.56 0.0001 0.0062 
FBXO44 -2.54 0.0007 0.0212 
MYO1E -2.54 3.47E-05 0.0022 
MN1 -2.54 0.0362 0.2463 
COL4A1 -2.54 0.0005 0.016 
S100A6 -2.54 1.57E-06 0.0002 
PDE4DIP -2.53 2.42E-05 0.0016 
DSC3 -2.53 1.16E-06 0.0001 
SHROOM3 -2.53 3.23E-05 0.0021 
TSPAN15 -2.52 2.25E-05 0.0015 
97 
 
DHTKD1 -2.52 9.81E-05 0.0048 
CDA -2.51 0.0019 0.0387 
TPD52L1 -2.5 2.06E-05 0.0015 
LAMC2 -2.49 0.0017 0.0364 
ITGB5 -2.49 6.37E-05 0.0035 
BEX1 -2.48 1.16E-06 0.0001 
MGST2 -2.48 4.15E-08 9.90E-06 
DNAJC15 -2.48 0.0001 0.0058 
COL4A2 -2.48 0.0008 0.0221 
SPTLC3 -2.47 0.0002 0.0095 
SNX9 -2.47 4.21E-08 9.93E-06 
TRMT12 -2.46 1.83E-06 0.0002 
GSTM2 -2.45 9.57E-06 0.0008 
PRSS23 -2.44 0.0002 0.0068 
NMU -2.44 3.09E-06 0.0003 
PARP9 -2.44 1.63E-05 0.0012 
DENND2A -2.43 2.54E-06 0.0003 
CFAP206 -2.42 3.52E-07 5.52E-05 
CLIC3 -2.41 0.0061 0.0855 
SEMA3A -2.41 0.0003 0.0125 
TMEM255A -2.41 9.34E-05 0.0046 
MTRR -2.4 0.0002 0.0068 
GLT8D2 -2.4 0.0007 0.0199 
PRKCA -2.38 1.44E-05 0.0011 
ST3GAL6 -2.38 0.0037 0.0614 
DPYD -2.38 5.58E-06 0.0005 
PTPRJ -2.38 4.89E-07 7.29E-05 
RARG -2.37 2.14E-07 3.56E-05 
PCDHGC3; PCDHGA12; 
PCDHGB4; PCDHGA8; PCDHGA1; 
PCDHGA10; PCDHGA11; 
PCDHGA2; PCDHGA3; PCDHGA4; 
PCDHGA5; PCDHGA6; PCDHGA7; 
PCDHGA9; PCDHGB1; PCDHGB2; 
PCDHGB3; PCDHGB5; PCDHGB6; 
PCDHGB7; PCDHGC4; PCDHGC5 
-2.37 0.0034 0.0588 
ITM2A -2.37 2.44E-06 0.0003 
PRKCQ -2.36 8.41E-05 0.0043 
TRPV4 -2.36 2.30E-08 6.94E-06 
NHS -2.36 0.005 0.0753 
PTOV1; MIR4749 -2.36 8.65E-05 0.0044 
EGFLAM -2.36 0.0023 0.044 
AGPAT4 -2.35 0.0033 0.0572 
FAM83B -2.35 4.23E-05 0.0026 
ASIC1 -2.34 0.0286 0.2168 
VCAN -2.34 0.0009 0.0234 
SLC18B1 -2.34 2.05E-06 0.0002 
FOXP1 -2.34 0.0003 0.0108 
PLEKHG4B -2.34 0.002 0.0402 
NDRG4 -2.33 0.001 0.0262 
TIAM1 -2.33 0.0037 0.0623 
SVIL -2.33 0.0463 0.2818 
PTPN6 -2.33 0.0021 0.0416 
ATP8B1 -2.32 7.53E-06 0.0007 
PIM1 -2.32 0.0173 0.1614 
BST1 -2.32 1.83E-06 0.0002 
ACAA2 -2.32 1.45E-06 0.0002 
CTAGE8; CTAGE4 -2.31 0.0006 0.0178 
RAB30 -2.31 2.90E-05 0.0019 
SRPX2 -2.3 0.0013 0.0295 
NDUFA13 -2.3 0.0048 0.0728 
CTSF -2.3 0.003 0.0532 
DGKD -2.29 1.64E-06 0.0002 
SERPINB9 -2.29 0.0023 0.0441 
SMAD7 -2.29 0.0165 0.1575 
CRISPLD1 -2.28 0.0003 0.0104 
KCNMA1 -2.28 0.0014 0.0312 
BAIAP2L1 -2.28 0.0003 0.0102 
NEDD9 -2.28 0.0008 0.0226 
DHRS13 -2.28 0.0001 0.0054 
CAPN3 -2.27 0.0017 0.0364 
PLBD1 -2.27 6.90E-06 0.0007 
EEF1A2 -2.27 6.02E-07 8.66E-05 
43160 -2.27 0.0008 0.0217 
SERPINB1 -2.26 0.0003 0.0117 
IGF1R -2.26 7.33E-06 0.0007 
IFIH1 -2.26 0.002 0.0401 
GPR161 -2.25 2.24E-05 0.0015 
ABRACL -2.25 4.44E-05 0.0027 
C5 -2.25 0.0362 0.2462 
SLC2A12 -2.24 0.0016 0.035 
TAPBPL -2.24 0.0007 0.0197 
MBOAT1 -2.24 0.0008 0.0217 
OLFML3 -2.24 0.0004 0.0143 
TRIM69 -2.24 1.79E-05 0.0013 
CASP1 -2.23 0.0038 0.0634 
MEIS3 -2.23 0.0072 0.0945 
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BDH2 -2.23 2.99E-05 0.002 
DSC2 -2.23 6.89E-05 0.0037 
SMAD7 -2.22 0.0002 0.008 
PKP2 -2.22 1.72E-06 0.0002 
TP53I3 -2.22 2.12E-06 0.0002 
BMP1 -2.22 0.0015 0.0338 
VAMP8 -2.21 2.16E-05 0.0015 
SYT16 -2.2 2.20E-05 0.0015 
SUSD4 -2.2 0.0312 0.2268 
DAW1 -2.2 0.0046 0.0712 
TPRA1 -2.2 0.0005 0.0173 
NIPSNAP1 -2.2 0.0272 0.2105 
CES4A -2.19 3.26E-05 0.0021 
DYRK1B -2.19 7.23E-06 0.0007 
MYO1D -2.18 0.0003 0.0103 
SERPINH1 -2.18 0.0004 0.0137 
ERAP2 -2.18 6.63E-05 0.0036 
MSLN -2.18 0.0036 0.0602 
LUM -2.18 0.0227 0.1901 
SERPINB4 -2.18 0.0074 0.0959 
VGLL3 -2.17 0.0036 0.0604 
GNL1 -2.17 0.0007 0.021 
SMO -2.17 2.74E-05 0.0018 
ROR2 -2.17 0.0006 0.0195 
KIAA1644 -2.17 0.0073 0.0951 
AP4M1 -2.17 7.19E-05 0.0038 
ARL4C -2.17 0.001 0.0259 
RNF144B -2.16 1.35E-05 0.0011 
EXT1 -2.16 1.54E-06 0.0002 
CCL28 -2.16 0.001 0.0262 
TCEAL2 -2.15 2.43E-06 0.0003 
IER3 -2.15 0.0002 0.0084 
ECI1 -2.15 0.0018 0.0381 
CYP1B1 -2.15 0.0021 0.042 
CALHM2 -2.14 0.0002 0.007 
PPIC -2.14 1.17E-05 0.001 
PRKD2 -2.13 6.51E-05 0.0036 
TFPI2 -2.13 2.58E-08 7.38E-06 
DUSP1 -2.13 8.66E-05 0.0044 
SPOCD1 -2.13 0.0162 0.1552 
CNTNAP3P2; CNTNAP3 -2.13 0.0002 0.0074 
TBL1X -2.13 0.0424 0.2689 
P2RX7 -2.13 0.0056 0.0813 
OR2A4 -2.13 0.0018 0.0375 
MBD5 -2.13 0.0036 0.0605 
MID2 -2.12 0.0004 0.0136 
PTGFRN -2.12 0.0284 0.2158 
S100A3 -2.11 0.001 0.0252 
FOXO1 -2.11 0.0031 0.0554 
EPB41L3 -2.11 2.97E-06 0.0003 
MYO3A -2.11 0.0002 0.0087 
43347 -2.11 0.0009 0.0234 
SCD5 -2.1 0.0026 0.0483 
CA13 -2.1 0.0146 0.146 
COL18A1 -2.1 0.0003 0.0114 
PSG4 -2.1 0.01 0.1159 
ETFB -2.1 0.001 0.0262 
CCBE1 -2.1 0.0008 0.0222 
GLB1L2 -2.1 5.64E-05 0.0032 
ARFRP1 -2.1 4.86E-06 0.0005 
NUAK1 -2.1 0.0064 0.0881 
CD163L1 -2.09 0.0015 0.0339 
CRIP1 -2.08 0.0041 0.0665 
SAMD15 -2.08 1.93E-05 0.0014 
PTPRK -2.08 1.63E-06 0.0002 
SERPING1 -2.08 0.0011 0.0264 
APOL6 -2.08 3.58E-05 0.0023 
MGAT4B -2.08 1.29E-05 0.001 
DCLK1 -2.08 0.0007 0.0197 
PTRF -2.07 0.0006 0.0177 
MOSPD3 -2.07 0.0155 0.1508 
EPCAM -2.06 4.34E-08 1.01E-05 
SEPW1 -2.06 0.0083 0.1034 
BTN3A2 -2.06 0.0115 0.1271 
SLC6A9 -2.06 0.0353 0.2428 
BEX4 -2.06 8.22E-06 0.0007 
MARVELD2 -2.06 9.78E-05 0.0048 
PCMTD2 -2.05 8.99E-05 0.0045 
C19orf66 -2.05 0.0025 0.0477 
CXXC5 -2.05 0.0075 0.0965 
LRRC6 -2.05 0.0037 0.0615 
TCEAL8 -2.05 0.0015 0.0337 
GTF2IRD2B -2.05 0.0012 0.0293 
TGFBR1 -2.05 0.0007 0.0211 
ALDH7A1 -2.05 0.0002 0.0081 
GLIPR2 -2.05 0.0003 0.0116 
SEL1L3 -2.04 0.0125 0.1327 
99 
 
ZFYVE28 -2.04 0.0042 0.0674 
RAB31 -2.04 3.32E-05 0.0021 
RRBP1 -2.04 0.0003 0.0102 
MYD88 -2.04 0.0012 0.0287 
SAT1 -2.03 0.0068 0.0914 
MPP7 -2.03 1.60E-06 0.0002 
GPC3 -2.03 0.0251 0.2018 
SMAD1 -2.03 5.45E-05 0.0032 
LRAT -2.03 0.0001 0.0058 
UCP2 -2.03 0.0002 0.0094 
STAT6 -2.03 2.88E-06 0.0003 
CYB561 -2.02 0.0014 0.0324 
CDKL2 -2.02 0.0002 0.0089 
SLITRK5 -2.02 4.86E-05 0.0029 
OAS3 -2.02 0.0019 0.0396 
C11orf70 -2.02 0.0019 0.0399 
FRRS1 -2.01 0.0118 0.1284 
LRP4 -2.01 0.0063 0.0876 
RHOBTB3 -2.01 5.76E-07 8.35E-05 
BDH1 -2.01 0.0046 0.0716 
PDE4D -2.01 0.0087 0.107 
SP110 -2.01 8.12E-05 0.0042 
FIS1 -2.01 0.002 0.0407 
CARHSP1 -2 0.001 0.0252 
GPC6 -2 0.0113 0.1254 
CD74 -2 0.0039 0.0639 
CACNA2D4 2 0.0008 0.0221 
NRIP3 2 0.0004 0.014 
PRAMEF19 2 0.0076 0.0976 
PHF20L1 2 0.0153 0.1498 
ITGB1BP2 2.01 0.0005 0.0152 
RAD54L2 2.01 1.37E-05 0.0011 
CCDC84 2.01 0.0135 0.1393 
LRIG1 2.02 1.92E-05 0.0014 
ACTR3B 2.02 0.001 0.0252 
FZD7 2.02 4.01E-05 0.0025 
GATA3 2.03 0.011 0.1234 
SERPINA1 2.03 0.0114 0.1268 
CSF2RA 2.03 0.0008 0.0222 
FABP6 2.03 0.0268 0.2093 
C8orf88 2.03 5.73E-07 8.35E-05 
DNAJB9 2.03 0.012 0.1297 
KLF14 2.03 0.0002 0.0089 
SERTAD2 2.03 0.0008 0.0217 
CCL19 2.03 0.0373 0.2497 
DIAPH2 2.03 5.06E-05 0.003 
GOLGA8J 2.04 0.0002 0.0086 
CSPP1 2.04 0.0003 0.0124 
CD274 2.04 0.0012 0.0285 
CALB2 2.05 0.0369 0.2491 
SAA2; SAA2-SAA4; SAA4 2.05 2.19E-05 0.0015 
WDFY2 2.05 2.82E-08 7.95E-06 
ANKRD20A3; ANKRD20A2 2.06 0.0057 0.0823 
ITPRIP 2.06 0.0011 0.0278 
CA2 2.06 6.79E-06 0.0006 
BMPER 2.06 0.0024 0.046 
GOLGA8N 2.07 2.20E-05 0.0015 
YES1 2.07 2.41E-09 1.08E-06 
PAG1 2.07 0.0002 0.007 
MMP16 2.07 0.0028 0.0506 
PPP4R4 2.08 0.0002 0.0074 
ADAMTS16 2.08 0.0055 0.0803 
NOL4L 2.08 0.0004 0.0136 
EEA1 2.08 0.0002 0.0076 
STK39 2.08 0.0001 0.0062 
ZNF438 2.09 8.50E-06 0.0007 
CHUK 2.09 0.0152 0.149 
ZDHHC11 2.09 0.0004 0.0144 
MERTK 2.09 2.68E-05 0.0018 
CIART 2.09 0.0108 0.1211 
CSF2RA 2.09 1.12E-05 0.0009 
RNF24 2.1 9.29E-05 0.0046 
GOLGA8T 2.1 7.29E-05 0.0039 
MAN1C1 2.11 0.0005 0.0152 
SERTAD1 2.11 0.0336 0.2362 
GLDC 2.11 1.60E-05 0.0012 
PHYHIPL 2.11 0.0007 0.0204 
SLC25A22 2.13 0.001 0.0262 
ANO4 2.13 0.0007 0.0197 
DENND3 2.13 0.0002 0.007 
GRB10 2.13 0.0005 0.0152 
GEM 2.13 0.0178 0.1642 
ECSCR 2.13 0.0006 0.0181 
SLIT2 2.14 0.0218 0.1858 
CLK1 2.14 0.0005 0.0172 
IGIP 2.14 0.0335 0.2357 
SLCO1B7; SLCO1B1 2.14 0.0032 0.0556 
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UACA 2.14 0.0004 0.0136 
LHX9 2.14 0.0304 0.224 
43163 2.17 6.73E-05 0.0037 
NGEF 2.18 0.001 0.0253 
FBXO48 2.18 0.0001 0.0065 
TTC21B 2.18 1.51E-07 2.66E-05 
SESN3 2.2 0.0318 0.2291 
ITGA6 2.2 0.0014 0.0324 
CPED1 2.2 1.58E-07 2.76E-05 
POP1 2.21 5.60E-05 0.0032 
RNF217 2.22 9.35E-05 0.0046 
MGEA5 2.22 0.042 0.2675 
SPRED3 2.22 0.0102 0.1171 
NFE4 2.22 6.96E-05 0.0038 
USP3 2.23 0.0477 0.2858 
NCF2 2.24 5.28E-05 0.0031 
DET1 2.25 0.0049 0.0746 
ZEB1 2.25 6.30E-06 0.0006 
XAGE1E; XAGE1B 2.25 1.62E-07 2.81E-05 
JMJD6 2.25 0.0004 0.0145 
LIMD1 2.26 2.35E-08 7.00E-06 
ARID3B 2.26 5.05E-05 0.003 
CHD7 2.27 7.97E-06 0.0007 
ZEB2 2.27 0.0001 0.0056 
LRRC20 2.27 0.0008 0.0222 
ZFP30 2.28 0.0025 0.0477 
ANKRD20A1 2.28 0.0061 0.0859 
OTUD6B 2.28 7.03E-08 1.46E-05 
R3HDM1 2.29 0.0266 0.209 
ZNF114 2.31 7.64E-05 0.004 
XAGE1B; XAGE1E 2.32 1.09E-08 3.67E-06 
E2F5 2.32 1.45E-05 0.0011 
CBLN2 2.33 0.0008 0.0221 
CLIP4 2.34 0.0009 0.0248 
GOLGA8N; GOLGA8H 2.34 0.0002 0.0074 
MAP3K14 2.35 0.0008 0.0217 
TBC1D4 2.35 1.74E-06 0.0002 
CLDN4 2.36 0.0004 0.0136 
EXPH5 2.36 0.0003 0.0109 
SATB2 2.37 5.59E-08 1.19E-05 
G0S2 2.38 0.0023 0.0447 
SNX16 2.38 3.73E-06 0.0004 
ELL2 2.38 1.29E-05 0.001 
ZC3H6 2.4 0.0027 0.0497 
ADAMTS1 2.4 0.0369 0.2491 
SYCP1 2.41 5.48E-05 0.0032 
FAM196B 2.42 0.0069 0.0918 
LAMB3; MIR4260 2.44 4.60E-07 6.93E-05 
TRIML2 2.45 3.45E-05 0.0022 
CPNE3 2.45 2.75E-09 1.11E-06 
FAM173B 2.45 0.0054 0.0789 
MYH15 2.47 1.43E-05 0.0011 
DOC2B 2.47 2.07E-05 0.0015 
MYBL1 2.48 5.09E-06 0.0005 
43162 2.49 1.45E-05 0.0011 
TMEM55A 2.5 0.0002 0.0092 
PDCD1LG2 2.51 0.0033 0.0567 
ENC1 2.51 0.0002 0.0076 
SYTL3 2.51 3.15E-08 8.24E-06 
DEFB124 2.51 0.006 0.0853 
ITPR1 2.52 7.51E-06 0.0007 
KIAA1549L 2.53 2.12E-07 3.56E-05 
CD82 2.54 8.47E-06 0.0007 
TRIM6-TRIM34 2.54 0.0415 0.2656 
COL6A1 2.56 1.24E-05 0.001 
ABHD3 2.56 0.0086 0.1061 
TIE1 2.56 0.0013 0.0305 
PCDH9 2.58 0.0004 0.0145 
PDE4DIP 2.58 0.0004 0.0145 
ADAMTS6 2.58 3.34E-06 0.0003 
RORB 2.59 3.24E-06 0.0003 
GPR135 2.59 0.044 0.2747 
AJAP1 2.6 0.0094 0.1118 
EIF2S2 2.6 0.0349 0.2416 
TBX2 2.62 9.13E-07 0.0001 
NCEH1 2.63 1.89E-06 0.0002 
MSR1 2.64 1.21E-05 0.001 
SERINC5 2.64 5.22E-08 1.14E-05 
FILIP1 2.66 6.95E-06 0.0007 
SAMD3 2.66 1.16E-06 0.0001 
ARHGEF10 2.66 0.0439 0.2743 
STAMBPL1 2.73 3.49E-05 0.0022 
HDAC9 2.75 5.26E-08 1.14E-05 
PDE2A 2.76 0.0006 0.0176 
MYEOV 2.76 7.14E-05 0.0038 
APCDD1L 2.77 1.59E-05 0.0012 
TMEM200A 2.79 7.90E-07 0.0001 
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C4orf22 2.8 7.53E-06 0.0007 
AP1S1 2.8 0.0093 0.1108 
ZNF697 2.8 1.39E-05 0.0011 
EIF5A2 2.8 3.03E-05 0.002 
DUSP6 2.82 0.0008 0.0222 
TAOK3 2.86 3.46E-08 8.72E-06 
PAX6 2.88 0.0229 0.1913 
DNAH5 2.88 0.0134 0.1383 
ADTRP 2.9 1.25E-05 0.001 
TRHDE 2.91 4.82E-09 1.81E-06 
MFAP3L 2.93 7.06E-06 0.0007 
TACSTD2 2.93 2.34E-06 0.0003 
ZNF582-AS1 2.94 5.52E-08 1.18E-05 
THRAP3 2.98 9.31E-07 0.0001 
SOX30 3.01 1.84E-06 0.0002 
SDCCAG8 3.01 3.62E-11 2.99E-08 
PITPNC1 3.01 2.30E-06 0.0003 
GRPR 3.02 0.0085 0.1052 
LRIG1 3.02 1.57E-06 0.0002 
NFE2L3 3.02 3.32E-08 8.50E-06 
GCNT2 3.04 4.62E-07 6.93E-05 
GAL 3.04 0.0039 0.0644 
NTN4 3.07 9.26E-06 0.0008 
FUBP3 3.08 0.0042 0.0674 
NFKB2 3.08 2.50E-09 1.09E-06 
RPS6KA5 3.11 0.0002 0.0072 
PLAUR 3.11 2.87E-10 1.71E-07 
KCNK1 3.15 1.23E-05 0.001 
PTPRB 3.16 3.28E-06 0.0003 
FMN1 3.16 5.27E-08 1.14E-05 
PDE10A 3.17 2.98E-08 8.08E-06 
BHLHE41 3.17 3.76E-05 0.0023 
EVI2A; EVI2B 3.22 2.88E-06 0.0003 
CRNDE 3.22 4.39E-08 1.01E-05 
RRAD 3.24 1.50E-05 0.0011 
ATP1A3 3.26 2.07E-05 0.0015 
ACTR3C 3.28 2.80E-09 1.11E-06 
CAMK2N1 3.38 2.37E-07 3.84E-05 
FST 3.4 9.86E-07 0.0001 
SERPINA9 3.45 0.0018 0.0381 
SPRY4 3.48 3.82E-05 0.0024 
FBXL13 3.63 2.87E-08 7.99E-06 
RCN3 3.72 4.88E-08 1.10E-05 
STC1 3.72 0.0091 0.1101 
SEMA7A 3.75 7.89E-09 2.82E-06 
PRDM1 3.8 1.70E-05 0.0012 
FAT4 3.93 9.09E-06 0.0008 
ADGRL2 4 2.95E-12 3.34E-09 
AKR1E2 4.02 1.08E-10 7.27E-08 
OTUD6B 4.06 0.0001 0.0052 
SPANXA1 4.15 3.34E-06 0.0003 
IL1A 4.19 0.0022 0.0426 
SERPINB7 4.26 1.92E-06 0.0002 
BIRC3 4.29 1.65E-05 0.0012 
GOLGA8M 4.43 2.38E-09 1.08E-06 
FMN1 4.52 1.46E-07 2.59E-05 
SPANXA2 4.6 8.42E-08 1.66E-05 
KCNK1 4.64 1.98E-07 3.37E-05 
AFF3 4.7 2.13E-08 6.53E-06 
SPANXC; SPANXD 4.72 9.57E-08 1.83E-05 
GGT1 4.86 2.02E-12 2.54E-09 
PAQR5 4.94 4.83E-10 2.73E-07 
ARHGAP18 5.01 2.78E-11 2.49E-08 
SPANXD 5.08 2.35E-07 3.84E-05 
DUSP10 5.36 6.55E-06 0.0006 
SCG5 5.74 7.98E-08 1.60E-05 
FGF5 6.04 2.68E-10 1.64E-07 
GFPT2 6.2 1.96E-08 6.10E-06 
TRIM6 6.29 4.33E-06 0.0004 
TRIM55 6.29 1.12E-10 7.30E-08 
ANTXR2 6.5 2.67E-12 3.18E-09 
GOLGA8J; GOLGA8IP 6.66 3.83E-11 3.04E-08 
BCL2A1 6.89 6.84E-05 0.0037 
PTPN7 7.14 2.46E-08 7.20E-06 
NAV3 7.5 8.84E-08 1.71E-05 
RFX8 7.56 4.21E-11 3.22E-08 
ESM1 7.64 6.97E-07 9.77E-05 
HCLS1 8.78 6.28E-11 4.49E-08 
SCN4A 8.79 6.61E-13 9.45E-10 
MCTP1 11.56 3.01E-11 2.58E-08 
ARHGDIB 12.7 2.59E-09 1.11E-06 
DNAH11 16.7 8.19E-09 2.83E-06 
FRMD4A 18.68 2.87E-14 8.78E-11 
KCTD4 19.09 4.68E-13 7.47E-10 
COL6A3 21.49 2.47E-11 2.30E-08 
HMGA2 24.19 1.89E-13 3.68E-10 
IL1B 25.75 1.91E-09 9.00E-07 
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SPANXB1 32.57 1.29E-13 2.76E-10 
LSAMP 42.05 8.74E-17 6.25E-13 
SLCO1B3 46.88 6.27E-14 1.49E-10 
IGF2BP3 79.01 6.20E-18 6.65E-14 
IL1RAPL1 83.4 2.11E-14 7.56E-11 













































Table S 2.5 Signatures from the GSEA Hallmark database that were enriched in the 
OVCAR8 parental spheroids compared to NUAK1-KO spheroids 
Signature SIZE NES NOM p-val FDR q-val 
HALLMARK_INTERFERON_ALPHA_RESPONSE 91 -2.7054312 0 0 
HALLMARK_INTERFERON_GAMMA_RESPONSE 191 -2.4021258 0 0 
HALLMARK_OXIDATIVE_PHOSPHORYLATION 190 -2.3491118 0 0 
HALLMARK_TGF_BETA_SIGNALING 53 -2.2527528 0 0 
HALLMARK_EPITHELIAL_MESENCHYMAL_TRA
NSITION 
192 -2.0939176 0 0 
HALLMARK_UV_RESPONSE_DN 138 -1.9165574 0 0.001234232 
HALLMARK_ESTROGEN_RESPONSE_LATE 194 -1.8456159 0 0.001557613 
HALLMARK_COAGULATION 134 -1.7818395 0 0.001941036 
HALLMARK_FATTY_ACID_METABOLISM 154 -1.6792668 0 0.005176689 
HALLMARK_GLYCOLYSIS 192 -1.6327271 0 0.007976532 
HALLMARK_ESTROGEN_RESPONSE_EARLY 192 -1.5897167 0 0.015067029 
HALLMARK_APOPTOSIS 155 -1.5840265 0.001996008 0.015184187 
HALLMARK_XENOBIOTIC_METABOLISM 193 -1.4987085 0.00631579 0.030580582 
HALLMARK_PEROXISOME 98 -1.470946 0.018828452 0.036381334 
HALLMARK_IL6_JAK_STAT3_SIGNALING 85 -1.4557805 0.02970297 0.038870838 
HALLMARK_COMPLEMENT 189 -1.4311881 0.012578616 0.04369105 
HALLMARK_ADIPOGENESIS 189 -1.4024873 0.008350731 0.054584257 
HALLMARK_DNA_REPAIR 138 -1.4016854 0.013861386 0.051881213 
HALLMARK_APICAL_JUNCTION 193 -1.3409612 0.021097047 0.08460455 
HALLMARK_P53_PATHWAY 192 -1.3290477 0.036053132 0.088990174 
HALLMARK_ANDROGEN_RESPONSE 95 -1.3151934 0.06464647 0.095708445 
HALLMARK_BILE_ACID_METABOLISM 110 -1.2827135 0.067510545 0.11766519 
HALLMARK_MYOGENESIS 193 -1.250651 0.077380955 0.14307003 
HALLMARK_HYPOXIA 195 -1.2473122 0.05394191 0.14089133 
HALLMARK_HEDGEHOG_SIGNALING 33 -1.2160786 0.19161677 0.17120273 
HALLMARK_NOTCH_SIGNALING 31 -1.1836603 0.23353294 0.20465736 
HALLMARK_CHOLESTEROL_HOMEOSTASIS 69 -1.1732962 0.20762712 0.21209985 
HALLMARK_UV_RESPONSE_UP 153 -1.0836782 0.26112187 0.37113476 
HALLMARK_HEME_METABOLISM 188 -1.057075 0.29892474 0.4191625 
HALLMARK_UNFOLDED_PROTEIN_RESPONSE 101 -0.99530345 0.4732334 0.5657768 
HALLMARK_ALLOGRAFT_REJECTION 194 -0.96332645 0.54545456 0.6399002 
HALLMARK_MTORC1_SIGNALING 194 -0.92412955 0.6653144 0.7322477 
HALLMARK_KRAS_SIGNALING_DN 189 -0.9128246 0.68801653 0.7430476 
HALLMARK_MYC_TARGETS_V1 182 -0.88959765 0.7632094 0.7847153 
HALLMARK_ANGIOGENESIS 34 -0.81437385 0.77124184 0.92550606 
HALLMARK_PI3K_AKT_MTOR_SIGNALING 102 -0.77584875 0.9198397 0.951884 
HALLMARK_REACTIVE_OXIGEN_SPECIES_PAT
HWAY 
























Table S 2.6 Signatures from the Curated Canonical database that were enriched in the 
OVCAR8 parental spheroids compared to NUAK1-KO spheroids 




117 2.4250476 0 0 
REACTOME_RESPIRATORY
_ELECTRON_TRANSPORT 








83 2.3558912 0 0 
KEGG_OXIDATIVE_PHOSP
HORYLATION 
118 2.172282 0 0.002648652 
KEGG_PARKINSONS_DISE
ASE 
114 2.1558495 0 0.002933157 




76 2.0570054 0 0.009632743 
PID_INTEGRIN3_PATHWAY 43 2.0240114 0 0.014649713 
REACTOME_INTERFERON_
ALPHA_BETA_SIGNALING 
62 2.0232646 0 0.013021966 
KEGG_HUNTINGTONS_DIS
EASE 
166 1.9060166 0 0.054231856 
REACTOME_CHOLESTERO
L_BIOSYNTHESIS 




58 1.8561774 0 0.082995996 
REACTOME_PEROXISOMA
L_LIPID_METABOLISM 
20 1.8259057 0.006369427 0.1092535 
KEGG_ALZHEIMERS_DISEA
SE 
154 1.8171077 0 0.11037827 
PID_ALK1_PATHWAY 24 1.7910784 0.004192872 0.13650955 
BIOCARTA_IL10_PATHWAY 17 1.7874752 0.005882353 0.13265434 
KEGG_TGF_BETA_SIGNALI
NG_PATHWAY 




43 1.7849728 0 0.12104583 
PID_INTEGRIN5_PATHWAY 17 1.7796471 0.002155172 0.120900206 
PID_INTEGRIN_A4B1_PATH
WAY 




38 1.745068 0.001949318 0.152775 
PID_SYNDECAN_4_PATHW
AY 




21 1.7352419 0.004338395 0.15202415 
NABA_ECM_GLYCOPROTEI
NS 








42 1.7166786 0.00203666 0.15961316 
KEGG_BUTANOATE_META
BOLISM 




23 1.707847 0.005882353 0.15925156 
KEGG_CITRATE_CYCLE_T
CA_CYCLE 
30 1.7071004 0.015350877 0.15484129 
KEGG_LYSOSOME 112 1.69712 0.002070393 0.1625121 
REACTOME_INTEGRIN_ALP
HAIIB_BETA3_SIGNALING 





16 1.6850712 0.012320329 0.1695966 
REACTOME_CITRIC_ACID_
CYCLE_TCA_CYCLE 




187 1.6830503 0 0.16256264 
BIOCARTA_TGFB_PATHWA
Y 
17 1.6720524 0.010438413 0.17372315 














32 1.6478745 0.018404908 0.19089222 
REACTOME_ADP_SIGNALLI
NG_THROUGH_P2RY12 
21 1.6463863 0.016771488 0.18813518 
PID_HNF3A_PATHWAY 40 1.6354098 0.013182675 0.20152982 
KEGG_ARGININE_AND_PR
OLINE_METABOLISM 





24 1.6316165 0.027559055 0.19779563 
NABA_CORE_MATRISOME 266 1.6309464 0 0.19421901 
REACTOME_DNA_STRAND
_ELONGATION 
30 1.6283588 0.028397566 0.19361688 
KEGG_ALLOGRAFT_REJEC
TION 
35 1.6252248 0.010504202 0.19454151 
REACTOME_G_ALPHA_Z_S
IGNALLING_EVENTS 




55 1.6214255 0.007920792 0.19180961 
KEGG_ECM_RECEPTOR_IN
TERACTION 




24 1.6184843 0.015873017 0.1887426 
REACTOME_APOPTOSIS 137 1.6184403 0.002123142 0.18514235 
BIOCARTA_AMI_PATHWAY 20 1.6128327 0.027083334 0.19010895 
BIOCARTA_INTRINSIC_PAT
HWAY 




21 1.6096189 0.01724138 0.18777327 
BIOCARTA_NKCELLS_PATH
WAY 




35 1.6031371 0.018595042 0.19020115 
PID_TAP63_PATHWAY 51 1.6026647 0.008333334 0.18769751 
PID_P75_NTR_PATHWAY 68 1.5984294 0.00625 0.1909825 
REACTOME_INTERFERON_
SIGNALING 
145 1.5983958 0 0.18776758 
REACTOME_SIGNALING_B
Y_BMP 
21 1.5963877 0.01996008 0.1874588 
REACTOME_ER_PHAGOSO
ME_PATHWAY 
57 1.5889894 0.012422361 0.19604644 
KEGG_DNA_REPLICATION 36 1.5863802 0.016985139 0.1970921 
REACTOME_INTRINSIC_PA
THWAY_FOR_APOPTOSIS 
28 1.5859164 0.024742268 0.19466896 
REACTOME_SYNTHESIS_O
F_DNA 
89 1.5851712 0.006122449 0.19273548 
REACTOME_G_PROTEIN_A
CTIVATION 




31 1.5838822 0.016064256 0.18908563 
REACTOME_INTERFERON_
GAMMA_SIGNALING 
59 1.5833796 0.006097561 0.18712942 
REACTOME_OPIOID_SIGNA
LLING 




17 1.5754918 0.028455285 0.19233225 
KEGG_GLYCEROLIPID_ME
TABOLISM 







63 1.5635766 0.008547009 0.20472707 
REACTOME_RECYCLING_P
ATHWAY_OF_L1 










17 1.5497735 0.042769857 0.21738997 





19 1.5380563 0.042283297 0.23040678 





19 1.5362239 0.054166667 0.22750781 
REACTOME_AQUAPORIN_
MEDIATED_TRANSPORT 
49 1.5340035 0.021611001 0.22799714 
PID_INTEGRIN1_PATHWAY 61 1.5332756 0.006423983 0.22650884 
PID_ECADHERIN_NASCENT
_AJ_PATHWAY 




62 1.529226 0.022633744 0.2281819 
PID_HES_HEY_PATHWAY 44 1.5289323 0.023861172 0.2259424 
NABA_BASEMENT_MEMBR
ANES 
38 1.5224735 0.031936128 0.2337058 
BIOCARTA_HER2_PATHWA
Y 




20 1.5197867 0.056962024 0.23223741 




23 1.5174003 0.048523206 0.23106578 
PID_AVB3_INTEGRIN_PATH
WAY 
70 1.515213 0.008032128 0.23194045 
BIOCARTA_COMP_PATHW
AY 
19 1.5141706 0.05394191 0.23093401 
PID_AJDISS_2PATHWAY 46 1.508477 0.018556701 0.23700342 
REACTOME_PHASE_II_CO
NJUGATION 




71 1.5042404 0.016877636 0.23883425 












48 1.501078 0.025423728 0.23369037 
BIOCARTA_CASPASE_PAT
HWAY 
23 1.4991196 0.039832287 0.23434655 
REACTOME_MRNA_SPLICI
NG_MINOR_PATHWAY 




46 1.4941695 0.034907598 0.237467 
REACTOME_G_PROTEIN_B
ETA_GAMMA_SIGNALLING 
28 1.4922813 0.042944785 0.2384413 
KEGG_ASCORBATE_AND_
ALDARATE_METABOLISM 




251 1.4859794 0.0041841 0.24373905 
REACTOME_MITOCHONDRI
AL_PROTEIN_IMPORT 








45 1.4738513 0.035789475 0.25693157 
REACTOME_METABOLISM_
OF_NUCLEOTIDES 
65 1.4695488 0.026915114 0.26149666 
BIOCARTA_ALK_PATHWAY 35 1.466976 0.039748956 0.26325598 
KEGG_HYPERTROPHIC_CA
RDIOMYOPATHY_HCM 
80 1.4649509 0.021653544 0.2639134 
KEGG_TRYPTOPHAN_MET
ABOLISM 
38 1.4645885 0.046184737 0.2621237 
REACTOME_REGULATION_
OF_APOPTOSIS 
54 1.4624798 0.050916497 0.26320863 
REACTOME_ORC1_REMOV
AL_FROM_CHROMATIN 




16 1.4615057 0.057082452 0.26017174 
REACTOME_CELL_CYCLE_
CHECKPOINTS 
109 1.4586178 0.018480493 0.26268274 
REACTOME_MHC_CLASS_II
_ANTIGEN_PRESENTATION 








46 1.4532164 0.032719836 0.26526627 
REACTOME_RESPONSE_T
O_ELEVATED_PLATELET_C














19 1.4376354 0.06823028 0.28373176 
REACTOME_AXON_GUIDA
NCE 








25 1.4359705 0.06521739 0.2797048 
KEGG_FATTY_ACID_META
BOLISM 
41 1.4352506 0.045454547 0.27877176 
BIOCARTA_STATHMIN_PAT
HWAY 
19 1.4341376 0.065979384 0.27850756 
BIOCARTA_BIOPEPTIDES_
PATHWAY 
41 1.4334395 0.06637168 0.27751234 
BIOCARTA_PPARA_PATHW
AY 




46 1.4302399 0.03862661 0.27889702 
REACTOME_GLUCONEOGE
NESIS 
31 1.4284494 0.06944445 0.2798538 
BIOCARTA_NTHI_PATHWA
Y 
22 1.4241819 0.07459678 0.28511232 
REACTOME_PLC_BETA_ME
DIATED_EVENTS 





20 1.4222279 0.09445585 0.28399003 
KEGG_BETA_ALANINE_ME
TABOLISM 





15 1.4190136 0.10759494 0.28531414 
ST_GRANULE_CELL_SURVI
VAL_PATHWAY 
26 1.4145983 0.080912866 0.29086304 
BIOCARTA_IGF1R_PATHWA
Y 
23 1.4081068 0.08130081 0.30137894 
REACTOME_M_G1_TRANSI
TION 
77 1.404145 0.022357723 0.30706486 
KEGG_PROTEASOME 43 1.4038216 0.05263158 0.3056058 
REACTOME_SEMAPHORIN
_INTERACTIONS 




45 1.4027147 0.05870021 0.30335867 
REACTOME_SIGNAL_AMPLI
FICATION 
31 1.4025677 0.06736842 0.3014733 
REACTOME_SIGNAL_TRAN
SDUCTION_BY_L1 




48 1.3943431 0.052287582 0.31198832 




46 1.3918942 0.055555556 0.312446 
PID_TOLL_ENDOGENOUS_
PATHWAY 
24 1.3889744 0.09221312 0.31561768 
PID_P53_REGULATION_PA
THWAY 
53 1.3886273 0.07355865 0.31401545 
KEGG_ANTIGEN_PROCESS
ING_AND_PRESENTATION 
68 1.3864337 0.0513347 0.3164378 
KEGG_DRUG_METABOLIS
M_OTHER_ENZYMES 




71 1.3825823 0.053892214 0.31977093 
BIOCARTA_PROTEASOME_
PATHWAY 
28 1.3795207 0.0927835 0.32381332 
REACTOME_SIGNALING_B
Y_WNT 
61 1.3795192 0.050607286 0.32169688 




56 1.3743217 0.067940556 0.32792503 
KEGG_LYSINE_DEGRADATI
ON 
40 1.3719423 0.07272727 0.33042938 
REACTOME_APC_CDC20_
MEDIATED_DEGRADATION








47 1.3685005 0.07858546 0.3306503 
PID_UPA_UPAR_PATHWAY 42 1.3655357 0.07643312 0.33455923 
REACTOME_REGULATION_
OF_MITOTIC_CELL_CYCLE 
76 1.363621 0.058139537 0.33615276 
REACTOME_APOPTOTIC_E
XECUTION_PHASE 
49 1.3584377 0.06048387 0.3441212 
REACTOME_GLYCOSPHIN
GOLIPID_METABOLISM 








53 1.3545519 0.06779661 0.3452327 
PID_SYNDECAN_2_PATHW
AY 
31 1.3529468 0.100603625 0.34632286 
KEGG_DRUG_METABOLIS
M_CYTOCHROME_P450 
60 1.35216 0.070866145 0.34573102 
REACTOME_BASE_EXCISI
ON_REPAIR 
19 1.3510861 0.118644066 0.34577295 
KEGG_CYSTEINE_AND_ME
THIONINE_METABOLISM 
33 1.3494531 0.08118812 0.34694788 




18 1.3464526 0.12228797 0.34845555 
REACTOME_HS_GAG_DEG
RADATION 
19 1.346061 0.12068965 0.34707668 
REACTOME_PURINE_META
BOLISM 
32 1.3449745 0.11196911 0.3472988 
REACTOME_DEVELOPMEN
TAL_BIOLOGY 










46 1.3418329 0.09650924 0.3474075 
KEGG_TERPENOID_BACKB
ONE_BIOSYNTHESIS 
15 1.3417426 0.11825726 0.3456439 
PID_SMAD2_3NUCLEAR_PA
THWAY 
79 1.340966 0.04592902 0.34527993 
PID_LYMPH_ANGIOGENESI
S_PATHWAY 
23 1.3390052 0.12698413 0.34728825 
REACTOME_CHONDROITIN
_SULFATE_BIOSYNTHESIS 
18 1.3381987 0.13948497 0.34675038 
PID_ENDOTHELIN_PATHW
AY 




21 1.3334126 0.10897436 0.35247245 
REACTOME_PYRIMIDINE_M
ETABOLISM 
22 1.3328283 0.13247864 0.35198689 








48 1.3266934 0.10123967 0.3584592 
PID_INTEGRIN_CS_PATHW
AY 
25 1.3259953 0.12179487 0.35778698 
PID_BMP_PATHWAY 42 1.3249217 0.08835341 0.35786015 
REACTOME_SULFUR_AMIN
O_ACID_METABOLISM 
24 1.3242701 0.108481266 0.3572813 




231 1.3202465 0.012552301 0.36134368 
BIOCARTA_CHEMICAL_PAT
HWAY 
21 1.3166109 0.14967462 0.3670731 
REACTOME_COMPLEMENT
_CASCADE 
29 1.3158318 0.10300429 0.36681148 
PID_CDC42_PATHWAY 68 1.3147354 0.08085106 0.36733884 
REACTOME_GLYCOSAMIN
OGLYCAN_METABOLISM 
104 1.3146957 0.06138614 0.36553633 
BIOCARTA_MITOCHONDRI
A_PATHWAY 
21 1.3143437 0.13219616 0.364259 
BIOCARTA_CYTOKINE_PAT
HWAY 
20 1.3117241 0.13943355 0.3677875 
BIOCARTA_MTA3_PATHWA
Y 
18 1.3114395 0.136 0.36656293 
PID_ECADHERIN_STABILIZ
ATION_PATHWAY 









55 1.3066349 0.081196584 0.3707941 
PID_ERBB1_DOWNSTREAM
_PATHWAY 
103 1.3038006 0.057654075 0.3747982 
REACTOME_ACTIVATION_
OF_BH3_ONLY_PROTEINS 
15 1.3001963 0.16561845 0.3804921 








191 1.2960998 0.03292181 0.38332626 
PID_BETA_CATENIN_NUC_
PATHWAY 
78 1.29261 0.08074534 0.388585 
REACTOME_SMOOTH_MUS
CLE_CONTRACTION 
21 1.2918873 0.13747646 0.38830063 





194 1.2891651 0.043841336 0.390076 
KEGG_HISTIDINE_METABO
LISM 
28 1.2890482 0.14649682 0.3884272 
PID_P53_DOWNSTREAM_P
ATHWAY 




19 1.2840316 0.16494845 0.3949651 
BIOCARTA_TNFR1_PATHW
AY 
28 1.2839679 0.14838709 0.39326632 
REACTOME_GLUCAGON_T
YPE_LIGAND_RECEPTORS 
33 1.28217 0.13100436 0.39534697 
REACTOME_ADP_SIGNALLI
NG_THROUGH_P2RY1 
25 1.278918 0.14880952 0.40044922 
REACTOME_DARPP_32_EV
ENTS 








18 1.2771515 0.15821502 0.40047273 
REACTOME_LAGGING_STR
AND_SYNTHESIS 
19 1.2763091 0.1724846 0.40036678 
BIOCARTA_FAS_PATHWAY 29 1.2748996 0.15169661 0.40142906 
BIOCARTA_TOLL_PATHWA
Y 
35 1.2725172 0.11904762 0.4048366 
BIOCARTA_GPCR_PATHWA
Y 
33 1.271753 0.13742071 0.40458906 
BIOCARTA_LAIR_PATHWAY 16 1.2710832 0.19361702 0.40416557 
REACTOME_METABOLISM_
OF_MRNA 




43 1.2698809 0.13763441 0.4033905 
REACTOME_SIGNALLING_B
Y_NGF 




50 1.2679164 0.1211499 0.40399522 
KEGG_REGULATION_OF_A
CTIN_CYTOSKELETON 
205 1.2657347 0.047904193 0.40670586 
KEGG_PYRUVATE_METAB
OLISM 
39 1.2650473 0.14315353 0.40641722 
PID_NFAT_TFPATHWAY 46 1.262468 0.15904573 0.41022274 
PID_ERBB1_RECEPTOR_P
ROXIMAL_PATHWAY 









23 1.2529324 0.16898608 0.4247278 
REACTOME_L1CAM_INTER
ACTIONS 
80 1.2526073 0.09430256 0.42368495 
KEGG_PROPANOATE_MET
ABOLISM 
32 1.2520785 0.18552037 0.42307425 
PID_FRA_PATHWAY 34 1.2517784 0.14020619 0.42196354 
BIOCARTA_NFAT_PATHWA
Y 
52 1.2513741 0.14314115 0.4210289 
KEGG_SYSTEMIC_LUPUS_
ERYTHEMATOSUS 
120 1.2509726 0.08423326 0.42015368 
PID_S1P_S1P2_PATHWAY 24 1.2463957 0.17054264 0.42823133 






17 1.245027 0.18085106 0.42757112 
PID_ANGIOPOIETIN_RECEP
TOR_PATHWAY 
50 1.2436651 0.13721414 0.42886978 
KEGG_OTHER_GLYCAN_D
EGRADATION 
15 1.241906 0.22678186 0.43075255 
KEGG_PHENYLALANINE_M
ETABOLISM 
17 1.2405703 0.1987315 0.43200192 
BIOCARTA_IL22BP_PATHW
AY 





75 1.2388806 0.13541667 0.43194094 
BIOCARTA_MPR_PATHWAY 34 1.2374402 0.17735043 0.43327296 
PID_A6B1_A6B4_INTEGRIN
_PATHWAY 
43 1.2357967 0.17729084 0.4352656 
KEGG_ADHERENS_JUNCTI
ON 




22 1.2350552 0.18393235 0.4335034 
REACTOME_NRAGE_SIGNA
LS_DEATH_THROUGH_JNK 
41 1.2349473 0.15918367 0.43201908 













17 1.2295223 0.21442886 0.43668836 
BIOCARTA_IL7_PATHWAY 16 1.2285291 0.22516556 0.43711108 
PID_NECTIN_PATHWAY 29 1.2244577 0.19027483 0.44409105 
REACTOME_CELL_CELL_C
OMMUNICATION 
112 1.224034 0.105058365 0.44319782 




34 1.2227597 0.17489712 0.44251665 
REACTOME_METABOLISM_
OF_RNA 
221 1.2208753 0.07676349 0.44482574 
BIOCARTA_IL6_PATHWAY 22 1.2176566 0.19315895 0.44985697 
REACTOME_EXTENSION_O
F_TELOMERES 
26 1.216419 0.21205822 0.4509872 
REACTOME_HOST_INTERA
CTIONS_OF_HIV_FACTORS 
115 1.2158347 0.13457558 0.45058656 
PID_LYSOPHOSPHOLIPID_
PATHWAY 
62 1.2122517 0.1573499 0.45680046 
REACTOME_GABA_B_REC
EPTOR_ACTIVATION 
37 1.2122144 0.18604651 0.45516706 
REACTOME_GLUTATHIONE
_CONJUGATION 
23 1.209929 0.19409283 0.45859396 
KEGG_GRAFT_VERSUS_H
OST_DISEASE 
33 1.2096334 0.187251 0.45751047 
REACTOME_DEADENYLATI
ON_OF_MRNA 
15 1.2083007 0.22520661 0.4588063 
KEGG_FOCAL_ADHESION 191 1.2074447 0.0734127 0.4588754 
PID_RHOA_REG_PATHWAY 44 1.2073356 0.1755102 0.45739502 




76 1.2065825 0.17731959 0.45562923 
REACTOME_TRIGLYCERID
E_BIOSYNTHESIS 
32 1.205922 0.176 0.45540994 
REACTOME_NETRIN1_SIG
NALING 
36 1.2051767 0.20594479 0.4554365 
KEGG_ASTHMA 28 1.2042783 0.20124482 0.45587027 
REACTOME_G_ALPHA1213
_SIGNALLING_EVENTS 
70 1.2033397 0.15463917 0.4564222 
REACTOME_G2_M_CHECK
POINTS 




448 1.2018013 0.0349345 0.45635274 
PID_MYC_PATHWAY 24 1.2007858 0.2208589 0.45694143 
KEGG_INOSITOL_PHOSPH
ATE_METABOLISM 
53 1.1988648 0.1755424 0.45968112 
REACTOME_CA_DEPENDE
NT_EVENTS 




61 1.1968601 0.18110237 0.46081057 
REACTOME_MEMBRANE_T
RAFFICKING 
119 1.1955295 0.13195877 0.46202788 








32 1.192358 0.20675105 0.46592125 
NABA_PROTEOGLYCANS 35 1.1859107 0.23382045 0.47842845 
REACTOME_PLATELET_HO
MEOSTASIS 




18 1.1847438 0.22175732 0.47782165 
REACTOME_SIGNALING_B
Y_NOTCH1 
66 1.1845057 0.17515275 0.4767474 
BIOCARTA_PYK2_PATHWA
Y 




113 1.1823074 0.15576923 0.47837254 
REACTOME_SIGNALING_B
Y_ROBO_RECEPTOR 
28 1.1806213 0.23173277 0.48052916 
KEGG_CARDIAC_MUSCLE_
CONTRACTION 
74 1.1800472 0.18548387 0.48020235 
KEGG_DILATED_CARDIOM
YOPATHY 
86 1.1786551 0.17453799 0.48166502 
REACTOME_G1_S_TRANSI
TION 
105 1.1780953 0.16962525 0.48130462 





25 1.177149 0.22360249 0.48028237 
KEGG_SMALL_CELL_LUNG
_CANCER 
81 1.1760714 0.16016427 0.4811401 




27 1.1748356 0.2402464 0.4806985 
REACTOME_TCR_SIGNALI
NG 
49 1.1748091 0.20758483 0.47915816 
PID_NFAT_3PATHWAY 51 1.1739318 0.21822034 0.4796431 
REACTOME_PHOSPHORYL
ATION_OF_THE_APC_C 
17 1.1714292 0.27405858 0.48346868 
BIOCARTA_TOB1_PATHWA
Y 




82 1.1690614 0.16839917 0.48565003 
KEGG_PURINE_METABOLI
SM 
147 1.1689179 0.13436124 0.48435017 
BIOCARTA_INFLAM_PATH
WAY 
27 1.1680384 0.2707889 0.48467195 
REACTOME_LYSOSOME_V
ESICLE_BIOGENESIS 
21 1.1663203 0.23991935 0.4870856 
REACTOME_HS_GAG_BIOS
YNTHESIS 
30 1.1662683 0.24236253 0.4856321 
BIOCARTA_ACTINY_PATH
WAY 
20 1.1658527 0.2795031 0.48501176 
REACTOME_INFLAMMASO
MES 
16 1.1602263 0.26844263 0.49611852 
PID_RETINOIC_ACID_PATH
WAY 
29 1.1581625 0.23732251 0.49907774 
BIOCARTA_GSK3_PATHWA
Y 




29 1.1549215 0.24536082 0.5032427 
PID_SHP2_PATHWAY 58 1.1546503 0.23061225 0.50224596 
BIOCARTA_ERK_PATHWAY 28 1.1527913 0.25792813 0.5047303 
PID_AR_NONGENOMIC_PA
THWAY 
30 1.1517929 0.252505 0.5054457 
KEGG_ABC_TRANSPORTE
RS 




131 1.1487507 0.20164609 0.50901383 
PID_P38_ALPHA_BETA_DO
WNSTREAM_PATHWAY 




60 1.1478461 0.21084337 0.50802785 
REACTOME_MRNA_SPLICI
NG 
96 1.1465719 0.19750519 0.5095155 
KEGG_BASE_EXCISION_RE
PAIR 
33 1.1460731 0.25531915 0.5091339 
KEGG_JAK_STAT_SIGNALI
NG_PATHWAY 
147 1.1458316 0.20295984 0.5080585 
BIOCARTA_GATA3_PATHW
AY 
16 1.145746 0.31543624 0.50669235 
PID_IL23_PATHWAY 37 1.1403216 0.27348644 0.51786673 








24 1.1396415 0.27865613 0.51631373 
REACTOME_ADAPTIVE_IM
MUNE_SYSTEM 
495 1.139043 0.09255533 0.51617795 
REACTOME_KERATAN_SUL
FATE_BIOSYNTHESIS 
24 1.1380419 0.26839826 0.5169712 




176 1.1344062 0.19246861 0.5221052 
REACTOME_PKB_MEDIATE
D_EVENTS 
28 1.1329242 0.2813187 0.5239958 
REACTOME_REGULATION_
OF_INSULIN_SECRETION 





25 1.1320785 0.27216494 0.5228225 
KEGG_MELANOGENESIS 97 1.1303623 0.22403258 0.525154 
PID_RHODOPSIN_PATHWA
Y 
24 1.1281251 0.31558186 0.5288796 
KEGG_CELL_ADHESION_M
OLECULES_CAMS 
130 1.1258861 0.19488189 0.53253585 
REACTOME_DAG_AND_IP3
_SIGNALING 









21 1.1232257 0.29613733 0.53434956 
REACTOME_G_ALPHA_I_SI
GNALLING_EVENTS 
185 1.1216449 0.17755102 0.53643286 
REACTOME_CELL_JUNCTI
ON_ORGANIZATION 
72 1.1187555 0.24418604 0.54171276 
PID_IFNG_PATHWAY 39 1.1172634 0.2815735 0.5434162 
REACTOME_GABA_RECEP
TOR_ACTIVATION 
50 1.117246 0.29508197 0.54186463 
REACTOME_PROTEIN_FOL
DING 
47 1.1153871 0.2860215 0.5446053 
REACTOME_INTRINSIC_PA
THWAY 




31 1.1113133 0.29411766 0.5508337 
KEGG_PATHWAYS_IN_CAN
CER 
312 1.1112031 0.182 0.5495383 
PID_TGFBR_PATHWAY 53 1.1100712 0.26640928 0.5507136 
SA_PTEN_PATHWAY 17 1.1090823 0.32317072 0.55148745 
REACTOME_SIGNALING_B
Y_ILS 
102 1.1086859 0.24894515 0.5509285 
REACTOME_IRON_UPTAKE
_AND_TRANSPORT 




15 1.1071781 0.31827113 0.55150265 
BIOCARTA_WNT_PATHWAY 25 1.1070898 0.31650487 0.55015707 
PID_RET_PATHWAY 39 1.103382 0.31327802 0.55746377 
KEGG_VASCULAR_SMOOT
H_MUSCLE_CONTRACTION 




82 1.0994343 0.26923078 0.56376946 
BIOCARTA_CK1_PATHWAY 17 1.0973475 0.34672305 0.56720513 
KEGG_GLYCEROPHOSPHO
LIPID_METABOLISM 
68 1.0971801 0.27083334 0.5660149 
KEGG_ARACHIDONIC_ACID
_METABOLISM 
56 1.0967717 0.28719008 0.56546414 
KEGG_PATHOGENIC_ESCH
ERICHIA_COLI_INFECTION 
54 1.0935924 0.30515465 0.5717673 
PID_HIF2PATHWAY 33 1.0930377 0.32238194 0.57158476 
BIOCARTA_CSK_PATHWAY 22 1.0913918 0.3254818 0.5739648 
REACTOME_GLYCEROPHO
SPHOLIPID_BIOSYNTHESIS 
78 1.091105 0.28163266 0.5730684 
BIOCARTA_BARRESTIN_SR
C_PATHWAY 
15 1.0907445 0.34790874 0.57236886 
REACTOME_MITOTIC_G1_
G1_S_PHASES 
129 1.0879343 0.2664016 0.577634 
REACTOME_SYNTHESIS_O
F_PA 
24 1.0867049 0.34055117 0.5790784 
REACTOME_PYRUVATE_M
ETABOLISM 
17 1.0861466 0.33909288 0.5788507 
PID_HDAC_CLASSII_PATH
WAY 
34 1.0859255 0.3304721 0.5778516 
KEGG_SPHINGOLIPID_MET
ABOLISM 





16 1.0802321 0.3713693 0.5885627 
PID_DELTA_NP63_PATHWA
Y 
46 1.0795356 0.3264887 0.58867943 
BIOCARTA_MCM_PATHWA
Y 
18 1.0784736 0.375969 0.589592 
PID_P73PATHWAY 74 1.0777467 0.34221312 0.589781 
KEGG_P53_SIGNALING_PA
THWAY 





24 1.0772135 0.33808553 0.5879675 
REACTOME_CIRCADIAN_C
LOCK 






132 1.0710846 0.305835 0.59988415 
REACTOME_NCAM1_INTER
ACTIONS 
38 1.0690138 0.37787056 0.6034601 
REACTOME_INNATE_IMMU
NE_SYSTEM 
250 1.0669271 0.2747934 0.6069042 
BIOCARTA_SHH_PATHWAY 16 1.0663655 0.34989202 0.606678 
KEGG_PPAR_SIGNALING_P
ATHWAY 




39 1.0649866 0.3548387 0.60681164 
SA_B_CELL_RECEPTOR_C
OMPLEXES 
24 1.0622936 0.37551022 0.6119343 
PID_CDC42_REG_PATHWA
Y 
26 1.0612622 0.35812134 0.6127678 
REACTOME_SIGNALING_B
Y_NOTCH 
91 1.0611032 0.3346856 0.6115392 
REACTOME_PHOSPHOLIPI
D_METABOLISM 
185 1.0585644 0.3140187 0.6161881 
KEGG_VIBRIO_CHOLERAE_
INFECTION 
50 1.0563129 0.34435797 0.6201513 
SIG_IL4RECEPTOR_IN_B_L
YPHOCYTES 




16 1.0519863 0.38562092 0.6278963 
REACTOME_SYNTHESIS_O
F_PC 
18 1.049786 0.37555555 0.6316769 
KEGG_PRION_DISEASES 34 1.0487392 0.38641188 0.63275087 
REACTOME_HDL_MEDIATE
D_LIPID_TRANSPORT 
15 1.0473258 0.398773 0.63487786 
BIOCARTA_NO1_PATHWAY 30 1.0465542 0.36575875 0.63526344 




26 1.041781 0.3970894 0.64412093 
PID_RB_1PATHWAY 61 1.0411791 0.37006238 0.64400136 
REACTOME_GLUCOSE_ME
TABOLISM 
62 1.0391171 0.3946281 0.6474477 
PID_S1P_S1P3_PATHWAY 28 1.0383162 0.39807692 0.64786816 
KEGG_TOLL_LIKE_RECEPT
OR_SIGNALING_PATHWAY 
96 1.034983 0.37021276 0.654331 
PID_INTEGRIN_A9B1_PATH
WAY 
25 1.0330826 0.39278132 0.6575539 
PID_RXR_VDR_PATHWAY 26 1.0326474 0.3863179 0.6569353 
PID_VEGFR1_2_PATHWAY 67 1.0284303 0.39034206 0.66601706 
REACTOME_SPHINGOLIPID
_METABOLISM 
64 1.0250795 0.41304347 0.6732003 
REACTOME_SIGNALING_B
Y_PDGF 
114 1.0249064 0.4097363 0.6719303 
BIOCARTA_IL12_PATHWAY 21 1.0221239 0.43644068 0.6772579 
REACTOME_HEMOSTASIS 433 1.0197251 0.3849287 0.68174374 
REACTOME_SEMA4D_IN_S
EMAPHORIN_SIGNALING 
29 1.0192342 0.39430895 0.68140656 
BIOCARTA_BAD_PATHWAY 26 1.0187533 0.4238683 0.6809814 
SIG_PIP3_SIGNALING_IN_C
ARDIAC_MYOCTES 
66 1.0178779 0.41431263 0.68162686 
BIOCARTA_TID_PATHWAY 17 1.0098147 0.45059288 0.700892 
BIOCARTA_CREB_PATHWA
Y 
27 1.0076572 0.45929018 0.70487696 
KEGG_MTOR_SIGNALING_
PATHWAY 
50 1.0073588 0.446 0.70393723 
KEGG_CALCIUM_SIGNALIN
G_PATHWAY 





155 1.0044982 0.4312115 0.7077482 
PID_BETA_CATENIN_DEG_
PATHWAY 
17 1.0043929 0.46072188 0.7063199 







124 1.0028334 0.44163424 0.7068459 
REACTOME_SIGNALING_B
Y_ERBB2 
94 1.001995 0.45859873 0.7073658 
KEGG_PRIMARY_BILE_ACI
D_BIOSYNTHESIS 
16 1.0006084 0.44813278 0.7092343 
PID_ARF_3PATHWAY 17 0.9992103 0.48131868 0.7112345 
PID_HEDGEHOG_GLI_PATH
WAY 
47 0.99681926 0.47420636 0.7158853 
KEGG_CHEMOKINE_SIGNA
LING_PATHWAY 




25 0.99635035 0.45041323 0.7136762 
ST_P38_MAPK_PATHWAY 35 0.99549687 0.45417514 0.7139666 
BIOCARTA_P53HYPOXIA_P
ATHWAY 
20 0.99547625 0.45887446 0.71236014 
BIOCARTA_GH_PATHWAY 26 0.994967 0.46092185 0.7119962 




28 0.9936149 0.4409938 0.7121954 
BIOCARTA_RARRXR_PATH
WAY 
15 0.9907814 0.47686118 0.71788996 
KEGG_NOTCH_SIGNALING
_PATHWAY 








91 0.98803216 0.48739496 0.7199503 
PID_FOXO_PATHWAY 47 0.9858352 0.47629312 0.7240869 
REACTOME_ADHERENS_J
UNCTIONS_INTERACTIONS 
27 0.98372626 0.4729459 0.72782224 
REACTOME_TRAF6_MEDIA
TED_IRF7_ACTIVATION 
28 0.9835073 0.47244096 0.72669244 
















25 0.9784213 0.48552337 0.7331017 
PID_S1P_META_PATHWAY 20 0.97728026 0.49565217 0.73438674 
REACTOME_TRNA_AMINOA
CYLATION 
39 0.97507006 0.47233203 0.7383962 
ST_DIFFERENTIATION_PAT
HWAY_IN_PC12_CELLS 




22 0.97334576 0.47544205 0.7394834 
BIOCARTA_EIF4_PATHWAY 20 0.96975935 0.5091278 0.74701697 
BIOCARTA_VEGF_PATHWA
Y 
28 0.9695914 0.47764227 0.7457991 
REACTOME_COLLAGEN_F
ORMATION 
51 0.96637636 0.506986 0.7523834 
ST_ERK1_ERK2_MAPK_PA
THWAY 
32 0.96310556 0.53974897 0.75907 
KEGG_PENTOSE_PHOSPH
ATE_PATHWAY 
25 0.9629634 0.51669943 0.75777364 





16 0.960817 0.5212766 0.7598589 
BIOCARTA_BCELLSURVIVA
L_PATHWAY 
15 0.96061987 0.51458335 0.758664 
PID_RHOA_PATHWAY 41 0.9564449 0.53070176 0.7679599 
KEGG_AUTOIMMUNE_THY
ROID_DISEASE 
50 0.9556277 0.5080972 0.7683724 
PID_HDAC_CLASSI_PATHW
AY 
64 0.953194 0.529661 0.77289903 




88 0.9507793 0.5708502 0.7755537 
REACTOME_TRAFFICKING_
OF_AMPA_RECEPTORS 
26 0.95053345 0.5308642 0.7744876 
REACTOME_CTNNB1_PHO
SPHORYLATION_CASCADE 






29 0.94768554 0.54393303 0.77841055 
BIOCARTA_HDAC_PATHWA
Y 
27 0.9475117 0.5546219 0.77715164 
PID_S1P_S1P1_PATHWAY 20 0.9458978 0.5173913 0.77969074 
REACTOME_DNA_REPLICA
TION 
181 0.9454168 0.5897436 0.7793615 
KEGG_COLORECTAL_CAN
CER 
60 0.94195765 0.5531915 0.7866234 
BIOCARTA_LONGEVITY_PA
THWAY 
15 0.9404234 0.5326316 0.7887831 
KEGG_NITROGEN_METAB
OLISM 
22 0.9394777 0.5407098 0.78939533 
KEGG_RIG_I_LIKE_RECEPT
OR_SIGNALING_PATHWAY 
67 0.9394243 0.56707317 0.7878405 
BIOCARTA_MAPK_PATHWA
Y 
83 0.93856436 0.55424064 0.78829104 
PID_THROMBIN_PAR1_PAT
HWAY 
42 0.9371623 0.5714286 0.7901412 
KEGG_STEROID_BIOSYNT
HESIS 
16 0.93631625 0.5521739 0.79057276 
KEGG_FC_GAMMA_R_MEDI
ATED_PHAGOCYTOSIS 
91 0.9347213 0.5587629 0.79314935 
KEGG_UBIQUITIN_MEDIAT
ED_PROTEOLYSIS 





25 0.9312163 0.5691383 0.7985174 
PID_ERBB_NETWORK_PAT
HWAY 
15 0.9296474 0.5513627 0.8008671 
REACTOME_PLATELET_SE
NSITIZATION_BY_LDL 
16 0.9295457 0.5532787 0.79943085 









67 0.9239644 0.6064257 0.808733 
REACTOME_PD1_SIGNALIN
G 
17 0.9237196 0.5382979 0.80766356 
KEGG_NUCLEOTIDE_EXCIS
ION_REPAIR 
43 0.92290473 0.5856031 0.8080818 
KEGG_AMINOACYL_TRNA_
BIOSYNTHESIS 
38 0.9214303 0.5995763 0.8099778 
BIOCARTA_MCALPAIN_PAT
HWAY 
23 0.9213864 0.56512606 0.80841553 
BIOCARTA_ARAP_PATHWA
Y 
15 0.9176202 0.5414938 0.8163195 
KEGG_OOCYTE_MEIOSIS 109 0.9171119 0.6350211 0.8159249 
PID_MET_PATHWAY 77 0.9170191 0.61087865 0.81448615 
KEGG_AMYOTROPHIC_LAT
ERAL_SCLEROSIS_ALS 
50 0.9166203 0.59417474 0.81375885 




123 0.914439 0.6494024 0.8159613 
BIOCARTA_IGF1MTOR_PAT
HWAY 
20 0.91271466 0.5687885 0.81842315 
KEGG_ALPHA_LINOLENIC_
ACID_METABOLISM 
17 0.9111396 0.5705394 0.8207373 
REACTOME_ZINC_TRANSP
ORTERS 
15 0.90814656 0.57947683 0.8266995 
PID_CXCR4_PATHWAY 99 0.90768623 0.6647174 0.8261195 
KEGG_ADIPOCYTOKINE_SI
GNALING_PATHWAY 
64 0.90529555 0.6388309 0.8303025 
KEGG_PRIMARY_IMMUNOD
EFICIENCY 
34 0.9047902 0.59615386 0.8298624 
BIOCARTA_EGF_PATHWAY 29 0.90476006 0.6124197 0.8282537 
REACTOME_CELL_CELL_J
UNCTION_ORGANIZATION 
56 0.9002157 0.64025694 0.83731145 
PID_EPHB_FWD_PATHWAY 40 0.8998171 0.62007874 0.8366475 
KEGG_WNT_SIGNALING_P
ATHWAY 
145 0.8994792 0.6983471 0.8358215 
PID_IGF1_PATHWAY 29 0.8994531 0.61924684 0.8342314 
REACTOME_GAP_JUNCTIO
N_TRAFFICKING 
26 0.8932848 0.5954825 0.84746975 
REACTOME_ACYL_CHAIN_
REMODELLING_OF_PE 
21 0.89175284 0.6004184 0.84947795 
REACTOME_PI3K_EVENTS
_IN_ERBB2_SIGNALING 
42 0.8902045 0.6268344 0.8515751 
PID_ER_NONGENOMIC_PA
THWAY 




22 0.88879645 0.63708085 0.85165256 




PID_P38_MK2_PATHWAY 20 0.88533485 0.6109937 0.8564066 
BIOCARTA_P38MAPK_PAT
HWAY 
35 0.8846373 0.6310273 0.85636514 





86 0.8795764 0.7006237 0.8644327 
PID_PS1_PATHWAY 45 0.87906986 0.67330676 0.8639964 
KEGG_CELL_CYCLE 122 0.8787839 0.75396824 0.86300147 
REACTOME_INWARDLY_RE
CTIFYING_K_CHANNELS 
31 0.8775433 0.6459227 0.864039 
REACTOME_PIP3_ACTIVAT
ES_AKT_SIGNALING 




64 0.8734306 0.69894737 0.870218 
KEGG_GNRH_SIGNALING_
PATHWAY 




50 0.8688852 0.67975205 0.8773002 
PID_IL3_PATHWAY 27 0.86387026 0.6422594 0.88707346 
REACTOME_MUSCLE_CON
TRACTION 









15 0.85673505 0.6572008 0.89781004 
BIOCARTA_KERATINOCYTE
_PATHWAY 
44 0.8563876 0.72317594 0.89689535 
REACTOME_TIGHT_JUNCTI
ON_INTERACTIONS 
29 0.8556426 0.6773504 0.8967854 
BIOCARTA_PAR1_PATHWA
Y 
36 0.85548604 0.6963563 0.8954051 
REACTOME_RNA_POL_III_T
RANSCRIPTION 
32 0.85493106 0.69033533 0.8950134 
KEGG_RIBOSOME 66 0.854607 0.7292111 0.89403427 
REACTOME_DOWNSTREA
M_TCR_SIGNALING 
33 0.85453206 0.68172485 0.8924853 
BIOCARTA_PTDINS_PATH
WAY 




38 0.8514116 0.6966068 0.8959777 
REACTOME_ACYL_CHAIN_
REMODELLING_OF_PS 
15 0.84953785 0.6809422 0.89824224 
KEGG_TYROSINE_METABO
LISM 
40 0.8484863 0.7133621 0.89882404 
BIOCARTA_TH1TH2_PATH
WAY 
19 0.84842706 0.66935486 0.89724183 
BIOCARTA_NDKDYNAMIN_
PATHWAY 




33 0.84801674 0.6979167 0.8947092 








43 0.84677845 0.71991247 0.89230126 
REACTOME_PI3K_AKT_ACT
IVATION 
35 0.84676874 0.6913043 0.8906726 
REACTOME_HIV_INFECTIO
N 




26 0.8448487 0.6889353 0.89154327 
REACTOME_SIGNALING_B
Y_FGFR 
106 0.84317696 0.796334 0.8933076 
KEGG_SELENOAMINO_ACI
D_METABOLISM 
25 0.84275216 0.7064579 0.8926225 
PID_PI3K_PLC_TRK_PATH
WAY 
35 0.84093994 0.72669494 0.894628 
PID_ERBB2_ERBB3_PATH
WAY 
43 0.8406051 0.75053304 0.89367855 
ST_GA12_PATHWAY 23 0.83868986 0.7276507 0.89588 
KEGG_GAP_JUNCTION 87 0.8383125 0.8203593 0.89502853 
REACTOME_TRANSLATION 116 0.8367547 0.8183716 0.896519 
REACTOME_PEPTIDE_CHAI
N_ELONGATION 
63 0.8367083 0.7808765 0.89498395 
PID_P38_MKK3_6PATHWAY 25 0.8365783 0.6784141 0.89364403 
KEGG_RENAL_CELL_CARC
INOMA 





29 0.8331327 0.73137254 0.89742726 




15 0.8303974 0.66324437 0.8995939 
PID_HNF3B_PATHWAY 43 0.8292749 0.7388535 0.90000486 
REACTOME_MRNA_PROCE
SSING 
142 0.8288461 0.860835 0.8992302 
BIOCARTA_CTCF_PATHWA
Y 




95 0.82823277 0.845679 0.89715844 









17 0.8233533 0.70564514 0.9019288 
KEGG_FRUCTOSE_AND_M
ANNOSE_METABOLISM 












24 0.81949043 0.72392637 0.90292686 
BIOCARTA_MAL_PATHWAY 19 0.8181502 0.7245509 0.9038405 
BIOCARTA_IGF1_PATHWAY 21 0.81737816 0.7219917 0.9036876 
KEGG_LINOLEIC_ACID_ME
TABOLISM 
26 0.8117299 0.7645788 0.91235405 
REACTOME_LIPOPROTEIN
_METABOLISM 





18 0.8096152 0.71398747 0.9129946 
BIOCARTA_MET_PATHWAY 36 0.8093269 0.7590361 0.91191614 
REACTOME_SIGNALLING_T
O_ERKS 
35 0.8069507 0.78028744 0.91453344 
KEGG_FC_EPSILON_RI_SI
GNALING_PATHWAY 
74 0.80688566 0.82340425 0.9130451 
BIOCARTA_STRESS_PATH
WAY 




15 0.80345273 0.74327123 0.91591054 
KEGG_ENDOMETRIAL_CAN
CER 
51 0.7992038 0.82086617 0.9217984 
REACTOME_FATTY_ACYL_
COA_BIOSYNTHESIS 





83 0.79475594 0.8901099 0.92622167 
PID_FAS_PATHWAY 37 0.794055 0.7827004 0.9258585 
KEGG_ENDOCYTOSIS 169 0.79044974 0.9361277 0.93021363 




51 0.78994626 0.84823287 0.92774075 
REACTOME_MICRORNA_MI
RNA_BIOGENESIS 
17 0.7866602 0.7698574 0.93145883 
BIOCARTA_PGC1A_PATHW
AY 
22 0.7851434 0.8080169 0.9322584 
PID_TCR_CALCIUM_PATH
WAY 





19 0.77784115 0.7839506 0.94045234 




118 0.77589446 0.9229209 0.94023013 
PID_TELOMERASE_PATHW
AY 
66 0.7758787 0.87323946 0.9386561 
BIOCARTA_TFF_PATHWAY 21 0.77003664 0.78630704 0.9456807 
KEGG_STEROID_HORMON
E_BIOSYNTHESIS 




24 0.76470506 0.793617 0.9500987 







67 0.76375395 0.8949495 0.9482509 
KEGG_BLADDER_CANCER 39 0.7626837 0.8510204 0.94812787 
REACTOME_GLOBAL_GEN
OMIC_NER_GG_NER 
32 0.7621747 0.8391039 0.9471598 
KEGG_PANCREATIC_CANC
ER 
68 0.7615029 0.8798371 0.9464661 
PID_ERA_GENOMIC_PATH
WAY 
61 0.7600164 0.8913934 0.9469572 
REACTOME_SIGNALING_B
Y_ERBB4 
87 0.75794214 0.9175476 0.9483724 
REACTOME_ENDOGENOUS
_STEROLS 
15 0.75373507 0.78418803 0.9524702 
REACTOME_TELOMERE_M
AINTENANCE 




20 0.74997836 0.827957 0.95431805 
PID_CONE_PATHWAY 23 0.74378407 0.8460039 0.9606654 
KEGG_THYROID_CANCER 29 0.7430283 0.84313726 0.9599241 
REACTOME_SIGNALLING_T
O_RAS 
27 0.7423138 0.8476821 0.95922995 
KEGG_BASAL_CELL_CARCI
NOMA 
53 0.74220157 0.9171843 0.95778304 
KEGG_HEDGEHOG_SIGNA
LING_PATHWAY 




27 0.73975444 0.8729839 0.9576899 
REACTOME_MITOTIC_M_M
_G1_PHASES 
161 0.73665184 0.98455596 0.95982784 
BIOCARTA_CERAMIDE_PAT
HWAY 
21 0.7357312 0.82051283 0.9593055 
PID_ILK_PATHWAY 43 0.7353843 0.9032967 0.95822537 
PID_SYNDECAN_3_PATHW
AY 




15 0.7343487 0.805492 0.9562833 
BIOCARTA_SPPA_PATHWA
Y 
21 0.73372746 0.86157024 0.95542353 
KEGG_LONG_TERM_DEPR
ESSION 




34 0.7302648 0.86070687 0.95638824 
BIOCARTA_INTEGRIN_PAT
HWAY 










79 0.72521037 0.9437751 0.9572174 
REACTOME_SIGNALLING_T
O_P38_VIA_RIT_AND_RIN 
15 0.7218852 0.8312236 0.95947325 
ST_INTERLEUKIN_4_PATH
WAY 




41 0.717672 0.89285713 0.9607349 
BIOCARTA_NOS1_PATHWA
Y 
21 0.7135105 0.86382115 0.9636503 
ST_INTEGRIN_SIGNALING_
PATHWAY 




29 0.70680076 0.8929293 0.9672362 
BIOCARTA_AT1R_PATHWA
Y 




17 0.69332045 0.88438135 0.976764 
KEGG_BASAL_TRANSCRIP
TION_FACTORS 
32 0.68737864 0.91803277 0.98026747 
PID_FANCONI_PATHWAY 43 0.6736614 0.9580838 0.9894448 
REACTOME_NUCLEOTIDE_
EXCISION_REPAIR 
46 0.67333484 0.9389474 0.9881173 
BIOCARTA_CCR3_PATHWA
Y 
23 0.6700779 0.90515465 0.9889568 
PID_NEPHRIN_NEPH1_PAT
HWAY 
28 0.6669936 0.9254902 0.98960584 
REACTOME_REGULATORY
_RNA_PATHWAYS 
20 0.66089803 0.8978723 0.99212813 
BIOCARTA_HCMV_PATHWA
Y 






49 0.6531078 0.96370965 0.9940178 





25 0.64776725 0.9585153 0.99416214 
KEGG_RNA_DEGRADATION 55 0.6424494 0.9795082 0.9956522 
REACTOME_NUCLEAR_SIG
NALING_BY_ERBB4 





18 0.63927543 0.91684437 0.9943255 
PID_HEDGEHOG_2PATHWA
Y 
21 0.6381688 0.9166667 0.99337465 
BIOCARTA_CHREBP2_PAT
HWAY 
42 0.63730603 0.9761431 0.9922984 
KEGG_ERBB_SIGNALING_P
ATHWAY 
83 0.6311795 0.9900398 0.9938757 
BIOCARTA_VIP_PATHWAY 25 0.6281859 0.94650203 0.9938426 
REACTOME_METABOLISM_
OF_NON_CODING_RNA 







45 0.62577415 0.99185336 0.991913 
PID_IL8_CXCR2_PATHWAY 33 0.624432 0.95578945 0.9910609 
REACTOME_STEROID_HOR
MONES 
29 0.6220332 0.9639066 0.9906562 
BIOCARTA_ACH_PATHWAY 16 0.61122954 0.94600433 0.9940123 
REACTOME_GLYCOLYSIS 25 0.59298855 0.9726891 0.99921495 
SA_TRKA_RECEPTOR 17 0.5839974 0.9419087 1 
PID_WNT_CANONICAL_PAT
HWAY 
18 0.57809037 0.9628099 1 
REACTOME_INFLUENZA_LI
FE_CYCLE 
110 0.56918806 1 1 
BIOCARTA_PTEN_PATHWA
Y 








80 0.54499364 1 1 
ST_G_ALPHA_S_PATHWAY 16 0.5348369 0.989339 1 
BIOCARTA_MTOR_PATHWA
Y 
19 0.5301952 0.98221344 1 
REACTOME_SHC1_EVENTS
_IN_EGFR_SIGNALING 
15 0.52890605 0.9717391 1 
BIOCARTA_NO2IL12_PATH
WAY 
17 0.5147179 0.979716 1 
REACTOME_CYTOSOLIC_T
RNA_AMINOACYLATION 
22 0.5003817 0.9979716 1 
PID_THROMBIN_PAR4_PAT
HWAY 
15 0.4918635 0.98715204 1 
PID_PDGFRA_PATHWAY 21 0.49103978 0.9940711 0.9987714 
REACTOME_PROLONGED_
ERK_ACTIVATION_EVENTS 
18 0.4747968 0.9897541 0.99846566 















Table S 2.7 Core enriched gene set from 
REACTOME_INTEGRIN_CELL_SURFACE_INTERACTION signature 
Gene  RANK IN GENE LIST 
RANK METRIC 
SCORE 




FN1 0 4.957 0.1002 Yes 745 
THBS1 17 3.305 0.1662 Yes 8.33 
F11R 107 1.971 0.2015 Yes 3.52 
ITGB5 110 1.951 0.2409 Yes 2.49 
ITGB8 114 1.892 0.279 Yes 10.21 
ITGA3 228 1.555 0.3046 Yes  
ICAM2 252 1.509 0.334 Yes  
COL4A1 276 1.481 0.3627 Yes 2.54 
ITGB4 321 1.367 0.3881 Yes  
COL4A2 325 1.358 0.4154 Yes  
ITGA2B 476 1.162 0.4313 Yes  
APBB1IP 546 1.105 0.4501 Yes  
COL4A5 571 1.091 0.4709 Yes  
LAMB1 620 1.048 0.4897 Yes  
LAMC1 734 0.98 0.5037 Yes  
LAMA1 897 0.9 0.5137 Yes  
FBN1 1034 0.853 0.524 Yes  
ITGAE 1220 0.784 0.5304 Yes  
COL4A4 1992 0.596 0.5031 No  
VTN 2111 0.574 0.5086 No  
ITGAX 3489 0.402 0.4465 No  
CSK 3503 0.4 0.4539 No  
COL2A1 3660 0.385 0.4537 No  
AKT1 4176 0.331 0.4341 No  
BCAR1 4379 0.313 0.4302 No  
GRB2 4894 0.27 0.4094 No  
FGG 4906 0.27 0.4143 No  
SRC 5571 0.218 0.3848 No  
JAM2 5995 0.188 0.367 No  
CDH1 6196 0.174 0.3603 No  
BSG 6835 0.134 0.3304 No  
AMICA1 6964 0.125 0.3264 No  
RAP1A 7201 0.11 0.3166 No  
FGA 7351 0.1 0.311 No  
PDPK1 7372 0.098 0.312 No  
ITGAL 7418 0.096 0.3116 No  
JAM3 7461 0.094 0.3114 No  
ITGAV 7520 0.091 0.3103 No  
VWF 7564 0.088 0.3099 No  
ITGA10 7815 0.075 0.2986 No  
SYK 8302 0.046 0.2747 No  
TNC 8349 0.043 0.2733 No  
SOS1 8591 0.028 0.2615 No  
ITGA5 9026 0.004 0.2395 No  
RAPGEF4 9118 -0.001 0.2349 No  
FGB 9460 -0.019 0.2178 No  
CRK 10222 -0.061 0.1802 No  
COL1A1 10369 -0.071 0.1742 No  
VCAM1 10823 -0.095 0.153 No  
SHC1 10880 -0.099 0.1522 No  
RASGRP2 12010 -0.164 0.0978 No  
RAP1B 12083 -0.169 0.0976 No  
PTK2 12406 -0.188 0.0849 No  
COL4A3 13809 -0.278 0.019 No  
PTPN1 14152 -0.304 0.0077 No  
ITGB6 14681 -0.341 -0.0124 No  
ITGB1 14747 -0.346 -0.0087 No  
ICAM4 14757 -0.347 -0.0021 No  
RAPGEF3 15142 -0.376 -0.0141 No  
ITGB2 15330 -0.389 -0.0158 No  
ITGB7 15962 -0.444 -0.0391 No  
COL1A2 16155 -0.46 -0.0396 No  
LAMB2 16215 -0.466 -0.0332 No  
ITGA8 16915 -0.536 -0.058 No  
IBSP 16920 -0.536 -0.0474 No  
PECAM1 17004 -0.544 -0.0406 No  
ITGB3 17587 -0.621 -0.0578 No  
ITGA9 17678 -0.634 -0.0495 No  
ITGA11 18103 -0.707 -0.0569 No  
LAMA2 18399 -0.769 -0.0564 No  
ITGAM 18631 -0.834 -0.0513 No  
ICAM3 18725 -0.865 -0.0386 No  
ICAM1 18856 -0.912 -0.0268 No  
RASGRP1 19046 -0.991 -0.0164 No  
ITGA2 19214 -1.099 -0.0027 No  







Table S 2.8 Core enriched genes from HALLMARK_ TNFA_SIGNALING_VIA_ NF-
κB 
GENE  RANK IN GENE LIST 
RANK METRIC 
SCORE 
RUNNING ES CORE ENRICHMENT 
NF-κB Target Gene 
(Gilmore lab's NF-κB 
Target Genes list ) 
IL6 6 3.944 0.0273 No 
Libermann & 
Baltimore, 
1990; Shimizu et al, 
1990;Son et al, 2008 
PMEPA1 14 3.484 0.0514 No  
LITAF 24 2.927 0.0714 No  
IL7R 43 2.569 0.0885 No  
HES1 65 2.233 0.1031 No  
IFIT2 66 2.201 0.1185 No  
SMAD3 70 2.143 0.1333 No  
KLF9 122 1.869 0.1438 No  
DUSP1 148 1.771 0.155 No  
DRAM1 168 1.729 0.1661 No  
PLK2 208 1.613 0.1754 No  
SAT1 281 1.473 0.182 No  
PPAP2B 288 1.452 0.1919 No  
IFIH1 297 1.428 0.2015 No  
ATF3 318 1.368 0.21 No  
TSC22D1 323 1.362 0.2194 No  
EFNA1 351 1.312 0.2272 No  
TNF 377 1.277 0.2348 No  
IER3 378 1.27 0.2437 No  
MARCKS 390 1.255 0.252 No  
RHOB 542 1.107 0.252 No  
IRF1 557 1.101 0.259 No  
JUNB 588 1.076 0.265 No  
DDX58 655 1.026 0.2688 No  
CXCL11 856 0.921 0.2649 No  
PDLIM5 857 0.92 0.2714 No  
EGR1 945 0.881 0.2731 No  
GADD45B 951 0.88 0.279 No  
CEBPD 1061 0.842 0.2793 No  
JAG1 1074 0.835 0.2845 No  
DUSP4 1207 0.788 0.2833 No  
CCL20 1450 0.72 0.2759 No  
INHBA 1577 0.688 0.2743 No  
CSF1 1647 0.669 0.2754 No  
SPHK1 2181 0.562 0.252 No  
LIF 2185 0.561 0.2558 No  
CXCL10 2256 0.549 0.256 No  
TAP1 2360 0.533 0.2545 No  
JUN 2751 0.484 0.2378 No  
PDE4B 2762 0.482 0.2407 No  
TNFAIP2 2787 0.479 0.2428 No  
ZFP36 2834 0.472 0.2437 No  
MSC 2862 0.469 0.2456 No  
TUBB2A 2916 0.464 0.2462 No  
GPR183 2944 0.461 0.248 No  
SGK1 3036 0.451 0.2465 No  
SOD2 3275 0.426 0.2373 No  
PTPRE 3625 0.388 0.2221 No  
TGIF1 3731 0.377 0.2193 No  
NFE2L2 3758 0.374 0.2206 No  
CXCL1 3760 0.373 0.2232 No  
SPSB1 3813 0.368 0.2231 No  
CCRL2 3889 0.361 0.2217 No  
KLF4 3971 0.352 0.22 No  
EGR3 4200 0.329 0.2106 No  
PNRC1 4212 0.328 0.2124 No  
FOSL2 4244 0.325 0.2131 No  
OLR1 4402 0.312 0.2072 No  
CXCL3 4574 0.298 0.2005 No  
BHLHE40 4621 0.294 0.2002 No  
B4GALT1 4940 0.267 0.1857 No  
CEBPB 5018 0.26 0.1836 No  
NINJ1 5114 0.252 0.1805 No  
CYR61 5155 0.248 0.1802 No  
SOCS3 5327 0.236 0.173 No  
EHD1 6195 0.174 0.1297 No  
TLR2 6214 0.173 0.13 No  
TNFSF9 6585 0.15 0.1121 No  
REL 6611 0.149 0.1118 No  
KLF6 6805 0.136 0.1029 No  
ID2 6902 0.129 0.0989 No  
IER2 6945 0.126 0.0976 No  
NAMPT 6951 0.126 0.0982 No  
NR4A3 6983 0.123 0.0975 No  
122 
 
EDN1 7197 0.11 0.0873 No  
HBEGF 7271 0.105 0.0843 No  
TNC 8349 0.043 0.0293 No  
SIK1 8456 0.037 0.0241 No  
NR4A1 8468 0.036 0.0238 No  
STAT5A 8507 0.033 0.0221 No  
B4GALT5 8708 0.022 0.012 No  
DENND5A 8806 0.016 0.0071 No  
DUSP2 8825 0.015 0.0063 No  
PTGS2 9281 -0.01 -0.017 No  
SNN 9284 -0.01 -0.017 No  
BIRC2 9287 -0.01 -0.0171 No  
ICOSLG 9353 -0.014 -0.0203 No  
IL18 9415 -0.017 -0.0233 No  
SLC16A6 10019 -0.049 -0.0539 No  
TIPARP 10634 -0.085 -0.0849 No  
IL12B 11470 -0.132 -0.1268 No  
FOS 11545 -0.137 -0.1297 No  
AREG 11548 -0.137 -0.1288 No  
IRS2 11708 -0.146 -0.1359 No  
MYC 11710 -0.146 -0.135 No  
TNFAIP6 11818 -0.153 -0.1394 No  
NFIL3 11906 -0.158 -0.1428 No  
SLC2A6 12080 -0.168 -0.1505 No  
VEGFA 12206 -0.177 -0.1556 No  
BTG2 12276 -0.182 -0.1579 No  
DNAJB4 12383 -0.187 -0.162 No  
RCAN1 12545 -0.197 -0.1689 No  
CD80 12588 -0.2 -0.1697 No  
NR4A2 12628 -0.202 -0.1703 No  
GCH1 12730 -0.208 -0.174 No  
PLAU 12769 -0.211 -0.1745 No  
CD69 12866 -0.217 -0.1779 No  
CCNL1 12879 -0.218 -0.177 No  
EIF1 13038 -0.229 -0.1835 No  
PANX1 13364 -0.25 -0.1984 No  
IL23A 13568 -0.263 -0.207 No  
MAP3K8 13873 -0.283 -0.2206 No  
SQSTM1 14337 -0.317 -0.2422 No  
CCL5 14444 -0.324 -0.2453 No  
TNIP2 14576 -0.334 -0.2497 No  
NFKBIA 14604 -0.335 -0.2488 No  
MAP2K3 14723 -0.344 -0.2524 No  
CLCF1 15043 -0.368 -0.2662 No  
TNFAIP3 15044 -0.368 -0.2636 No  
CD44 15179 -0.378 -0.2679 No  
FOSB 15351 -0.391 -0.2739 No  
BMP2 15456 -0.4 -0.2765 No  
EGR2 15462 -0.401 -0.2739 No  
CSF2 15656 -0.416 -0.2809 No  
PFKFB3 15866 -0.436 -0.2886 No  
IL15RA 16067 -0.453 -0.2957 No  
TNFAIP8 16080 -0.454 -0.2931 No  
BCL6 16320 -0.476 -0.302 No  
TANK 16344 -0.479 -0.2999 No  
IFNGR2 16535 -0.497 -0.3061 No  
YRDC 16547 -0.499 -0.3032 No  
SLC2A3 16783 -0.522 -0.3116 No  
PPP1R15A 16863 -0.53 -0.312 No  
RELA 16867 -0.531 -0.3084 No  
PLEK 17199 -0.569 -0.3214 Yes  
TRIP10 17234 -0.572 -0.3191 Yes  
KDM6B 17267 -0.577 -0.3167 Yes  
IER5 17401 -0.596 -0.3194 Yes  
SERPINB2 17488 -0.608 -0.3196 Yes  
CXCL6 17575 -0.62 -0.3196 Yes  
KYNU 17576 -0.62 -0.3153 Yes  
MAFF 17628 -0.627 -0.3135 Yes  
ETS2 17672 -0.632 -0.3113 Yes  
ZBTB10 17817 -0.659 -0.3141 Yes  
CXCL2 17853 -0.664 -0.3112 Yes  
GEM 17872 -0.668 -0.3075 Yes  
RELB 17910 -0.674 -0.3046 Yes  
PTGER4 17938 -0.678 -0.3013 Yes  
SERPINB8 17982 -0.686 -0.2987 Yes  
TNIP1 18110 -0.708 -0.3002 Yes  
CFLAR 18162 -0.717 -0.2978 Yes  
CCND1 18208 -0.727 -0.295 Yes  
NFKB1 18314 -0.749 -0.2952 Yes  
PTX3 18443 -0.782 -0.2963 Yes  
TRIB1 18492 -0.794 -0.2932 Yes  
FUT4 18536 -0.807 -0.2897 Yes  
SDC4 18553 -0.813 -0.2849 Yes  
CDKN1A 18633 -0.835 -0.2831 Yes  
KLF2 18652 -0.839 -0.2781 Yes  
CCL2 18653 -0.839 -0.2722 Yes  
F3 18695 -0.853 -0.2684 Yes  
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TNFRSF9 18702 -0.856 -0.2627 Yes  
BTG3 18718 -0.862 -0.2574 Yes  
KLF10 18768 -0.879 -0.2538 Yes  
ICAM1 18856 -0.912 -0.2518 Yes  
RNF19B 18909 -0.932 -0.248 Yes  
GADD45A 18920 -0.937 -0.2419 Yes  
IL6ST 18988 -0.964 -0.2386 Yes  
TRAF1 19012 -0.974 -0.233 Yes  
NFAT5 19061 -1.004 -0.2284 Yes  
FOSL1 19084 -1.014 -0.2224 Yes  
MXD1 19087 -1.018 -0.2154 Yes  
FJX1 19120 -1.037 -0.2098 Yes  
ABCA1 19153 -1.064 -0.2039 Yes  
RIPK2 19197 -1.084 -0.1986 Yes  
ATP2B1 19209 -1.092 -0.1915 Yes  
MCL1 19233 -1.111 -0.1849 Yes  
G0S2 19278 -1.148 -0.1791 Yes  
SERPINE1 19281 -1.152 -0.1711 Yes  
F2RL1 19353 -1.237 -0.1661 Yes  
CD83 19410 -1.34 -0.1596 Yes  
NFKBIE 19455 -1.415 -0.1519 Yes  
PHLDA2 19460 -1.421 -0.1422 Yes  
DUSP5 19511 -1.562 -0.1338 Yes  
BIRC3 19563 -1.787 -0.1239 Yes 
You et al, 
1997; Stehlik et al, 
1998a, 1998b; Simon 
et al. 2007  
PHLDA1 19568 -1.819 -0.1114 Yes  
GFPT2 19610 -2.244 -0.0977 Yes  
IL1A 19627 -2.446 -0.0814 Yes Mori & Prager, 1996 
BCL2A1 19632 -2.546 -0.0638 Yes Lombardi et al, 1995 
PLAUR 19633 -2.578 -0.0457 Yes  
NFKB2 19635 -2.589 -0.0276 Yes Lombardi et al, 1995 








Chapter 3  
3 Discussion  
3.1 Summary of Findings 
Advanced–stage EOC is characterized by the accumulation of ascites fluid in the 
peritoneal cavity (Al Habyan et al., 2018; Sodek et al., 2009). Ascites contains spheroids 
which are a key mediator of peritoneal metastasis and can facilitate chemoresistance (Al 
Habyan et al., 2018; Desoize & Jardillier, 2000; Lengyel et al., 2014; Pease et al., 2012). 
Our group previously reported that the master kinase LKB1 is required for efficient 
ovarian cancer metastasis (Buensuceso et al., 2018; Peart et al., 2015).  Therefore, the 
aim for this study was to elucidate the downstream target eliciting the pro-metastatic 
function of LKB1. We identified NUAK1 as a top candidate substrate and confirmed that 
its expression in spheroids and tumor samples is regulated by LKB1. NUAK1 is down-
regulated in quiescent spheroids compared to proliferative monolayer cells and this 
differential expression is regulated by lysosome degradation and the UPS. To investigate 
the function of NUAK1 in ovarian cancer, we generated lines in which NUAK1 was 
knocked out by CRISPR/Cas9 or overexpressed by stable transfection. OVCAR8 
NUAK1-KO cells had significantly lower cell adhesion while HEYA8 and OVCAR3 
NUAK1 overexpressing lines had significantly increased cell adhesion. Moreover, 
OVCAR8 NUAK1-KO spheroids had impaired spheroid integrity and OVCAR8 NUAK1-
KO-GFP spheroids had an abundance of dead cells accumulate around the periphery. To 
identify a molecular basis for this adhesion phenotype, we completed transcriptome 
analysis using OVCAR8 parental spheroids and OVCAR8 NUAK1-KO spheroids. Using 
GSEA, we identified a cell attachment signature that was up-regulated in OVCAR8 
parental spheroids compared to OVCAR8 NUAK1-KO spheroids. We validated multiple 
adhesion genes in this gene set by qPCR, including FN1, L1CAM, ITGB8, ITGB5, 
THBS1, and F11R. We continued to confirm this signature on the protein level, focusing 
on FN1 because it was the most differentially expressed gene with a 745-fold change. By 
western blot and immunofluoresnce we showed that OVCAR8 NUAK1-KO spheroids 
had no detectable expression of FN1 compared to OVCAR8 parental spheroids. In the 
reciprocal system, there was a dramatic increase in FN expression in HEYA8 NUAK1 
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overexpressing spheroids compared to their respective control. To demonstrate that 
NUAK1 is controlling spheroid integrity through fibronectin deposition, we added 
plasma fibronectin to OVCAR8 NUAK1-KO spheroids and completely restored the 
native phenotype. These findings suggest that through LKB1 regulation NUAK1 is 
promoting spheroid integrity through increasing fibronectin deposition.  
In addition to examining the role of NUAK1 in cell adhesion, we tested whether it 
controls cell growth. NUAK1-KO spheroids had significantly increased viability and this 
was corroborated with our knockdown data. NUAK1 overexpressing spheroids had 
significantly decreased viability. Surprisingly, we found no change in doubling time 
when NUAK1 was knocked out or chemically inhibited with the WZ4003 compound. 
Cells that were treated with the WZ4003 compound also showed no difference in 
thymidine incorporation. These results suggest that loss of NUAK1 increases spheroid 
viability however this effect is not due to increased cell proliferation. To understand the 
mechanism behind this increased viability, we completed GSEA and found that a NF-κB 
pathway was enriched in OVCAR8 NUAK1-KO spheroids compared to OVCAR8 
parental spheroids. To validate this gene set, we found increased nuclear translocation of 
p65 in OVCAR8 NUAK1-KO spheroids compared to the respective control. qPCR 
confirmed that NF-κB target genes were also up-regulated, including IL-1β, IL-1α, NF-κ 
B2, BCL2A1, and BIRC3. Interestingly, previous work has implicated NF- κB signaling 
as having pro-metastatic functions in ovarian cancer (House et al. 2017). Therefore, 
NUAK1 loss increases spheroid viability potentially through up-regulation of NF-κB 
signaling.  
3.2 LKB1-NUAK1 Signaling  
LKB1 is known as a master kinase due to its ability to regulate AMPK as well as 12 
AMPK-related kinases (Shackelford & Shaw, 2009). Through these substrates, LKB1 can 
have multiple functions related to cell polarity, metabolism and growth. While LKB1 is 
commonly known as a tumor suppressor, there is a growing body of literature implicating 
it as having pro-metastatic roles under certain contexts (S. W. Lee et al., 2015; 
Shackelford et al., 2013; Shackelford & Shaw, 2009). In fact, we previously 
demonstrated that LKB1 is required for EOC spheroid viability and metastasis in 
xenograft models (Buensuceso et al., 2018; Peart et al., 2015) Because LKB1 can have a 
126 
 
broad range of functions it is critical to elucidate its downstream targets to identify 
specific substrates that could serve as more suitable therapeutic targets. Most of the 
literature examining targets of LKB1 have focused on AMPK, which is a regulator of 
metabolic stress (Shackelford & Shaw, 2009). However, our prior work indicated that in 
EOC, LKB1 elicits its tumorigenic functions through AMPK-independent signaling 
(Buensuceso et al., 2018; Peart et al., 2015). Thus to determine the critical target for 
LKB1 in EOC, we completed multiplex inhibitor bead-mass spectrometry and identified 
the ARK NUAK1 as a top candidate substrate. To confirm these findings, we showed that 
LKB1 regulates the phosphorylation and expression of NUAK1 in EOC adherent cells, 
spheroids, and tumor samples. We found that early in spheroid formation NUAK1 is 
highly expressed and this correlates with the levels of phosphorylated-LKB1. However, 
later during spheroid formation NUAK1 levels decrease but are still expressed at 
detectable levels. Total LKB1 expression starts to increase later during spheroid 
formation and this is consistent with our data showing that this kinase has pro-metastatic 
functions in EOC.  The down-regulation of NUAK1 was observed in several HGSOC 
established cell lines and patient-derived ascites cells cultured as spheroids. We showed 
that the UPS and lysosome degradation both contribute to the down-regulation of 
NUAK1 in spheroids. Indeed, previous studies have shown that the UPS plays a role in 
regulating NUAK1. NUAK1 can be phosphorylated by cyclin-dependent kinases and 
polo kinase which leads to the recruitment of SCFBTrcp E3 ligase, NUAK1 ubiquitination 
and subsequent degradation (Banerjee et al., 2014). NUAK1 was also shown to be 
ubiquitinated by unique Lys29 and or Lys33 linkages which block phosphorylation and 
activation by LKB1 (Al-Hakim et al., 2008). USP9X can bind to NUAK1 and cleave the 
polyubiquitin modification, allowing for LKB1 phosphorylation and activation. In this 
report, we show that USP9X also regulates NUAK1 expression in EOC spheroids. 
Therefore, we found that NUAK1 is a target of LKB1 in EOC and is differentially 
expressed in proliferative adherent cells and quiescent spheroids. 
3.3 Pro-metastatic function of NUAK1 in ovarian cancer  
Multiple studies have provided evidence that NUAK1 can have tumor-promoting 
functions. In human hepatoma cells, NUAK1 blocked cell death by inhibiting caspase 8 
(Atsushi Suzuki et al., 2003). Along with increasing cell survival through inhibiting 
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apoptosis, NUAK1 can induce the S-phase in the cell cycle and increase cell proliferation 
(Banerjee et al., 2014). Several reports have shown that NUAK1 can also enhance cancer 
survival through supporting metabolic homeostasis in tumors overexpressing myc (Liu et 
al., 2012). A tumor-promoting role for NUAK1 is strengthened by studies showing that 
elevated levels of NUAK1 correlate with poor prognosis (Phippen et al., 2016; Port et al., 
2018). High NUAK1 transcript levels in serous ovarian cancer patients was correlated 
with lower progression free survival and overall survival (Phippen et al., 2016). The 
molecular basis underlying the poor prognosis in EOC had not previously been 
elucidated. Herein, we found that NUAK1 regulates EOC cell adhesion and the formation 
of spheroids, which are key mediators of metastasis in ovarian cancer. 
 
In the context of EOC metastasis, cell adhesion is critical as cancer cells aggregate 
through cell-ECM interactions to form spheroids which then spread through the 
peritoneal cavity (Casey et al., 2001). Previous research has suggested NUAK1 controls 
cell adhesion due to its roles in promoting EMT and invasion. In ovarian cancer cells, 
NUAK1 increases EMT and migration of cells by inhibiting miR-1181 (Zhang et al., 
2015). Furthermore, NUAK1 overexpression in a pancreatic cancer mouse model 
increased in vivo metastasis (Kusakai et al., 2004). Mechanistically, NUAK1 has been 
shown to promote cell detachment by controlling the myosin phosphatase complex in 
HEK293 and MEF cells (Zagórska et al., 2010). Moreover, in colorectal cancer, loss of 
NUAK1 reduced tumor-initiating capacity because spheroids appeared smaller in size 
and were less abundant. To identify the molecular basis for this phenotype, the authors 
proposed that NUAK1 protects tumors from oxidative stress through nuclear 
translocation of Nrf2 (Port et al., 2018). In our study, we show that loss of NUAK1 
impairs single cell adhesion and spheroid formation as spheroids appeared less compact. 
By examining spheroid formation in real-time, we observed NUAK1-KO-GFP spheroids 
exhibiting decreased integrity with an accumulation of dead cells around the spheroid. 
We propose that the ability of NUAK1 to control adhesion molecules is likely the 
primary mechanism mediating EOC spheroid formation. Two of the top signatures up-
regulated in OVCAR8 parental spheroids compared to OVCAR8 NUAK1-KO spheroids 
were related to cell attachment. Interestingly, in the Nrf2 study described above they also 
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observed several cell adhesion pathways using the Metacore GeneGO analysis (Port et 
al., 2018). These cell adhesion pathways had a higher ranking than the Nrf2 oxidative 
stress response pathway yet were not pursued in that study. We observed FN1 as the most 
differentially expressed gene in OVCAR8 NUAK1-KO spheroids with a 745-fold 
decrease. Importantly, the addition of soluble fibronectin to NUAK1-KO spheroids also 
completely restored the native phenotype. Altogether, we have elucidated a novel 
mechanism of NUAK1 in promoting EOC cell adhesion and spheroid compaction 
through fibronectin matrix production.     
 
Our GSEA indicated a cell attachment signature that was enriched in OVCAR8 spheroids 
compared to OVCAR8 NUAK1-KO spheroids. Multiple adhesion molecules were 
identified in the signature, including FN1, L1CAM, ITGβ8, ITGβ5, THBS1, and F11R, 
(Table 2.7), suggesting that NUAK1 regulates a network of adhesion molecules. We 
focused our validation experiments on fibronectin because it demonstrated the greatest 
differential expression and prior studies have shown it plays a key role in spheroid 
formation. Previous work in OVCAR5 cells showed that fibronectin mediates the 
formation of spheroids (Casey et al., 2001). The authors showed that the fibronectin 
receptor α5β1 integrin also contributes to spheroid integrity. Interestingly, the canonical 
fibronectin receptor subunits were not present in our transcriptome analysis with only the 
ITGβ5 and ITGβ8 subunits being differentially expressed (Table 2.4). A prior study 
showed that β8-integrin may interact with fibronectin, however this interaction has only 
been shown in chick sensory neurons and the alpha subunit has not yet been elucidated 
(Venstrom & Reichardt, 1995). In addition, ITGβ8 had a smaller fold change of 10, while 
FN1 had a fold change of 745, suggesting that regulation of matrix expression is the 
principal mechanism by which NUAK1 is controlling cell adhesion in spheroids. Another 
study similarly demonstrated the importance of fibronectin in spheroids generated from 
fallopian tube epithelial (FTE) cells, which represent the putative cell of origin in 
HGSOC (Iwanicki et al., 2016; Labidi-Galy et al., 2017). FTE cells with TP53 mutations 
have an increased propensity to aggregate into spheroids due to autocrine fibronectin 
deposition. Besides FN1, L1CAM was differentially expressed in our analysis with a fold 
change of 10. Indeed, L1CAM was previously shown to promote OVCAR8 and FTE 
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spheroid formation (Doberstein et al., 2018). In FTE spheroids, L1CAM up-regulated 
expression of integrins and fibronectin to facilitate spheroid formation. In our study, we 
similarly showed an interesting relationship between L1CAM and fibronectin expression. 
In OVCAR8 NUAK1-KO spheroids there was no detectable levels of either L1CAM or 
fibronectin expression. Therefore, we may have identified a novel signaling pathway 
controlling fibronectin and its molecules that mediates the formation of EOC spheroids.   
3.4 Loss of NUAK1 up-regulates NF-κB signaling  
Besides controlling cell adhesion and spheroid integrity, we examined whether NUAK1 
could be playing a role in cell growth. While loss of NUAK1 increased spheroid viability 
there was no change in cell proliferation. Interestingly, GSEA revealed that a NF-κB 
pathway was up-regulated in OVCAR8 NUAK1-KO spheroids compared to OVCAR8 
parental spheroids.  We validated this pathway by showing enhanced nuclear 
translocation of the p65 transcription factor and increased expression of its target genes. 
House et al. (2017) demonstrated that in the ovarian cancer cell lines, OV90 and ACI-23, 
NF-κB activation can support tumor heterogeneity. They showed that the canonical NF-
κB pathway promotes cell proliferation, while the non-canonical NF-κB pathway 
supports spheroid formation, chemoresistance, and a stem cell population in spheroids. 
But the function of NF-κB in ovarian cancer may be more complex as it was shown to 
have a biphasic role by either inhibiting or promoting ovarian cancer growth (Gill et al., 
2011). In chemosensitive ovarian cancer cells (SKOV3 and HEY), NF-κB has pro-
apoptotic functions.  In chemoresistant cell lines (SKOV3i.p1 and HEYA8), NF-κB could 
be reprogrammed to function as an oncogene.  Furthermore, increased nuclear 
localization of the p65 transcription factor was correlated with enhanced chemosensitivity 
and longer overall survival in patients.  Altogether, our data suggests that loss of NUAK1 
leads to increased spheroid viability. This enhanced viability could be due to enhanced 
NF-κB signaling. Alternatively, it is also possible that because NUAK1-KO spheroids are 
less compact it might have been easier to dissociate the spheroids prior to measuring cell 
counts with trypan blue, leading to increased viability readings as compared with parental 
cell spheroids. Future studies will need to be completed to test whether up-regulated NF-
κB signaling is contributing to enhanced spheroid viability.  
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3.5 Limitations of current study and future studies  
To examine how levels of NUAK1 change in an in vitro model system of metastasis, I 
compared NUAK1 expression between proliferative adherent cells and quiescent 
spheroids. I found an interesting trend where NUAK1 was commonly down-regulated in 
HGSOC established cells lines and patient-derived cells cultured as spheroids compared 
to monolayer cells. Using a proteasome inhibitor, I determined that the UPS contributes 
to the differential expression of NUAK1 in spheroids. Therefore, I sought to determine 
whether NUAK1 may be more highly ubiquitinated in spheroids compared to monolayer 
cells. To test this, endogenous ubiquitinated proteins were first pulled down using 
TUBEs. Following this precipitation, the ubiquitinated protein of interest could be 
detected by immunoblotting with the NUAK1 antibody.  While I detected ubiquitinated 
c-myc (positive control) in spheroids, I did not identify ubiquitinated-NUAK1 in adherent 
cells or spheroids. Multiple modifications were made in an attempt to troubleshoot this 
precipitation experiment. For example, to preserve the ubiquitin modification on proteins 
for the pull-down I treated cells with a proteasome inhibitor and a deubiquitinase 
inhibitor (PR-619). This deubiquitinase inhibitor was also included into the lysis buffer. I 
collected spheroids at both early times points and late time points in case ubiquitinated-
NUAK1 was being rapidly cleared by the proteasome at 72 hours. The western blot 
protocol was also optimized for ubiquitin proteins by altering the transfer conditions and 
keeping the stacking gel to avoid discarding high molecular weight proteins (Emmerich 
& Cohen, 2015). My results suggest that NUAK1 may not be highly ubiquitinated in 
ovarian cancer cells or potentially TUBEs are not an effective method to detect certain 
ubiquitinated proteins. It is possible that levels of ubiquitinated NUAK1 are very low in 
the cell and other more highly ubiquitinated species are saturating the agarose-TUBEs. 
Alternatively, the epitope for the NUAK1 antibody may be blocked by the ubiquitin 
modification. A future experiment could be implemented to examine the levels of 
ubiquitinated-NUAK1 in spheroids by overexpressing ubiquitin in OVCAR8 cells with 
HA-ubiquitin using the PMT123 plasmid (provided by C. Schild-Poulter, Western 
University). Following immunoprecipitation of ubiquitinated proteins, ubiquitinated-
NUAK1 could be detected by immunoblotting with the NUAK1 antibody.  By over-
expressing ubiquitinated proteins, this alternative experiment may be able to detect 
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ubiquitinated-NUAK1 in EOC cells. I predict that spheroids have higher levels of 
ubiquitinated-NUAK1 compared to adherent cells.  
Another future experiment would investigate the molecular basis for the increased 
viability in NUAK1-KO spheroids. We suggested that this result could be because the 
spheroids are less compact or because loss of NUAK1 enhances NF-κB signaling. To test 
whether up-regulated NF-κB signaling contributes to this increased viability, we could 
treat our OVCAR8 NUAK1-KO spheroids with an inhibitor of the NF-κB pathway. The 
BAY 11-7082 compound hinders the phosphorylation and subsequent degradation of 
IκBα, leading to the sequestration of the NF-κB subunits in the cytoplasm (Lee, Rhee, 
Kim, & Cho, 2012). I predict that treating OVCAR8 NUAK1-KO spheroids with the 
BAY 11-7082 compound would decrease their viability. This experiment would clarify at 
least one mechanism behind the increased viability in NUAK1-KO spheroids.  
3.6 Therapeutic implications  
Our results suggest that NUAK1 may have pro-metastatic functions because it enhances 
ovarian cancer spheroid formation. Thus, the use of a NUAK1 inhibitor may be 
therapeutically beneficial in ovarian cancer metastasis. In fact, the ON123300 dual 
NUAK1/CDK4 inhibitor was developed to address the modest efficacy with single agent 
CDK inhibitors in multiple myeloma (Perumal et al., 2016). ON123300 led to cell cycle 
arrest and apoptosis in multiple myeloma cells. This inhibitor also reduced tumor growth 
in multiple myeloma mouse models. Similarly, in ovarian cancer the addition of a 
NUAK1 inhibitor to the standard combination therapy of carboplatin and paclitaxel may 
provide a therapeutic advantage by targeting spheroid formation. Spheroids are a key 
mediator of metastasis and have the potential to acquire chemoresistance (Al Habyan et 
al., 2018; Desoize & Jardillier, 2000; Lengyel et al., 2014; Pease et al., 2012). There is an 
urgent need to identify novel therapeutic targets because with the current standard of care 
majority of patients will go on to develop disease recurrence and chemoresistance 





3.7 Overall Conclusion  
In conclusion, we have identified NUAK1 as a key target of LKB1 in EOC. We show 
that NUAK1 has pro-metastatic functions because it increases EOC cell adhesion and 
promotes spheroid integrity. Mechanistically, NUAK1 controls the deposition of 
fibronectin in spheroids to facilitate spheroid formation. Altogether, we provide evidence 
that the LKB1 substrate NUAK1 could serve as a potential therapeutic target in ovarian 
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